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Abstract
 The IFI16 protein (gamma interferon-inducible protein 16) is a DNA sensor that recognizes 
pathogenic DNA both in the cytoplasm and the nucleus. Activation of IFI16 after infection with a 
range	of	viruses	induces	the	production	of	type	I	IFNs	and	the	formation	of	an	inflammasome	complex	
that	leads	to	the	maduration	of	IL-1β.	In	addition	to	its	role	as	an	innate	immune	receptor,	IFI16	also	
participates in the DNA damage response due to its physical interaction with the tumour suppressor 
proteins p53 and BRCA1. In particular, IFI16 collaborates with BRCA1 in the induction of p53-
mediated apoptosis in response to DNA damage. The initial aim of this thesis was to study whether the 
functions of IFI16 in these contexts of cancer and viral infection were related.
 Initial experiments showed that the levels of IFI16 protein were greatly diminished during 
herpes simplex virus type 1 (HSV-1) infection. During the course of this thesis other groups published 
describing this phenomenon, however, the mechanisms underlying the degradation of IFI16 and, in 
particular, the role of the HSV-1 ICP0 protein in this process remained controversial. Thus here, the 
effect of ICP0 on IFI16 expression levels was reassessed and this work demonstrated that ICP0 is 
required	to	efficiently	trigger	IFI16	loss,	although	the	degree	of	reduction	of	IFI16	expression	varied	
between different cell lines.
 These observations posed the question of how HSV-1 infection might affect other proteins 
known to interact with IFI16 and the HSV-1 genome, such as p53 and BRCA1. p53 expression was not 
consistently	affected	by	HSV-1	infection	in	the	cell	lines	analyzed,	confirming	previous	publications.	
Surprisingly, however, analysis of BRCA1 expression during HSV-1 infection revealed a marked 
increase in a protein of approximately 120 kDa. This phenotype was observed in all the cell lines 
examined	and	was	specific	for	HSV-1	infection.	Since	full-length	BRCA1	has	an	apparent	molecular	
weight	of	around	220	kDa,	a	proteomic	characterization	of	this	120	kDa	was	undertaken	to	definitively	
establish its identity. These experiments revealed that the 120 kDa protein up-regulated during HSV-1 
infection	was		the	viral	tegument	protein	UL37	and	further	experiments	rigorously	confirmed	this	result.	
A number of BRCA1-reactive antibodies show cross-reactivities with other cellular proteins, but this 
is	the	first	description	of	the	cross-reactive	binding	of	a	BRCA1	antibody	to	a	viral	protein.	These	data	
emphasise the importance of careful characterisation of antibody reagents for correct interpretation of 
immunochemical data.
 Since IFI16 enhances p53 transcriptional activity we wondered whether p53 in turn might 
regulate IFI16 expression or activity. The observation that IFI16 expression was markedly reduced in a 
p53	deficient	subline	of	the	HCT116	colorectal	carcinoma	cell	line	was	consistent	with	this	hypothesis.	
However, restoration of p53 expression had no appreciable effect on IFI16 expression. Similarly, 
analysis of a panel of breast cancer cell lines revealed that although the loss of IFI16 expression was 
common, no clear relation between IFI16 expression and p53 status was found. 
12
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Resumen
 La proteína IFI16 (del inglés gamma interferon-inducible protein 16) es un sensor de ADN que 
reconoce ADN patogénico tanto en el citoplasma como en el núcleo celular. La activación de IFI16 tras 
la infección por un amplio espectro de virus induce la producción de IFNs de tipo I y la formación de 
un	complejo	proteico,	llamado	inflamasoma,	que	desencadena	la	maduración	de	IL-1β.	Además	de	su	
papel como receptor del sistema inmunitario innato, IFI16 también participa en la respuesta al daño en 
el ADN debido a su capacidad de interaccionar directamente con las proteínas supresoras de tumores 
p53 y BRCA1. En particular, IFI16 colabora con BRCA1 en la inducción de la apoptosis mediada por 
p53 en respuesta a daño en el ADN. El objetivo inicial de esta tesis consistió en estudiar si las funciones 
de	IFI16	se	encontraban	relacionadas	en	los	contextos	de	cáncer	e	infección	viral.	
Experimentos iniciales mostraron que los niveles de la proteína IFI16 se reducían marcada-
mente durante la infección por el virus herpes simple de tipo 1 (en inglés HSV-1). Durante el transcurso 
de esta tesis otros grupos describieron este fenómeno, sin embargo, el mecanismo que subyace a esta 
degradación y, en particular, el papel de la proteína ICP0 del HSV-1 en este proceso, ha sido objeto de 
controversia. Por lo tanto, en este trabajo se decidió revisar el efecto de ICP0 en la expresión de IFI16, 
y	demostramos	que	 ICP0	es	necesaria	para	desencadenar	una	 reducción	eficiente	en	 los	niveles	de	
IFI16, aunque el grado de esta disminución varía entre líneas celulares.
Esta observación nos llevó a plantearnos cómo podría el HSV-1 estar afectando a otras proteínas 
que interaccionan con IFI16 y el genoma del virus, como p53 y BRCA1. En las líneas celulares anali-
zadas	la	expresión	de	p53	no	se	vio	afectada	de	manera	consistente,	lo	que	confirma	publicaciones	pre-
vias.	Sorprendentemente,	sin	embargo,	el	análisis	de	la	expresión	de	BRCA1	durante	la	infección	por	
el HSV-1 mostró un importante aumento de una proteína de aproximadamente 120 kDa. Este fenotipo 
se	observó	en	todas	las	líneas	celulares	analizadas	y	fue	específico	de	la	infección	por	el	HSV-1.	Puesto	
que la proteína BRCA1 canónica tiene un peso molecular aparente de 220 kDa, se llevó a cabo una car-
acterización por proteómica de la banda de 120 kDa para determinar su identidad. Estos experimentos 
revelaron que la proteína de 120 kDa que aumenta sus niveles tras la infección por HSV-1 era la proteí-
na	del	tegumento	viral	UL37,	como	confirmaron	rigurosamente	experimentos	adicionales.	Se	sabe	que	
una serie de anticuerpos frente a BRCA1 muestran reactividad cruzada con otras proteínas celulares, 
pero nuestros datos representan la primera descripción de una reactividad cruzada entre un anticuerpo 
contra BRCA1 y una proteína viral. Estos datos subrayan la importancia de realizar una cuidadosa car-
acterización de los anticuerpos para una correcta interpretación de los datos de inmunoquímica.
Dado que IFI16 potencia la actividad transcripcional de p53,  nos planteamos si éste, a su vez, 
podría regular la expresión o actividad de IFI16. El hecho de que la expresión de IFI16 se viera muy 
reducida	en	la	línea	celular	de	carcinoma	colorrectal	HCT116	deficiente	en	p53	era	consistente	con	esta	
hipótesis; sin embargo la restauración de la expresión de p53 no tuvo efecto apreciable en la expresión 
de	IFI16.	De	manera	similar,	el	análisis	de	un	panel	de	líneas	celulares	de	cáncer	de	mama	mostró	que	
aunque la pérdida de la expresión de IFI16 es común, no se aprecia una relación clara entre la expresión 
de IFI16 y el estado de p53. 
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Abbreviations
Abbreviation Description
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
Vero    “verda reno”,”green kidney” in speranto. African green monkey cells.
p21   21 kilodalton cellular protein fraction
TKM buffer   25 mM Tris-HCl pH 7.4, 5 mM KCl, 1 mM MgCl2
p53    53 kilodalton cellular protein fraction
AIM2    Absent in melanoma 2
AP-1   activator protein-1 
AR   Androgen Receptor
ASC   apoptosis-associated speck-like protein containing a CARD domain
ATM   ataxia-telangiectasia mutated
ATRX    ATP-dependent helicase alpha thalassemia/mental retardation syndrome 
   X-linked
BHK   baby hamster kidney 
BLAST   Basic Local Alignment Search Tool
Bcl-2    B-cell lymphoma 2
Bax    Bcl-2-associated X protein
BRCT2   BRCA1 C Terminus domain 2
BASC    BRCA1-associated genome surveillance complex
BARD1  BRCA1-associated RING domain protein 1
BRCA1  breast cancer type 1 susceptibility protein
BT-474  breast tumor cell line 474
BT-549   breast tumor cell line 549
CARDIF   CARD adapter inducing interferon beta
COSMIC  Catalogue of Somatic Mutations in Cancer 
CADM3   cell adhesion molecule 3
CA   cell-associated 
cGAS    cGAMP synthethase
chk2    Checkpoint kinase 2
CRM1   chromosome region maintenance 1
CD34   Cluster of Differentiation 34
CLRs   C-type lectin receptors 
Cos-7    CV-1 (simian) in Origin, carrying  SV40
cGAMP  cyclic di-GMP-AMP 
c-di-AMP  cyclic-diadenosine monophosphate 
c-di-GMP  cyclic-diguanosine monophophate 
DAMPs  damage-associated molecular patterns 
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Abbreviations
DHX36  DEAH (Asp-Glu-Ala-His) Box Helicase 36
DHX9    DEAH (Asp-Glu-Ala-His) Box Helicase 9
DDX   DExD/H-box helicase 
DDX41   DExD/H-box helicase 41
DTT   dithiotreitol
DDR   DNA damage response 
DAI   DNA-dependent activator of IRFs 
DNA-PK  DNA-dependent protein kinase
Mdm2   Double minute 2 protein
dsDNA  double-strand DNA
DMEM	 	 Dulbecco’s	modified	Eagle’s	medium	
E2F   E2 transcriptional factor 
E genes  early genes
EGFR   epidermal growth factor receptor 
EBV   Epstein Barr Virus 
EDTA   Ethylenediaminetetraacetic acid
FADD    FAS-associated death domain protein
c-Fos    FBJ murine osteosarcoma viral oncogene homolog
FcR   Fc-receptor 
FBS   fetal bovine serum 
FACS			 	 fluorescence	activated	cell	sorting
LacZ    Gene Z of lac operon
G418    Geneticin
GR   glucocorticoid receptor 
gI   Glycoprotein I
Gy   Gray
GFP    Green Fluorescent Protein
HeLa    Henrietta Lacks
HSV-1   herpes simplex virus type I 
HSV-2   herpes simplex virus type II
HVEM  herpesvirus entry mediator 
HMGBs   High-mobility group box proteins
HR   homologous recombination
HRP   horseradish peroxidase 
HCF-1   host cell factor-1
hpi   hours post infection
HCMV  human cytomegalovirus
hDaxx    human death domain-associated protein 6
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Abbreviations
HEK293T  human embryonic kidney clone 293 SV40 large T antigen
HEL   human embryonic lung cells
HER1   human epidermal growth factor receptor 1
HER2   human epidermal growth factor receptor 2 
HER4    human epidermal growth factor receptor 4
HFs	 	 	 human	fibroblasts
HFF	 	 	 human	foreskin	fibroblasts	
HepaRG  human hepatocellular carcinoma cell line
HHV   human herpesviruses
HIV	 	 	 human	immunodeficiency	virus
U2OS   human osteosarcoma 
HPV   human papilloma virus 
hTERT  human telomerase reverse transcriptase
ΔICP0		 	 ICP0-null	virus	
ISG15    IFN-stimulated gene 15
ISGs   IFN-stimulated genes 
IE genes  immediate early genes
IF	 	 	 Immunofluorescence
IgG   immunoglobulin G
IP    Immunoprecipitation
ICP0   Infected Cell Polypeptide 0
ICP22   Infected Cell Polypeptide 22
ICP27   Infected Cell Polypeptide 27
ICP4   Infected Cell Polypeptide 4
ICP47   Infected Cell Polypeptide 47
IFN   interferon
IPS-1    Interferon beta promoter stimulator protein 1
IFI200 family   interferon inducible 200 family
IRF3   interferon regulatory factor 3 
IRF5   interferon regulatory factor 5
IRF7    interferon regulatory factor 7
IRFs    Interferon regulatory factors
IFI16   gamma interferon-inducible protein 16 
ISREs   Interferon-Stimulated Response Elements
IL-18   Interleukin 18
IL-1β	 	 	 Interleukin	1β
IARC   International Agency for Research on Cancer 
ICTV   International Committee on the Taxonomy of Viruses
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Abbreviations
KSHV   Kaposi’s sarcoma-associated herpesvirus
kDa   kilo Dalton
L genes  late genes
LRRFIP1		 	 Leucine-rich	repeat	flightless-interacting	protein	1
LSm14A   Like-Sm protein 14A
UL30   long unique region 30
UL37   long unique region 37
UL42   long unique region 42
UL47   long unique region 47
MHC    major histocompatibility complexmajor histocompatibility complex
MS   mass spectrometry 
MALDI   Matrix-assisted laser desorption/ionization
Mdc1   Mediator of DNA damage checkpoint protein 1
MP	 	 	 Medium	Purified
MRE11  meiotic recombination 11 protein 
SK-OV3   Memorial Sloan Kethering Ovarian Carcinoma 3
SK-BR-3  Memorial Sloan–Kettering Cancer Center Breast 3
MCF10A  Michigan Cancer Foundation-10
MCF7    Michigan Cancer Foundation-7
MAVS   Mitochondrial antiviral-signaling protein
MRN   Mre11-Rad50-Nbs1 complex
m.o.i.   multiplicity of infection 
MNDA  Myeloid cell nuclear differentiation antigen 
MyD88   myeloid differentiation primary response 88
NALP3   NACHT, LRR and PYD domains-containing protein 3
nm   nanometers
Nbs1   Nijmegen breakage syndrome protein 1
NLRP3   NOD-like receptor family, pyrin domain containing 3
NHEJ   non-homologous end-joining 
NP-40   Nonidet P-40 
ND10   nuclear domains 10 
NES   nuclear export signals 
NF-κB		 	 Nuclear	factor	kappa-light-chain-enhancer	of	activated	B	cells
NLS   nuclear localization signal 
NLRs   nucleotide-binding oligomerization domain (NOD)-like receptors
Oct-1   Octamer-binding protein 1 
OB   oligonucleotide/oligosaccharide binding 
p53RE   p53 responsive elements 
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Abbreviations
53BP1   p53-binding protein 
pfu   particle forming units
PAMPs  pathogen-associated molecular patterns
PRRs   pattern recognition receptors 
PAXIP1  PAX-interacting protein 1
PCM1   Pericentriolar material 1
PMSF	 	 	 phenylmethylsulfonyl	fluoride	
PBS   phosphate-buffered saline 
PAGE   Polyacrylamide gel electrophoresis 
PCR   Polymerase Chain Reaction 
PVDF	 	 	 polyvinylidene	fluoride	
PML   promyelocytic leukemia protein
PYCARD   PYD and CARD domain-containing protein
PYHIN   pyrin and HIN domain-containing
PYHIN1  Pyrin and HIN domain-containing protein 1
PYD    pyrin domain 
POP3   Pyrin domain only protein 3
qRT-PCR  quantitative Real Time Polymerase Chain Reaction
RING    Really Interesting New Gene
pRb   retinoblastoma protein 
RLRs   retinoic acid inducible gene-I (RIG-I)-like receptors
RIG-I   retinoic acid-inducible gene 1
rpm    revolutions per minute
RNF168	 	 RING	finger	protein	168
RNF8	 	 	 RING	finger	protein	8
RT   Room temperature
RPMI   Roswell Park Memorial Institute
Saos2    Sarcoma osteogenic
Ser15   Serine 15
(S-T-P)-rich spacer  serine-threonine-proline -rich spacer
ssDNA   single stranded DNA 
SUMO		 	 small	ubiquitin-like	modifier
SDS   sodium dodecyl sulfate 
NaF   Sodium Fluoride
Na3VO4  Sodium Orthovanadate
Sp100    speckled protein 100kDa
STING  stimulator of interferon genes protein 
TBK1   TANK-binding kinase 1 
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TLR9    Toll-like receptor 9
TLRs   Toll-like receptors 
TMEM173  Transmembrane Protein 173
TAP    transporter associated with antigen processing
TAE buffer  Tris base, acetic acid and EDTA.
UV    Ultraviolet
VACV   vaccinia virus 
VSZ   Varicella Zoster Virus 
gE   viral glycoprotein E 
vhs    virion host shutoff protein
VISA    Virus-induced-signaling adapter
wt   wild type 
ZBP1   Z-binding protein 1 
α-TIF		 	 	 α	gene	trans-inducing	factor
gD   Glycoprotein D
gH   Glycoprotein H
IFIX   interferon inducible protein X
MEK1/2   MAPK/ERK kinase 1/2
TBS   tris buffer solution
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Introduction
1. DNA sensors
 The key signals that initiate the innate immune responses are mediated by cellular germline-
encoded pattern recognition receptors (PRRs) that detect microbial structurally conserved motifs 
known as pathogen-associated molecular patterns (PAMPs) or endogenous ligands released under 
stress called damage-associated molecular patterns (DAMPs). Several families of PRRs, such as 
Toll-like receptors (TLRs) (reviewed in (O’Neill, Golenbock et al. 2013)), nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs) (reviewed in (Barbe, Douglas et al. 2014)), 
C-type lectin receptors (CLRs) (reviewed in (Hoving, Wilson et al. 2014)), retinoic acid inducible 
gene-I (RIG-I)-like receptors (RLRs) (reviewed in (Loo and Gale 2011)) and certain DNA sensors 
(reviewed	in	(Paludan	and	Bowie	2013)),	have	already	been	identified.	Stimulation	of	these	receptors	
triggers	signalling	pathways,	involving	the	activation	of	transcription	factors	such	as	NF-κB	(Nuclear	
factor kappa-light-chain-enhancer of activated B cells) and IRFs (Interferon regulatory factors), which 
culminate	in	the	induction	of	expression	of	host	inflammatory	cytokines,	chemokines	or	interferons	
(IFNs).	These	effector	molecules	also	contribute	to	the	initiation	and	development	of	pathogen-specific	
adaptive immune responses (reviewed in (Medzhitov 2007)).
 IFNs are a family of cytokines known to play a crucial role in host defense against viral 
infections and in additional activities including immunomodulation and regulation of cell growth and 
differentiation in a variety of cell types (reviewed in (Gutterman 1994; Goodbourn, Didcock et al. 
2000)).	The	 three	classes	of	 IFNs	 identified,	 type	 I	 (α	and	β),	 type	 II	 (γ)	and	 type	 III	 (λ), regulate 
cellular	activities	 through	 the	binding	 to	 their	specific	cell	 surface	receptors	 that	activate	 the	Janus	
kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway leading to the 
expression of a wave of hundreds of IFN-stimulated genes (ISGs), whose products mediate distinct 
biological	functions	including	antiviral	activities	(reviewed	in	(Sadler	and	Williams	2008)).	Specifically,	
type I IFNs are known to be essential for a robust antiviral response (reviewed in (Ivashkiv and Donlin 
2014)).
 Although the PAMPs that have been best described are microbial proteins, lipids, carbohydrates 
and RNA, it is well-known that DNA is also a potent immunostimulatory molecule. Detection of 
pathogen-derived DNA is one major mechanism of type I IFN induction (Tokunaga, Yano et al. 
1992; Ishii, Coban et al. 2006; Stetson and Medzhitov 2006), and generally involves signalling via 
the stimulator of interferon genes protein (STING), which triggers TANK-binding kinase 1 (TBK1)-
mediated activation of interferon regulatory factor 3 (IRF3). Thus, STING (also called MITA, ERIS, 
TMEM173) functions as a central adaptor protein between detection of DNA and the TBK1/IRF3 
signaling axis (Ishikawa and Barber 2008; Zhong, Yang et al. 2008; Ishikawa, Ma et al. 2009; Tanaka 
and Chen 2012).
 The PRRs known to be able to sense the presence of pathogen-derived intracellular DNA include 
several proteins with differential cell population distribution and subcellular localization. These DNA 
sensors are located within the cell at vesicles in the cytoplasm, within the cytoplasm or within the 
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nucleus (reviewed in (Nie and Wang 2013; Paludan and Bowie 2013; Orzalli and Knipe 2014)) (Figure 
I1). 
	 The	first	DNA	sensor	identified	was	TLR9 (Hemmi, Takeuchi et al. 2000), a member of the TLR 
family that is expressed in the endoplasmic reticulum and translocated to the membrane of endosomal 
and lysosomal compartments for ligand binding and signal transduction (Latz, Schoenemeyer et al. 
2004). TLR9 leads to type I IFN induction via the adaptor protein MyD88 (myeloid differentiation 
primary response 88) and IRF7 (Kawai, Sato et al. 2004).
 The DNA-dependent activator of IRFs (DAI) protein (also called ZBP1, Z-binding protein 1) 
was	the	first	cytosolic	DNA	sensor	identified,	which	induces	the	production	of	type	I	IFN	in	a	TBK1-
IRF3-dependent pathway (Takaoka, Wang et al. 2007). 
	 The	second	cytosolic	DNA	sensor	identified	was	RNA polymerase (pol) III, which transcribes 
AT-rich dsDNA to produce 5’-triphosphate dsRNA that is recognized by RIG-I, a DExD/H-box helicase 
(DDX) protein that belongs to the RLR family of PRRs, which subsequently initiates the production of 
type I IFN (Ablasser, Bauernfeind et al. 2009; Chiu, Macmillan et al. 2009) via a pathway that includes 
the adaptor protein MAVS (Mitochondrial antiviral-signaling protein), also called IPS-1 (Interferon 
beta promoter stimulator protein 1), VISA (Virus-induced-signaling adapter) or CARDIF (CARD 
adapter inducing interferon beta), which subsequently triggers activation of the TBK1-IRF3 pathway 
leading to type I IFN genes transcription (Kawai, Takahashi et al. 2005; Meylan, Curran et al. 2005; 
Seth, Sun et al. 2005; Xu, Wang et al. 2005).
 Other members of the DDX protein family have also been implicated in cytosolic DNA sensing, 
such as DHX9 (DEAH box protein 9) and DHX36 (DEAH box protein 36), which interact with the 
MyD88 adaptor protein (Kim, Pazhoor et al. 2010), as well as DDX41 (DEAD box protein 41) (Zhang, 
Yuan et al. 2011b) that depends on STING to induce type I IFN. DDX41 has also been involved in 
the binding of the bacterial secondary messengers cyclic-diguanosine monophophate (c-di-GMP) and 
cyclic-diadenosine monophosphate (c-di-AMP). Upon recognition of these bacterial dinucleotides, 
DDX41 interacts with STING to induce the expression of type I IFNs (Parvatiyar, Zhang et al. 2012). 
Additionally, c-di-GMP and probably c-di-AMP also bind to STING (Burdette, Monroe et al. 2011; 
Barker, Koestler et al. 2013).
 cGAS	 (cGAMP	synthethase)	has	recently	been	identified	as	a	cytosolic	DNA	sensor	 that	 in	
response to DNA catalyzes the synthesis of cyclic di-GMP-AMP (cGAMP). The endogenous cGAMP, 
whose structure resembles the bacterial cyclic dinucleotides, directly binds to and activates STING 
(Sun, Wu et al. 2013; Wu, Sun et al. 2013). 
  STING, in addition to its capacity to bind cyclic dinucleotides and its established role as a key 
adaptor in the IFN response for most DNA sensors, has also been reported to function as a direct sensor 
of DNA (Abe, Harashima et al. 2013).
 Additionally, some key components of the DNA damage repair machinery are involved in 
the detection of immunostimulatory DNA. For example, DNA-dependent protein kinase (DNA-PK), 
a heterotrimeric protein complex consisting of Ku70, Ku80 and the catalytic subunit DNA-PKcs 
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(reviewed in (Smith and Jackson 1999)), and the meiotic recombination 11 protein (MRE11) have 
also	been	 identified	as	cytosolic	DNA	sensors	(Zhang,	Brann	et	al.	2011a;	Ferguson,	Mansur	et	al.	
2012; Kondo, Kobayashi et al. 2013). Both proteins induce immune responses in a STING-dependent 
manner (Ferguson, Mansur et al. 2012; Kondo, Kobayashi et al. 2013).
 Other proteins that have been proposed to function as cytosolic DNA sensors are LRRFIP1 
(Leucine-rich	repeat	flightless-interacting	protein	1)	(Yang,	An	et	al.	2010), HMGBs (High-mobility 
group box proteins) (Yanai, Ban et al. 2009) and LSm14A (Like-Sm protein 14A) (Li, Chen et al. 
2012b).
 In addition to the activation of the STING-dependent signalling pathway, which results in the 
induction of type I IFNs, innate recognition of pathogenic DNA also leads to the assembly of caspase-
1-activating multiprotein complexes termed inflammasomes that promote the proteolytic processing 
of	certain	proinflammatory	cytokines	into	their	mature	active	and	secreted	forms	(Muruve,	Petrilli	et	
al. 2008).
	 An	inflammasome	is	composed	of	a	PRR, the adaptor molecule ASC (apoptosis-associated 
speck-like protein containing a CARD domain) and the procaspase-1. The adaptor ASC, also known 
as	PYCARD	(PYD	and	CARD	domain-containing	protein),	provides	a	link	between	the	specific	PRR	
and the procaspase-1 through homotypic interactions via the PYD and CARD domains. Upon PRR 
activation, its PYD domain interacts with the PYD domain of ASC, whose CARD domain recruits 
the CARD of procaspase-1 permitting the autocleavage and formation of the active caspase-1 p10/
p20	tetramer,	which	in	turn	cleaves	proinflammatory	cytokines,	such	as	interleukins	IL-1β	and	IL-18,	
leading to their maturation (reviewed in (Rathinam, Vanaja et al. 2012)) (Figure  I1). 
	 PRRs	 able	 to	 sense	 DNA	 and	 activate	 inflammasome	 signalling	 include	 NLRP3 protein 
(NOD-like receptor family, pyrin domain containing 3), also called NALP3 (NACHT, LRR and PYD 
domains-containing protein 3), which is a member of the NLR family of PRRs. It senses a large 
range of molecules including cytosolic microbial DNA and subsequently forms an ASC-dependent 
inflammasome	resulting	in	the	activation	of	caspase-1	and	hence	the	maturation	of	IL-1β	(Muruve,	
Petrilli et al. 2008). AIM2 (Absent in melanoma 2), a member of the PYHIN (pyrin and HIN domain-
containing)	protein	family,	recognizes	cytoplasmic	DNA	and	forms	an	inflammasome	complex	that	
leads	 to	 the	 release	 of	 IL-1β	 (Burckstummer,	 Baumann	 et	 al.	 2009;	 Fernandes-Alnemri,	Yu	 et	 al.	
2009; Hornung, Ablasser et al. 2009). Another member of the PYHIN family of proteins, the gamma 
interferon-inducible protein 16 (IFI16) has also been described to function as a DNA sensor, acting 
both in the cytosol and the nucleus, which is involved in STING-mediated type I IFN production 
(Unterholzner,	Keating	et	al.	2010)	as	well	as	inflammasome	signalling	(Kerur,	Veettil	et	al.	2011).	
 
30
Introduction
2. The PYHIN family
 Both AIM2 and IFI16 proteins belong to a family of ISGs regulated by type I and II IFNs termed 
the IFI200 family (interferon inducible 200 family) or the HIN-200 family, which described their 
initially observed hematopoietic expression, IFN-inducibility, nuclear localization and characteristic 
200	 amino-acids	 repeat.	 This	 family	 comprises	 mammalian-specific	 proteins	 with	 similar	 domain	
structures, although it is not known whether they are true structural and functional orthologues, 
excluding AIM2 that is the only HIN-200 protein with orthology across various species (Deschamps, 
Meyer	et	al.	2003;	Brunette,	Young	et	al.	2012;	Cridland,	Curley	et	al.	2012).	This	family	was	first	
identified	 in	mice	 (Kingsmore,	Snoddy	et	al.	1989;	Opdenakker,	Snoddy	et	al.	1989)	and	 the	gene	
cluster	is	found	in	a	syntenic	region	in	many	mammals,	flanked	by	the	CADM3 (cell adhesion molecule 
3) gene and by a set of olfactory receptors genes and the SPTA1 (spectrin alpha, erythrocytic 1) gene, 
on chromosome 1q21-q23 in mouse and 1q23 in human (Brunette, Young et al. 2012; Cridland, Curley 
et al. 2012). 
 More recently, this family has also been called the PYHIN family because most of their 
members contain an amino-terminal PYRIN domain (known also as PYD, DAPIN or PAAD domain) 
and	in	most	cases	at	least	one	carboxy-terminal	HIN	domain.	The	α-helical	PYRIN	domain,	a	member	
Figure I1. DNA sensors proposed and their signalling pathways. Simplified representation of 
several candidate DNA receptors and their main signalling pathways that activate type I IFN 
production and IL-1β maturation. 
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of the death domain superfamily, is involved in homotypic protein-protein interactions associated with 
the	regulation	of	apoptotic	and	inflammatory	signalling	pathways	(Pawlowski,	Pio	et	al.	2001;	Staub,	
Dahl et al. 2001; Hiller, Kohl et al. 2003; Liepinsh, Barbals et al. 2003) while the HIN domain, a 
partially conserved repeat motif of 200-aminoacid residues, is involved in DNA binding and protein-
protein interactions for transcriptional regulation (Koul, Obeyesekere et al. 1998; Johnstone, Kerry et 
al.	1998a;	Johnstone,	Wei	et	al.	2000;	Yan,	Dalal	et	al.	2008).	The	HIN	domain	is	classified	into	three	
subtypes, designated as A, B and C, based on consensus motifs (Ludlow, Johnstone et al. 2005). Each 
200-aminoacid repeat consists of two consecutive oligonucleotide/oligosaccharide binding (OB) folds 
(Albrecht, Choubey et al. 2005; Jin, Perry et al. 2012), commonly found in a number of single stranded 
DNA (ssDNA)-binding proteins (Liao, Lam et al. 2011). 
 The mouse family contains at least fourteen members (Brunette, Young et al. 2012; Cridland, 
Curley et al. 2012), among them p202 and p204 (Samanta, Engel et al. 1986; Choubey, Snoddy et al. 
1989) (Figure I2) while in humans this family includes five members: IFI16 (Trapani, Browne et al. 
1992), AIM2 (DeYoung, Ray et al. 1997), the Myeloid cell nuclear differentiation antigen (MNDA) 
(Burrus, Briggs et al. 1992), the Pyrin and HIN domain-containing protein 1 (PYHIN1, also called 
IFIX)	(Ding,	Wang	et	al.	2004)	and	the	most	recently	identified	Pyrin	domain	only	protein	3	(POP3),	
which lacks the HIN domain found in other PYHIN proteins (Khare, Ratsimandresy et al. 2014) (Figure 
I2).
Figure I2. Domain organization of several human and mouse HIN-200 family members. The Pyrin and HIN domains are indicated by grey and yellow boxes 
respectively. Adapted from Liao et al., 2011.
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3. The human gamma interferon-inducible protein 16 (IFI16)
General features
 The IFI16	gene	was	first	described	in	1992	by	Trapani	and	colleagues.	IFI16	mRNA	was	found	
to be constitutively expressed in lymphoid cells whereas the mRNA was not expressed in cells which 
represent early stages of myeloid development.  (Trapani, Browne et al. 1992). However, treatment 
with	IFNs	α	or	γ	strongly	induced	IFI16	mRNA	and	protein	synthesis	in	myeloid	cells	(Trapani,	Browne	
et al. 1992; Seelig, Ehrfeld et al. 1994). 
	 Dawson	and	Trapani	were	also	the	first	to	propose	that	IFI16	was	able	to	bind	DNA	(Dawson	
and	Trapani	1995a)	and	they	identified	a	DNA-binding	site	within	the	amino	terminal	159	aminoacids	
(Dawson and Trapani 1995b). Therefore, IFI16 was clustered into the family of related human and 
mouse DNA-binding proteins known as the IFI200 family.
 A particularity of IFI16 is the presence of two HIN domains, termed HIN-A and HIN-B 
separated by a serine-threonine-proline (S-T-P)-rich spacer region (hinge region). Moreover, three 
spliced transcript variants encoding different isoforms, clustered at 85-95 kDa, have been found. 
The nucleotide sequences of IFI16 A, B, and C (also called transcript variant 1, 2 and 3) are identical 
except for the region between the end of exon 6 and the start of exon 8. IFI16A contains exons 1 through 
10 including exon 7a. The absence of exon 7a is characteristic of IFI16B, while IFI16C lacks both 
exons 7 and 7a (Johnstone, Kershaw et al. 1998b) (Figure I3). These splice variants encode proteins 
with different lengths of the hinge region, consequently changing the distance between the HIN A 
and B domains, and possibly changing the conformation of the molecule. However the functional 
significance,	if	any	of	the	existence	of	these	different	proteins	has	not	been	studied.	Notably,	the	B	
isoform is the predominant form detected in most cell types tested to date.
Figure I3. Schematic representation of the three different IFI16 isoforms arise due to 
alternative RNA splicing in the exons encoding the S/T/P region. Based on Johnstone 
et al., 1998b.
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Tissue expression and subcellular localization 
 Since IFI16	was	first	cloned,	expression	of	this	gene	was	considered	specific	for	hematopoietic 
cells.	Specifically,	IFI16	has	been	detected	in	a	wide	variety	of	hematopoietic	cells	such	as	lymphocytes,	
specific	myeloid	progenitor	cells	(CD34+	progenitor	cells)	and	monocytes.	In	contrast,	its	expression	
is down-regulated or not detected in other myeloid populations such as macrophages, granulocytes, 
erythrocytes and megakaryocites (Trapani, Browne et al. 1992; Dawson and Trapani 1995b; Dawson, 
Elwood et al. 1998). Nevertheless, IFI16 expression can be strongly induced in certain myeloid cell 
lines	after	exposure	to	IFN-γ,	IFN-α	(to	a	lesser	extent)	and	chemical	agents	that	drive	differentiation	
along the myeloid lineage (Trapani, Browne et al. 1992; Dawson and Trapani 1995a).
However, in contrast to what was originally thought, IFI16 expression is not restricted to cells of the 
immune system since it is also present in non-hematopoietic cells,	such	as	fibroblasts,	endothelial	
and epithelial cells (Seelig, Ehrfeld et al. 1994; Gariglio, Azzimonti et al. 2002; Wei, Clarke et al. 
2003).
 IFI16 was originally considered as a strictly nuclear protein (Dawson and Trapani 1995a) due 
to the presence of a multipartite nuclear localization signal (NLS) (Dawson and Trapani 1995a; Briggs, 
Johnstone et al. 2001; Li, Diner et al. 2012a). In particular, although IFI16 was found in both nucleoli 
and nucleoplasm, it showed prominent nucleolar localization (Seelig, Ehrfeld et al. 1994; Dawson and 
Trapani 1995b). Indeed its expression was suggested to be restricted to transcriptionally active cells that 
have nucleoli (Dawson and Trapani 1995b). However, more recent studies have revealed that IFI16 
can also be found in the cytoplasm in a variety of cell types (reviewed in (Veeranki and Choubey 
2011)). Although several factors such as the presence of stimulatory DNA and the interactions of IFI16 
with	other	proteins	have	been	shown	to	influence	the	subcellular	localization	of	IFI16	(reviewed	in	
(Veeranki	and	Choubey	2011)),	the	acetylation	of	the	IFI16	NLS	has	been	defined	as	a	key	molecular	
mechanism	that	regulates	IFI16	distribution.	Specifically,	acetylations	at	two	critical	sites	within	the	
NLS promote cytoplasmic localization by inhibiting nuclear import, and the acetyltransferase p300 has 
been	identified	as	an	enzyme	involved	in	this	process	(Li,	Diner	et	al.	2012a).	
Biological	Functions
	 Prior	to	the	finding	that	IFI16	functions	in	pathogen	recognition,	studies	focused	on	its	roles	in	
transcriptional regulation, cell differentiation, cell growth, senescence, apoptosis, tumour suppression, 
and autoimmunity.
 As described previously, the levels of IFI16 vary with the differentiation state of the myeloid 
lineage. Moreover, it has been observed that IFI16 expression was induced with agents that promote 
myeloid	differentiation	(Dawson	and	Trapani	1995a).	These	first	data	suggested	an	association	between	
IFI16 and myeloid cell differentiation.
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 Additionally, due to the double-strand (ds) DNA-binding capacity of IFI16 and its preferentially 
nuclear localization, early studies on IFI16 focused on its possible role in transcriptional regulation 
and cell cycle control.	This	hypothesis	was	reinforced	by	the	previous	findings	that	the	related	mouse	
protein p202 could interact with and modulate the transcriptional activities of several transcription 
factors including the retinoblastoma protein (pRb) (Choubey and Lengyel 1995), the E2 factor (E2F) 
family (Choubey, Li et al. 1996; Choubey and Gutterman 1997), the nuclear factor kappa-light-chain-
enhancer	of	activated	B	cells	(NFκB),	the	activator	protein-1	(AP-1)	heterodimer	comprising	c-Fos	
and c-Jun proteins (Min, Ghosh et al. 1996) as well as p53 protein (indirectly via the interaction of 
p202 with the murine homolog of the human p53-binding protein (53BP1)) (Datta, Li et al. 1996). 
 IFI16 can also interact with several transcription factors, among which the members of the p53/
Rb/E2F cell cycle regulatory axis are of particular importance for the antiproliferative activity of IFI16. 
Firstly, it was demonstrated that the N-terminal HIN-A domain of IFI16 bound the C-terminal region of 
p53, increasing p53-mediated transcriptional activity, and it was suggested that the interaction of IFI16 
with p53 might be important for binding of p53 to DNA (Johnstone, Wei et al. 2000). More recently, 
it	has	been	shown	that	the	HIN-B	domain	of	IFI16	also	interacts	with	p53,	specifically	it	recognizes	
the core domain of p53 stabilizing the p53-DNA binding (Liao, Lam et al. 2011). p53 functions as a 
transcriptional activator targeting key cellular genes such as the cell cycle kinase inhibitor p21 and 
the proapoptotic Bcl-2 (B-cell leukemia/lymphoma-2-alpha protein) family member Bax (Bcl-2-like-
protein 4) among many others (reviewed in (Kruse and Gu 2009)). Knockdown of IFI16 expression 
in	fibroblasts	suppressed	p53-mediated	 transcription	resulting	 in	down-regulated	p21	protein	 levels	
and extended cell proliferation (Xin, Pereira-Smith et al. 2004). Moreover, IFI16 may also upregulate 
expression of p21 in a p53-independent manner (Xin, Curry et al. 2003). In addition to p21, IFI16 also 
enhanced the expression of the p53 target gene Bax (Fujiuchi, Aglipay et al. 2004).
IFI16 has also been implicated in the binding to both E2F1 and Rb (Xin, Curry et al. 2003). pRb 
suppresses cell cycle progression, in part, by binding to E2F transcription factors and inhibiting their 
transcriptional functions (reviewed in (Giacinti and Giordano 2006)). Thus, the binding of IFI16 to 
both proteins may potentiate the transcriptional repression of growth-promoting genes mediated by the 
binding of pRb to E2F (Xin, Curry et al. 2003) (Figure I4).
Further support for the involvement of IFI16 in p53 and Rb growth arrest pathways came from the 
finding	that	inactivation	of	both	p53	and	pRb	by	the	E6	and	E7	oncogenes	of	human	papilloma	virus	
(HPV) inhibited the cell growth suppression activity of IFI16 (Raffaella, Gioia et al. 2004). 
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 These results indicate that IFI16 generally collaborates with p53 to inhibit G1 to S phase 
transition. However, one report has suggested that IFI16 negatively regulates p53 because knockdown 
of IFI16 induced p53-dependent expression of p21 and reduced Rb phosphorylation leading to cell 
cycle arrest (Kwak, Ongusaha et al. 2003).
 In addition to the ability of IFI16 to modulate the transcription function through the interaction 
with transcription factors, it seems that IFI16 can also directly regulate gene expression. Indeed, initially 
IFI16 was considered a potent transcriptional repressor and the 200-amino acids repeat regions were 
identified	as	the	responsible	of	the	repressive	activity	(Johnstone,	Kerry	et	al.	1998a).	Moreover,	it	has	
been shown that IFI16 can also interact directly with the gene promoters of p53 and c-myc (Egistelli, 
Chichiarelli et al. 2009).
 All these pieces of evidence supported the idea that IFI16 could function as a transcriptional 
regulator, acting indirectly by modulating the activity of different transcription factors or even directly 
via the association of IFI16 with DNA on gene promoters.
 In line with the ability of IFI16 to suppress cell growth, IFI16 can also regulate cellular 
senescence and apoptosis.
 Bypassing the irreversible cell growth arrest associated with cellular senescence and becoming 
immortal is an early event in the malignant cell transformation. Among the key genes regulating 
Figure I4. Schematic representation of cell cycle regulation by IFI16. After certain stress 
stimuli, the expression of cyclin-dependent kinase inhibitors such as p21 increases, 
mainly induced by p53, leading to an hypophosphorylated form of the retinoblastoma 
protein (pRb). In this state, pRb binds to E2F transcription factors inhibiting their activities, 
thereby suppressing cell growth. IFI16 can bind to pRb and E2F. IFI16 can also enhance the 
expression of p21 by interacting with p53 or in a p53-independent manner.
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senescence/immortalization	 are	 the	 IFN-related	 genes.	 Specifically,	 the	 IFN-related	 pathways	 have	
been shown to be associated with cellular senescence (Fridman and Tainsky 2008). Consistent with a 
role of IFI16 in cellular senescence, IFI16 expression increased in normal human prostate epithelial 
cells as they approached cellular senescence. However, prostate cancer cell lines did not express IFI16. 
Furthermore, overexpression of IFI16 in human prostate cancer cells inhibited colony formation and 
resulted in a senescence-like phenotype associated with a reduction of cells in S-phase (Xin, Curry et al. 
2003).	Similarly,	elevated	levels	of	IFI16	were	found	in	human	“old”	fibroblasts	compared	to	“young”	
cells,	and	immortalization	of	fibroblasts	resulted	in	diminished	IFI16	expression	(Xin,	Pereira-Smith	
et al. 2004). 
 As mentioned before, a plausible mechanism by which IFI16 could inhibit proliferation and thus 
promote senescence would be the up-regulation of p21 expression and inhibition of E2F-stimulated 
transcription (Figure I4). Thus, loss of IFI16 function might contribute to bypass cellular senescence 
providing a proliferation advantage to cells.
 As previously stated, IFI16 is also known to regulate apoptosis. IFI16 has been shown to 
bind BRCA1, a protein that plays a central role in several pathways that maintain genomic stability 
including DNA-damage response and DNA damage repair pathways (reviewed in (Wu, Lu et al. 2010)). 
The Pyrin domain of IFI16 binds to BRCA1 and this interaction has been reported to be involved in 
the p53-mediated cell death pathway in response to DNA damage, suggesting that IFI16 may play a 
role in DNA damage-induced apoptosis (Aglipay, Lee et al. 2003).  Additionally, IFI16 is considered 
to a member of the multi-protein complex known as BASC (BRCA1-associated genome surveillance 
complex) (Aglipay, Lee et al. 2003), which contains tumor suppressors and DNA damage and DNA 
repair proteins (Wang, Cortez et al. 2000). These observations suggest that IFI16 could contribute to 
DNA damage and repair pathways.
 Overall these data support the idea that IFI16 could play a role in tumor-suppression functions 
mediated by p53 and BRCA1 proteins, suggesting that loss of IFI16 function could result in deregulation 
of p53-mediated apoptosis, leading to cancer development. In accordance with the tumor suppression 
activity of IFI16, IFI16 expression is lost in several human tumours such as breast and prostate cancer 
cells (Xin, Curry et al. 2003; Fujiuchi, Aglipay et al. 2004). 
 The role of HIN-200 proteins, in particular IFI16, in regulating the processes of apoptosis 
and	 inflammation	 has	 also	 led	 to	 the	 suggestion	 that	 IFI16	 could	 influence	 the	 development	 of	
autoimmunity	 (Gugliesi,	 De	Andrea	 et	 al.	 2010).	 Indeed,	 prior	 to	 the	 finding	 that	 IFI16	 triggers	
inflammasome	 complex	 formation,	 it	 had	 been	 suggested	 that	 IFI16	 could	modulate	 inflammation	
through	 the	 induction	 of	 expression	 of	 proinflammatory	molecules,	 and	 so	 it	 could	 play	 a	 role	 in	
the pathogenesis of autoimmune diseases (Caposio, Gugliesi et al. 2007). In addition, elevated levels 
of IFI16 autoantibodies were detected in serum samples from patients with different autoimmune 
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diseases including systemic lupus erythematosus (Seelig, Ehrfeld et al. 1994; Uchida, Akita et al. 
2005; Mondini, Vidali et al. 2006), Sjögren’s syndrome (Uchida, Akita et al. 2005; Mondini, Vidali et 
al. 2006) and systemic sclerosis (Mondini, Vidali et al. 2006). However, more studies are needed to 
better understand the role of IFI16 in autoimmunity. 
 As mentioned previously, although early studies focused on roles for IFI16 in transcriptional 
regulation, cell cycle control, cell differentiation and tumour suppression, more recently a role for 
IFI16 as an innate immune sensor	of	intracellular	DNA	has	been	identified	(Unterholzner,	Keating	
et al. 2010). Previous studies had provided evidences that other members of the PYHIN family, 
AIM2 and p202 proteins, could recognize DNA in the cytoplasm and upon sensing DNA the AIM2 
protein	formed	and	inflammasome	leading	to	IL-1β	maturation	(Burckstummer,	Baumann	et	al.	2009;	
Fernandes-Alnemri, Yu et al. 2009; Hornung, Ablasser et al. 2009). However, no PYHIN protein had 
been involved in type I IFN response to DNA until Unterholzner et al.	identified	IFI16	as	a	critical	
protein	for	the	IFN-β	response	after	transfection	with	cytoplasmic	dsDNA	derived	from	vaccinia	virus	
or infection with herpes simplex virus type I (HSV-1) (Unterholzner, Keating et al. 2010). Later, IFI16 
was	also	suggested	to	be	involved	in	inflammasome	assembly	promoting	proinflammatory	cytokines	
maturation during Kaposi’s sarcoma-associated herpesvirus (KSHV) (Kerur, Veettil et al. 2011).
 To date, it is known that IFI16 protein acts as a sensor for DNA during infection with a range 
of viruses including HSV-1 (Unterholzner, Keating et al. 2010; Orzalli, DeLuca et al. 2012; Li, Diner 
et al. 2012a; Johnson, Chikoti et al. 2013), KSHV (Kerur, Veettil et al. 2011; Singh, Kerur et al. 2013), 
human cytomegalovirus (HCMV) (Cristea, Moorman et al. 2010; Li, Chen et al. 2013), Epstein-Barr 
virus (EBV)	 (Ansari,	Singh	et	 al.	2013),	human	 immunodeficiency	virus	 (HIV) (Jakobsen, Bak et 
al. 2013) and vaccinia virus (VACV) (Unterholzner, Keating et al. 2010) to induce the expression of 
type I IFNs	and/or	the	maturation	of	proinflammatory	cytokines	such	as	IL-1β. These observations 
also revealed that IFI16 could sense pathogenic DNA in both the nucleus and the cytoplasm, being 
consistent with its dual subcellular localization.
 In addition, IFI16 has been shown to exert a novel role in antiviral defense since it is involved 
in the silencing of herpesvirus genomes, via promoting the assembly of heterochromatin on HSV-
1 genomic DNA (Orzalli, Conwell et al. 2013) and reducing the binding of various transcription 
factors to promoters of herpesviral genes (Gariano, Dell’Oste et al. 2012; Johnson, Bottero et al. 
2014).	Specifically,	 during	HCMV	 infection	 IFI16	 forms	a	 stable	 complex	with	 the	 transcriptional	
activator Sp1, therefore, displacing it from its promoters and consequently leading to a decrease in 
viral replication and gene expression (Gariano, Dell’Oste et al. 2012). IFI16 has also been found to be 
a restriction factor in HSV-1 infection by reducing the association of important transcription factors 
with promoters of several HSV-1 genes (Johnson, Bottero et al. 2014). 
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4. Herpes simplex virus type 1 (HSV-1)
The Herpesviridae family: A brief introduction
 HSV-1 is a member of the Herpesviridae family, a group of large DNA viruses which contain 
linear, dsDNA. All herpesvirus share a common structure that consists of a core containing the 
lineal ds-DNA genome, an icosahedral capsid containing 162 capsomers, an amorphous layer of 
proteins that surround the capsid known as the tegument, and an envelope membrane containing viral 
glycoproteins spikes on its surface (Figure I5). The size of herpes virions varies from 120 nm to 300 
nm. Herpesviruses are highly disseminated in nature infecting both vertebrates and nonvertebrates. 
All known herpesviruses promote lytic infection resulting in the production of infectious progeny 
virus accompanied by the destruction of the infected cell. They also have the unique ability to remain 
latent for the entire lifetimes of their hosts. In latency the viral genomes become circular and only a 
small subset of viral genes is expressed until some stimulus provokes the reactivation of the virus. The 
specific	cell	type	in	which	they	establish	the	life-long latency varies from one herpesvirus to another, 
but it primarily occurs in the ganglia of the nervous system and lymphoid tissue (Fields 1990).
 
 The members of the Herpesviridae family	 have	 been	 classified	 by	 the	 Herpesvirus	 Study	
Group of the International Committee on the Taxonomy of Viruses (ICTV) into three subfamilies- 
the Alphaherpesvirinae, the Betaherpesvirinae and the Gammaherpesvirinae- based on biological 
properties and genetic criteria (Roizman, Carmichael et al. 1981). To date, eight human herpesviruses 
have been described (Table I1).
Figure I5. Herpesvirus morphology. Virion structure of herpesviruses consisting of 
a core with the linear ds- DNA, an icosahedral capsid, the tegument and an envelope 
which contains the glycoproteins. (Left panel) Electron micrograph of a HSV-1 
particle. All herpesviruses have identical morphology and cannot be distinguished 
from each other under electron microscopy. (Right panel) Schematic representation.
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Subfamily Species
Alphaherpesvirinae
HHV-1, Herpes Simplex Virus type 1 (HSV-1)
HHV-2, Herpes Simplex Virus type 2 (HSV-2)
HHV-3, Varicella Zoster Virus (VSZ)
Betaherpesvirinae
HHV-5, Human Cytomegalovirus (HCMV)
HHV-6
HHV-7
Gammaherpesvirinae
HHV-4, Epstein Barr Virus (EBV)
HHV-8, Kaposi’s Sarcoma-associated herpesvirus (KSHV)
 HSV-1 (also called human herpesvirus 1,	HHV-1)	is	one	of	the	herpesvirus	that	specifically	
infects humans and belongs to the subfamily Alphaherpesvirinae and the genera Simplexvirus.  There 
are two herpes simplex viruses, HSV-1 and HSV-2, which although very closely related by sequence 
homology and biological properties can be differentiated by a predilection for oral and genital mucosa 
respectively and the establishment of latency in the trigeminal and sacral ganglia respectively (Fields 
1990).
 Infection of human herpes simplex viruses is one of the oldest known orally and/or sexually 
transmitted	 infections	and	has	been	documented	since	ancient	Greece.	Hippocrates	was	 the	first	 to	
formally describe the spreading lesions that seem to be creeping or crawling through the skin (reviewed 
in (Nahmias and Dowdle 1968)). Indeed the word herpes comes from the Greek word “herpein” that 
means “to creep” (Beswick 1962). Shakespeare also described the recurrent labial lesions in “Romeo 
and Juliet” (“O’er ladies lips, who straight on kisses dream, which oft the angry Mab with blisters 
plagues, because their breaths with sweetmeats tainted are.” Act 1. Scene IV) (noted by (Wildy 1973)).
 HSV-1 is one of the most common human pathogens worldwide. Primary or initial infection 
occurs at mucosal and skin surfaces and is most often asymptomatic. While most diseases associated 
with primary and recurrent HSV-1 infections are relatively mild in the majority of patients (skin and 
lip lesions, gingivostomatitis, pharyngitis…), HSV-1 infection can occasionally cause severe and/
or life-threatening diseases such as herpes simplex encephalitis, neonatal disseminated infection and 
blindness due to herpes simplex keratoconjunctivitis (Fields 1990).
 Primary HSV-1 infection most often takes place at oral mucosal and epithelial tissue. 
Following replication of virus at portal of entry, the viral progeny infects the nerve termini of sensory 
neurons. The virions are carried by retrograde axonal transport to the neuronal cell bodies where 
they establish a lifelong latency, primarily in the trigeminal ganglia. Quiescent viral genomes can 
Table I1. Classification of human herpesviruses. HHV is the acronym for human herpesvirus.
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occasionally reactivate into the lytic cycle due to a variety of stimuli, such as stress, fever and UV 
exposure. The new viral progeny travels by anterograde transport to the sites innervated by the infected 
neurons giving rise to recurrent infections (reviewed in (Diefenbach, Miranda-Saksena et al. 2008)).
An overview of the HSV-1 lytic replication cycle
 To initiate infection, the virus must enter target cells. The initial attachment of the virion to the 
cell surface is followed by the fusion of the viral envelope with the plasma membrane and these events 
depend	on	the	binding	of	certain	viral	glycoproteins	to	specific	cell	receptors.	Briefly,	virus	attachment	
occurs via gC or gB binding to cell surface heparan sulfate proteoglycans. Following this initial 
attachment, gD interacts with one of its cellular entry receptors: nectin-1, herpesvirus entry mediator 
(HVEM) or 3-O-sulfated heparan sulfate. After this interaction, gD undergoes conformational changes 
that activate the interaction of gB and the heterodimer gH-gL with the cellular membrane leading to 
membranes fusion (reviewed in (Reske, Pollara et al. 2007)). Fusion of the viral membrane with the 
host membrane releases into the cytoplasm the majority of tegument proteins including vhs (virion host 
shutoff	protein)	and	α-TIF	(α	gene	trans-inducing	factor,	also	called	Vmw65	or	VP16).	vhs	triggers	
inhibition of host cell protein synthesis, disruption of preexisting polyribosomes and degradation of 
host	mRNAs	before	the	onset	of	de	novo	viral	gene	expression.	This	increases	the	efficiency	of	viral	
gene expression (reviewed in (Smiley, Elgadi et al. 2001)). VP16 interacts with the host cell factor-1 
(HCF-1), which is involved in the transport of VP16 to the nucleus (La Boissiere, Hughes et al. 1999). 
Following fusion of the membranes the viral capsid is also released to the cytoplasm and rapidly 
transported via microtubules to the nuclear pore complexes (Sodeik, Ebersold et al. 1997), where 
viral DNA is released into the nucleoplasm. The linear HSV-1 DNA is circularized (Garber, Beverley 
et al. 1993; Strang and Stow 2005), serving as a template for transcription and replication of the viral 
genome.
 HSV-1 gene expression is organised into a temporally regulated cascade, where three temporal 
classes	of	viral	genes	are	sequentially	expressed:	immediate	early	(IE	or	α),	early	(E	or	β)	and	late	(L	or	
γ)	genes	(Honess	and	Roizman	1974).	The	five	IE	genes	are	the	first	to	be	expressed	(known	as	infected	
cell polypeptides ICP0, ICP4, ICP22, ICP27 and ICP47). The transcription of these IE genes by cellular 
proteins is stimulated by the VP16 protein (Campbell, Palfreyman et al. 1984). The VP16/HCF-1 
complex induces a trimeric DNA binding complex by interacting with the cellular Octamer-binding 
protein 1 (Oct-1) on regulatory elements located upstream of the IE genes promoters (reviewed in 
(Wysocka and Herr 2003)). All the IE proteins except ICP47, which blocks viral peptide loading onto 
nascent MHC (major histocompatibility complex) class I molecules by binding to TAP (transporter 
associated with antigen processing) (York, Roop et al. 1994; Hill, Jugovic et al. 1995), are involved in 
the	regulation	of	viral	gene	expression	both	transcriptionally	and	posttranscriptionally.	Briefly,	ICP4	
is the major transactivator of gene expression and is necessary for transcription of both E and L genes. 
ICP27 is also an essential gene, which is responsible for L gene expression and normal expression 
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levels of several E genes. It predominantly functions at a post-transcriptional manner through mRNA 
processing.  ICP0 is not absolutely essential for productive infection in cell culture systems; however, 
ICP0-deficient	mutants	 are	 severely	 impaired	 for	 viral	 growth,	 particularly	 at	 low	multiplicities	 of	
infection. It has been considered a promiscuous transactivator of gene expression due to its ability to 
stimulate expression of IE, E and L genes, as well as several cellular genes in transient transfection 
assays. ICP0 also induces the degradation of a number of cellular proteins. ICP22 is not an essential 
gene for viral growth and viability in most cell types and is required for optimal expression of a subset 
of L genes (reviewed in (Weir 2001)). Therefore, IE gene expression leads to the expression of E 
genes,	the	“leaky-late”	(L1	or	γ-1)	genes	prior	to	viral	DNA	replication,	and	finally	the	“true-late”	(L2	
or	γ-2)	at	the	onset	of	DNA	replication.	Generally,	the	E	genes	encode	proteins	required	for	viral	DNA	
replication and the L genes give rise to the structural proteins. 
 Given that the virus encodes its own replication machinery, the viral DNA strands are 
synthesized by viral DNA polymerase (UL30) complexed with the processivity factor UL42. In 
addition to the viral proteins necessary for viral DNA synthesis, several cellular proteins take part in 
viral replication (reviewed in (Weller and Coen 2012)). As mentioned, viral DNA replication begins 
prior to the expression of L genes. After an initial phase of theta replication, viral DNA replication 
switches to a rolling-circle mechanism generating concatemers that are cleaved into monomers and 
packaged into preassembled capsids (Skaliter and Lehman 1994).
 After the capsid assembly and viral genome packaging in the nucleus, the nucleocapsids have 
to cross the nuclear envelope in order to complete their maduration in the cytosol. A model largely 
accepted comprises the budding of the nucleocapsids at the inner nuclear membrane resulting in the 
formation of a primary envelope. Then, this envelope fuses with the outer nuclear membrane releasing 
the maturing capsids into the cytoplasm (reviewed in (Mettenleiter, Muller et al. 2013)). Following 
nuclear egress, most of the tegument proteins are added to the capsids. Moreover, the capsids acquire 
the	final	envelope	and	surface	glycoproteins	by	budding	into	trans-Golgi	vesicles.	Final	mature	virions	
are released by fusion of the vesicles with the plasma cell membrane (reviewed in (Mettenleiter, Klupp 
et al. 2009)).
ICP0	modulation	of	host	cell	responses	to	HSV-1	infection
 Viruses are obligate intracellular parasites that provoke complex responses from the infected 
host cells, which have developed numerous mechanisms in order to restrict viral infections. However, 
during the course of coevolution with their hosts, viruses have evolved varied mechanisms to circumvent 
the deleterious effects of the cellular pathways or exploit these signaling pathways for their own gain. 
Viral neutralisation of host antiviral responses relies on the ability to mimic structure or function of 
cellular proteins. For example several viruses, including HSV-1, encode proteins that are similar to 
cellular E3 ubiquitin ligases. A particular focus of the work presented in this thesis is the HSV-1 E3 
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ubiquitin ligase ICP0.
 As mentioned before, ICP0 expression begins during the initial stages of infection. Although it 
is	not	absolutely	essential	for	productive	lytic	infection,	it	is	required	for	efficient	viral	replication	since	
ICP0-null mutants are severely impaired for viral growth, particularly at low multiplicities of infection 
(reviewed in (Weir 2001)). It also stimulates the reactivation of latent viral genomes. Therefore, it 
plays a key role in regulating both lytic and latent infections. These requirements of ICP0 have been 
linked to its ability to stimulate gene expression from a wide range of viral promoters. ICP0 has also 
been suggested to regulate multiple other aspects of the cellular response to viral infection including 
protein	stability,	chromatin	modification,	the	intrinsic	antiviral	resistance,	the	IFN	response	and	the	
DNA damage response (DDR) pathways (reviewed in (Boutell and Everett 2013; Lanfranca, Mostafa 
et al. 2014)). 
 ICP0 contains an N-terminal RING finger domain that confers E3 ubiquitin ligase activity, 
which mediates ubiquitination and therefore proteasome-dependent degradation of a number of cellular 
proteins during infection. Basically the E3 ubiquitin ligases interact with both E2 ubiquitin-conjugating 
enzymes and substrate proteins mediating the transfer of ubiquitin from E2 enzymes to the substrates 
(reviewed in (Deshaies and Joazeiro 2009)). Ubiquitination in turn targets the substrate for degradation 
by	the	proteasome,	although	this	modification	can	also	have	other	effects	on	the	targeted	protein.	ICP0	
uses diverse mechanisms to target different cellular proteins. It can interact directly with the substrate 
through	specific	recognition	motifs	or	in	a	phosphorylation-dependent	manner.	On	the	other	hand,	it	
can	target	other	substrates	in	a	SUMO	(small	ubiquitin-like	modifier)-dependent	way	or	indirectly	via	
binding partner(s) (reviewed in (Boutell and Everett 2013)
 The	 RING	 finger	 domain	 of	 ICP0	 plays	 a	 fundamental	 role	 in	 the	 biology	 of	 ICP0	 since	
mutations	resulting	in	defective	RING	finger	domain	not	only	impaired	its	ubiquitin	ligase	activity	but	
also resulted in replication defects equivalent to that of ICP0-null mutants and failed de-repression of 
latent HSV-1 genomes (reviewed in (Boutell and Everett 2013)
 The targets of ICP0 for proteasome-dependent degradation include different proteins, many 
of which are implicated in host cellular defences that restrict viral infection (reviewed in (Boutell and 
Everett 2013; Lanfranca, Mostafa et al. 2014)). This indicates the dynamic nature of the interactions of 
ICP0 with cellular components during the infection, a few of which are described in more detail below.
 PML (promyelocytic leukemia protein) is one of the best characterized substrates of ICP0. It is 
a principal component of nuclear domains 10 (ND10, also known as PML nuclear bodies), which are 
accumulations of several proteins important for  repressing viral replication and transcription (reviewed 
in (Tavalai and Stamminger 2008)). These proteins participate in intrinsic immunity, which is a form 
of innate immunity composed of constitutively expressed proteins ready to immediately and directly 
repress viral infection (reviewed in (Bieniasz 2004; Yan and Chen 2012)).  In addition to PML, other 
ND10 members include Sp100 (speckled protein 100kDa), hDaxx (human death domain-associated 
protein 6) and ATRX (ATP-dependent helicase alpha thalassemia/mental retardation syndrome 
X-linked). ND10 components have been shown to relocate to sites associated with incoming HSV-1 
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genomes during initial stages of infection (Everett and Murray 2005). However, ICP0 promotes the 
disruption of ND10 by inhibiting the recruitment of PML, Sp100, hDaxx, ATRX and the SUMO 
family of proteins (Maul, Guldner et al. 1993; Everett and Maul 1994; Lukashchuk and Everett 2010; 
Cuchet-Lourenco, Boutell et al. 2011) as well as inducing the degradation of PML (Everett, Freemont 
et al. 1998; Chelbi-Alix and de The 1999); thereby counteracting this type of intrinsic antiviral defense.
Another part of the intrinsic cellular defense against HSV-1 infection depends on proteins of the DNA 
damage response (DDR) (reviewed in (Weitzman, Lilley et al. 2010)). The DDR is a complex network 
of cellular pathways which detect, signal and repair DNA lesions in order to maintain the genomic 
stability and prevent the transmission of genetic mutations. The presence of a DNA lesion is detected 
by sensor proteins that activate signalling pathways leading to a broad range of cellular responses 
(reviewed in (Jackson and Bartek 2009)).
 The primary signalling pathway mediators that initiate DDR are the kinases ATM (ataxia-
telangiectasia mutated), ATR (ATM and Rad3-related protein) and DNA-PK (DNA-dependent protein 
kinase). While ATM and DNA-PK are activated in response to dsDNA breaks, ATR is recruited to 
ssDNA breaks.
 In the case of ATM-dependent signalling pathway, dsDNA breaks are recognized by the cellular 
Mre11-Rad50-Nbs1 (MRN) complex, which activates the ATM (ataxia-telangiectasia mutated) 
kinase resulting in the phosphorylation of histone H2AX on the chromatin surrounding the break. 
The mediator protein Mdc1 (mediator of DNA damage checkpoint protein 1), which is anchored to 
the	phosphorylated	H2AX	(γ-H2AX),	recruits	the	downstream	factor	RNF8	(RING	finger	protein	8).	
Then RNF8, which is an E3 ubiquitin ligase, ubiquitinates proteins at the site of the break including 
the histones H2A and H2AX. These ubiquitin chains in turn promote the recruitment of RNF168 
(RING	finger	protein	168),	another	E3	ubiquitin	ligase.	These	sets	of	ubiquitination	events	orchestrate	
the recruitment of downstream proteins such as 53BP1 (p53 binding protein 1) and BRCA1.  Finally, 
effector proteins including chk2 (checkpoint kinase 2) and p53 trigger the cellular response to DNA 
damage such as cell cycle modulation, apoptosis and DNA repair (reviewed in (Weitzman, Lilley et al. 
2010)).
 DNA-PK plays a central role in dsDNA break repair via non-homologous end-joining (NHEJ) 
activity. DNA-PK comprises a large catalytic subunit (DNA-PKcs) and two regulatory subunits (Ku70 
and Ku86). The Ku complex binds to the broken DNA and then recruits DNA-PKcs which interacts 
with the DNA (reviewed in (Jette and Lees-Miller 2015)).
 Many viruses including HSV-1 activate the same cellular cascades induced by DNA damage. 
The DDR factors may recognize the incoming viral genomes as damaged DNA and provide a defense 
against these pathogens. In turn, viruses have evolved ways to manipulate the DDR repressing or 
activating it to promote their own replication (reviewed in (Weitzman, Lilley et al. 2010; Turnell and 
Grand 2012)). In the case of HSV-1, it has a complex relationship with the DDR pathways (reviewed 
in Turnell 2012). For example, although HSV-1 infection induces the activation of ATM and the 
subsequent activation of the downstream targets including chk2 and p53 (Shirata, Kudoh et al. 2005; 
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Li, Baskaran et al. 2008), the ATM-dependent signaling pathway is only partially activated since ICP0 
has been shown to induce the degradation of RNF8 and RNF168 (Lilley, Chaurushiya et al. 2010). 
This could prevent the deposition of repressive ubiquitin marks and hence counteract the transcriptional 
silencing of the viral genomes (Lilley, Chaurushiya et al. 2011).
 In addition to RNF8 and RNF168, ICP0 has also been shown to mediate the degradation 
of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) (Lees-Miller, Long et al. 
1996; Parkinson, Lees-Miller et al. 1999), thereby counteracting the NHEJ repair function of DNA-
PK. Additionally, DNA-PK has been shown to act as a DNA sensor that leads to the production of type 
I IFN, cytokines and chemokines in an IRF-3-dependent manner during infection with DNA viruses, 
such as HSV-1 (Ferguson, Mansur et al. 2012). Thus, it is possible that ICP0 could also act to counter 
this innate immune response.
 As well as “intrinsic antiviral factors”, other innate immune factors are also activated during 
viral infections via the detection of viral components that leads to the induction of host cytokines, such 
as type I IFNs. Type I IFNs trigger the expression of ISGs, which establish an antiviral state in cells 
(reviewed in (Ivashkiv and Donlin 2014)). ICP0 has been shown to counteract the activation of the 
type I IFN response by targeting several regulatory factors including IFI16.
 As already stated, as well as viral DNA sensor that triggers the expression of type I IFN or 
proinflammatory	 cytokines,	 IFI16	 exerts	 “intrinsic”	 antiviral	 activity	 by	 silencing	 HSV-1	 genome	
and hence inhibiting viral gene expression. Therefore, it is not surprising that IFI16 is targeted for 
degradation by ICP0, presumably in response to evolutionary pressures to counteract the antiviral 
functions of IFI16.
	 The	first	evidence	for	IFI16	degradation	promoted	by	ICP0	was	presented	by	Orzalli	et	al.,	who	
observed	that	shortly	after	infection	of	human	foreskin	fibroblasts	(HFF)	with	a	mutant	HSV-1	virus	
which expresses ICP0, but not additional IE gene products, nuclear IFI16 was partially localized with 
ICP0 and its expression was markedly reduced by 4-6 hours post infection. They also observed that 
treatment of HFFs with a proteasome inhibitor inhibited the loss of IFI16 observed during infection 
with	wild	type	(wt)	virus,	and	an	ICP0	RING	finger	mutant	virus	was	not	able	to	trigger	the	loss	of	
IFI16. Thus, they concluded that ICP0 promoted the IFI16 degradation in a proteasome- and RING 
finger	domain-dependent	mechanism	(Orzalli,	DeLuca	et	al.	2012).
	 These	observations	were	confirmed	and	extended	by	subsequent	work	(Johnson,	Chikoti	et	al.	
2013).	More	recently,	however,	conflicting	data	have	been	presented	by	Cuchet-Lourenço	et	al.,	who	
indicated	that	ICP0	is	neither	sufficient	nor	necessary	for	the	degradation	of	IFI16	during	the	course	of	
HSV-1 infection and suggested that the effects of ICP0 on IFI16 degradation were indirect and related 
to the role of ICP0 in modulating the progression of viral infection (Cuchet-Lourenco, Anderson et al. 
2013).
	 The	findings	of	Cuchet-Lourenço	et al. demand a reassessment of the changes in IFI16 levels 
during HSV-1 infection. We have approached this problem using HSV-1 mutants that express ICP0 but 
from which the ICP4 and the rest of IE genes have been deleted. These viruses are unable to complete 
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a normal cycle of viral replication due to the absence of the major transcriptional activator ICP4. 
Therefore, infection with these viruses allows the effect of ICP0 to be distinguished from those of the 
progression of viral infection. This work is the main subject of the section 1 of Results.
 Furthermore, during these experiments a possible effect of HSV-1 infection on BRCA1 
expression was studied and a detailed exploration of these experiments is presented in the Section 
2 of Results. The progress of these experiments also involved other aspects of the biology of IFI16 
including the expression of this receptor in a range of tumor cell lines and these data are presented in 
the Section 3.
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The main objectives addressed in the experimental work of this thesis were the following:
1. Analyse the effect of HSV-1 infection on IFI16 expression and study the role of ICP0 in IFI16
 destabilization.
2. Examine the effect of HSV-1 infection on the expression of IFI16-interacting proteins such as
 p53 and BRCA1.
3. Identify the 120 kDa protein, recognised by a BRCA1-reactive antibody, upregulated after 
 HSV-1 infection.
4. Analyse the expression of IFI16 protein in a range of tumour cell lines.
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Cells	
	 Telomerase-immortalized	human	foreskin	fibroblast	(HFF)	cells	(McSharry,	Jones	et	al.	2001),	
(a gift from Gavin Wilkinson), the Vero cell line, derived from kidney epithelial cells of an African 
green monkey, the human osteosarcoma (U2OS) and baby hamster kidney (BHK) cell lines were 
maintained	in	Dulbecco’s	modified	Eagle’s	medium	(DMEM).	49-44	cells	(a	complementing	cell	line	
derived by transfection of Vero cells to express gH, ICP4, and ICP27) were grown in DMEM with 
0.6 mg/mL G418 and 4 µg/mL puromycin. The cell line U2OS stably expressing GFP-BRCA1 and 
FLAG-BARD1 (a gift from Jackson’s lab, The Gurdon Institute, University of Cambridge, UK) were 
cultivated in DMEM with 0.6 mg/mL G418.
 The human colorectal carcinoma (HCT116) cell line expressing wild-type p53 and the HCT116 
cell line with both p53 alleles inactivated by homologous recombination (Bunz, Dutriaux et al. 1998) 
were provided by Dr. Bert Vogelstein (Johns Hopkins University, Baltimore, MD) and cultured in 
Roswell Park Memorial Institute (RPMI) medium.
 The cellular pellets from the breast cell lines MCF10A, MDA-MB-468, BT-474, SK-BR-3, 
MDA-MB-361, MDA-MB-453, T-47D, Hs578T and BT-549 were provided by Dr. Pedro Torres 
Ayuso (National Centre for Biotechnology, Madrid). The HB4a cell line was a gift from Dr. Paul 
Edwards (Stamps, Davies et al. 1994) (Department of Pathology, University of Cambridge, UK). The 
breast cancer cell lines MCF7 and MDA-MB-231 (a gift from Dr. Lourdes Planelles, National Centre 
for Biotechnology, Madrid) were cultivated in Minimum Essential Medium (MEM) and DMEM 
respectively.
 The cellular pellets from all the bladder cancer cell lines (RT4, J82, UM-UC-3, T24 and RT-
112) were provided by Eva Mª García Cuesta from the group of Dr. Mar Valés (National Centre for 
Biotechnology, Madrid).
 All	 cell	 lines	were	maintained	 at	 37°C	 and	 5%	CO2	 in	 a	 humidified	 incubator.	All	media	
were supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2mM L-Glutamine, 0.1mM 
non essential amino-acids, 10mM HEPES, 1mM sodium pyruvate, 100U/mL penicillin, 100U/mL 
streptomycin	and	50µm	β-mercaptoethanol.
Viruses
	 The	HSV-1	SC16	∆gE,	in1814, tsK, in1382 and HSV-2 viruses were provided by Dr. Stacey 
Efstathiou’s group (Division of Virology, Department of Pathology, University of Cambridge, UK).
The dh1 series of HSVs (Chisholm, Howard et al. 2007), derived from gH-null HSV-1 strain 17 
(Forrester, Farrell et al. 1992) were gifts from Xenova Research. The HSV-1 dl1403 and the control 
revertant dl1403R (Stow and Stow 1986) were gifts from Dr. R. Everett and Dr. N. Stow (MRC 
Virology Unit, Institute of Virology, Glasgow, UK). 
 VACV (strain WR) and HCMV (strain AD169) were provided by Dr. Antonio Alcamí (CBMSO, 
CSIC) and Drs. Helena Browne and Tony Minson (Division of Virology, Department of Pathology, 
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University of Cambridge, UK) respectively.
Production of virus stocks
	 Cell-associated	virus	stocks	(Standard	virus	stocks)
 Confluent	BHK	cells	in	150	cm2	flasks	were	infected	with	virus	stocks	at	0.01	pfu/cell	in	a	
small volume of culture media and incubated for 1h at 37°C in constant rocking to allow the virus 
adsorb and enter. After which cells were overlaid with more volume of media and incubated at 37°C 
for	2-4	days.	Cells	were	harvested	by	scraping	the	culture	flasks	and	pelleted	by	centrifugation	(1400	
rpm 5 min RT). The cell pellet was resuspended in a small volume of culture media (1-3 ml) and 
sonicated at 50% amplitude for 2 min aprox. before being divided into aliquots and stored at -70°C. 
Viral titres were then determined by plaque assay.
  To produce the stock of in1814 was necessary to supplement the media with N,N’-hexamethylene 
bisacetamide 98% (Sigma Aldrich). This compound stimulates IE gene expression and thus enables 
in1814 to initiate productive infection (McFarlane, Daksis et al. 1992).
Stocks of dl1403 and dl1403R viruses were prepared in Vero cells and the dh1a, dh1b, dh1c and dh1f 
stocks were prepared in 49-44 cells.
	 Purified	virus	stocks
 The procedure was started as for standard virus stocks, however, when cells were pelleted 
by low speed centrifugation, the resultant supernatant was collected and subjected to high-speed 
centrifugation (18000 rpm 2h 4°C) to recover the virions from the supernatant. Viral pellets were 
resuspended in small volume of culture media (2-3 ml), sonicated as described above and aliquoted for 
storage at -70°C. Viral titres were then determined by plaque assay.
Plaque assay by toluidine blue staining
 Titers of infectious virus were determined by plaque assay on BHK cells. BHK cells were 
grown in 6-well plates and 10x serial dilutions in serum-free DMEM of viral stocks were incubated 
on BHK monolayers for 1h at 37°C. The inoculum was overlaid with DMEM containing 0.3% 
carboxymethylcellulose. After 2-3 days of incubation at 37°C, the inoculum was aspirated and 
monolayers	were	fixed	in	4%	formaldehyde	for	30	min	and	stained	with	0.1%	toluidine	blue	for	30	
min. Plaques were counted using a plate microscope.
Stocks of dl1403 and dl1403R viruses were titered in U2OS cells and the dh1a, dh1b, dh1c and dh1f 
stocks were titered in 49-44 cells.
Infections 
Cells were mock-infected or infected at the indicated m.o.i. for 2 h at 37°C in serum free DMEM, 
incubated overnight in DMEM supplemented with 10% with FBS and washed with phosphate-buffered 
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saline (PBS) before harvesting and lysis in RIPA lysis buffer (50mM Tris-Cl pH 7.4, 150mM NaCl, 
1% Triton X-100, 1% Deoxycholate, 0,1% sodium dodecyl sulfate (SDS)) in the presence of protease 
inhibitors (1μg/ml Pepstatin A, 1μg/ml Leupeptin, 1mM Iodoacetamide, 10mM 1, 10-Phenanthroline) 
and phosphatase inhibitors (0,02M Sodium Fluoride (NaF) and 2mM Sodium Orthovanadate 
(Na3VO4)) and 1μg/ml DNase for 30 minutes on ice. After centrifugation at 14000 rpm for 15 minutes 
at 4°C to remove debris, supernatants were collected as cell lysates.
During the stay at the University of Cambridge the cells were mock-infected or infected in DMEM 
supplemented with 10% fetal calf serum (FCS) and incubated overnight prior the lysis in lysis buffer 
(50mM Tris pH 7.4, 150mM NaCl, 1% Triton X-100, 0.1% Sodium Deoxycholate, 0.1% SDS, 5mM 
EDTA	,	1mM	phenylmethylsulfonyl	fluoride	(PMSF))	supplemented	with	protease	inhibitor	cocktail	
(Roche).
Western blot analysis.
 Cells were lysed in RIPA lysis buffer (50mM Tris-Cl pH 7.4, 150mM NaCl, 1% Triton X-100, 
1% Deoxycholate, 0,1% SDS) with protease inhibitors (1μg/ml Pepstatin A, 1μg/ml Leupeptin, 1mM 
Iodoacetamide, 10mM 1, 10-Phenanthroline) and phosphatase inhibitors (0,02M NaF and 2mM 
Na3VO4) and 1μg/ml DNase for 30 minutes on ice. Lysates were then centrifugated at 14000 rpm 
for 15 min at 4°C to pellet nuclei and remove debris. Supernatants were collected as cell lysates and 
protein	concentration	was	quantified	using	the	Coomassie	protein	assay	reagent	(Thermo	Scientific).	
2x loading buffer (125mM Tris pH 6.8, 4% SDS, 20% glycerol and bromophenol blue) with 100mM 
dithiotreitol (DTT) (Melford Laboratories) was added to the indicated µg of the proteins lysates and 
then the samples were heated 100°C for 5 min and resolved by SDS-Polyacrylamide gel electrophoresis 
(PAGE) on either 8% or 10% resolving gels at 200 V for 1h aprox. (Electrophoresis running buffer: 
195 mM Glycine, 24.8 mM Tris Base, 1% w/v SDS). Then the proteins were transferred to activated 
polyvinylidene	 fluoride	 (PVDF)	 membranes	 (Immobilon-P	Millipore).	 The	 PVDF	membrane	 was	
placed	underneath	the	gel	flanked	by	thick	filter	paper	(BioRad),	all	soaked	in	transfer	buffer	(192	mM	
Glycine, 25mM Tris base, 20% methanol and 0.03 % w/v SDS), and proteins were transferred using a 
Trans-Blot® Semi-Dry Electrophoretic Transfer Cell (Bio-Rad) in accordance with the manufacturer’s 
instructions. The membrane was blocked using 5% skimmed milk in TBS (150mM NaCl, 50mM Tris-
Cl pH7.5) with 0.05% Tween-20 (TBS-T) for 1h at room temperature. After washing three times using 
TBS-T (10 min per wash), the membrane was incubated with the corresponding primary antibody 
diluted in TBS-T overnight (o/n) at 4°C, washed again with TBS-T and incubated with the appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibody (Dako) diluted in TBS-T for 1h at room 
temperature. The membrane was washed and bound primary antibody was visualized by reaction with 
Amersham™	ECL™	Western	Blotting	Analysis	System	(GE	Healthcare)	and	exposure	to	x-ray	films	
(Konica Minolta and Agfa).
 For the experiments carried out at the University of Cambridge, this protocol was varied slightly 
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(Figs. R12-R17, R33-R36). Cells were lysed in lysis buffer (50mM Tris pH 7.4, 150mM NaCl, 1% 
Triton X-100, 0.1% Sodium Deoxycholate, 0.1% SDS, 5mM EDTA, 1mM PMSF) supplemented with 
protease inhibitor cocktail (Roche). Primary and secondary antibodies were incubated with 5% skimmed 
milk in TBS-T. Primary antibody was incubated o/n unless otherwise indicated. The incubation with 
the secondary antibody was performed in the dark due to its light sensitivity. And the bound primary 
antibody was detected using an Odyssey infra-red imaging system (LICOR Biosciences).
Cell	fractionation	and	preparation	of	nuclear	extracts
 Cell fractionation was performed as described previously (Meyer and Radsak 2000). Cells 
pellets were resedimented in TKM buffer (25 mM Tris-HCl pH 7.4, 5 mM KCl, 1 mM MgCl2) 
and resuspended in 0.5 ml of the same buffer (5 min 4°C). Then 0.5 ml of TKM buffer containing 
1% Nonidet P-40 (NP-40) was added and the mixture was incubated (5 min 4°C) with occasional 
vortexing. Nuclei were sedimented (1000 x g 5 min 4°C) and resuspended in TKM buffer containing 
0.5% NP-40 and 100 mM NaCl. The supernatant fraction was saved as the postnuclear fraction (called 
cytosolic fraction in this thesis). Nuclei were separated from inner membranes by centrifugation (2100 
x g 15min 4°C) through a 3 ml cushion of 1.62 M sucrose in TKM buffer. The pelleted nuclei were 
washed with TKM buffer containing 0.5% NP-40 and 100 mM NaCl. The postnuclear fraction and the 
nuclear pellet were lysed in RIPA buffer prior to SDS-PAGE and western blot analysis.
Immunoprecipitation
 Cells were lysed in lysis buffer (50mM Tris pH 7.4, 150mM NaCl, 1% Triton X-100, 0.1% 
Sodium Deoxycholate, 0.1% SDS, 5mM EDTA, 1mM PMSF or 10 mM Tris pH 7.6, 150 mM NaCl, 
1% Triton X-100, 5 mM EDTA, 1mM PMSF, 10% glycerol, 1 mM Na3VO4, 1 mM NaF) with 
protease inhibitors cocktail (Roche) for 20 min on ice. Insoluble debris was removed by centrifugation 
(14000	 rpm,	10	min	4°C)	and	cell	 lysates	were	 incubated	with	2µg	of	 the	specific	antibody	o/n	at	
4°C on a rotating wheel followed by addition of pre-cleaned Protein A/G PLUS-Agarose (Santa Cruz 
Biotechnology) beads for 2h at 4°C with constant rotation (beads were previously cleaned by washing 
and resuspending the Protein A/G PLUS-Agarose beads in lysis buffer). Beads were pelleted by 
centrifugation (13000 rpm 30 s) and washed 2x in the ice-cold lysis buffer. Beads were then repelleted 
by centrifugation (13000 rpm 1 min) and 40 µl of 2x SDS-PAGE loading buffer were added to bead 
samples and boiled for 5 min to elute the immunoprecipitated proteins from the beads prior to SDS-
PAGE analysis.
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Primary antibodies Supplier
IFI16 (1G7) Santa Cruz Biotechnology
ICP0 (11060) A gift of Dr. Roger Everett
ICP4 (58S) A gift of Dr. Roger Everett
VP16 (1246) A gift of Dr. Enrique Tabares
gD (r27) A gift of Dr. Enrique Tabares
UL42 (13C9) Santa Cruz Biotechnology
p53 (DO-1) Santa Cruz Biotechnology
BRCA1 (I-20) Santa Cruz Biotechnology
gD (LP14) A gift of Dr. Colin Crump
BRCA1 (D-20) Santa Cruz Biotechnology
EGFR A gift of Dr. Pedro Torres
GFP (ab290) Abcam
GFP (JL8) A gift of Dr. Colin Crump
UL37 A gift of Dr. Colin Crump
LaminA/C (636) Santa Cruz Biotechnology
MEK1/2 (47E6) Cell Signaling
β-actin AC-15 Sigma-Aldrich
β-actin (AC-40) Sigma-Aldrich
Secondary antibodies Supplier
Goat anti-rabbit HRP Dako
Goat anti-mouse HRP Dako
IRDye 800CW donkey anti-
mouse/rabbit
LICOR Bioscience
IRDye 680 donkey anti-mouse/
rabbit
LICOR Bioscience
Table M1. Primary and secondary antibodies used for immunoprecipitation 
and western blot analyses. The commercial source or the academic lab that 
provided the antibody are listed.
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Coomassie	staining	of	SDS-PAGE	gels
 The immunoprecipitated proteins separated by SDS-PAGE were stained with Coomassie Blue 
dye. After electrophoresis, gels were incubated with 0.1% (w/v) Coomassie Brilliant Blue R-250 in 
fixing	 solution	 (40%	methanol	 and	 10%	 acetic	 acid)	 for	 60	min	 at	RT.	The	 staining	 solution	was	
removed and gels were incubated with destain solution I (50% methanol) for 30 min at RT and destain 
solution II (40% methanol, 10% acetic acid) at RT for 1-2h or until the background staining had been 
removed.
Mass spectrometry 
	 The	proteins	visualized	by	Coomassie	blue	stain	were	identified	by	Peptide	Mass	Fingerprinting.	
Basically, the protein bands visualized by Coomassie stain were excised from the gel and the proteins 
in the excised gel band were digested using trypsin. The resulting peptides were analyzed by MALDI/
TOF mass spectrometry (MS).  MS analysis was completed by Cambridge Centre for Proteomics 
Core	Services	(http://www3.bioc.cam.ac.uk/paservices.html).	The	identification	of	each	protein	was	
determined using Mascot software.
 Off Gel analysis was performed by the Proteomics Facility of the Spanish National Centre for 
Biotechnology.
Immunofluorescence	and	confocal	microscopy
 Cells grown on glass coverslips were subjected to virus infection or not. After the appropriate 
time, the media was discarded and cells were washed with PBS (138mM NaCl, 2.7mM KCl, 8mM 
Na2HPO4,	 1.5mM	 KH2HPO4	 pH	 7.6)	 and	 fixed	 in	 4%	 paraformaldehyde	 for	 20	 min	 at	 room	
temperature. Then cells were washed with PBS-0.1% Tween (PBS-T) and permeabilised with PBS 
containing 0.1% Triton X-100 for 15 min at RT before further wash steps. Cells were blocked with 
3% bovine serum albumin (BSA) in PBS-T for 1h at RT and then primary antibodies were incubated 
in the same blocking buffer for 1h at RT. Cells were washed three times and incubated with secondary 
antibodies in the blocking buffer (1:1000 dilution)  for 1h at RT in dark. After three washes, coverslips 
were mounted onto glass microscope slides using ProLong Gold antifade reagent with the nuclear 
stain DAPI (Invitrogen). Before being visualized, the samples were stored in dark at 4°C. Confocal 
images were captured using a Leica SP5 Confocal microscope. All the images were acquired at 40x 
magnification.	Representative	images	of	the	experiments	are	shown.	Non-specific	immunoreactivity	
was assessed by including a negative control where the primary antibodies were omitted (given that 
the images were negative they are not shown in the experiments). 
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Primary antibodies Supplier
BRCA1 (I-20) Santa Cruz Biotechnology
BRCA1 (D-20) Santa Cruz Biotechnology
BRCA1 (MS110) Millipore
gD (LP2) A gift of Dr. Colin Crump
GFP (ab290) Abcam
GFP (JL8) A gift of Dr. Colin Crump
Secondary antibodies Supplier
Alexa Fluor 488 goat anti-rabbit Invitrogen
Alexa Fluor 488 goat anti-mouse Invitrogen
Alexa Fluor 488 goat anti-mouse IgG2a Invitrogen
Alexa Fluor 488 goat anti-mouse IgG1 Invitrogen
Alexa Fluor 568 donkey anti-mouse Invitrogen
Alexa Fluor 568 goat anti-rabbit Invitrogen
Alexa Fluor 568 goat anti-mouse IgG2a Invitrogen
Alexa Fluor 633 goat anti-mouse Invitrogen
Alexa Fluor 633 goat anti-mouse IgG1 Invitrogen
FACS	fluorescence	activated	cell	sorting
 GFP positive U2OS stable cells were isolated by the Flow Cytometry Facility of the University 
of Cambridge.
Molecular cloning of IFI16
	 Polymerase	Chain	Reaction	(PCR)
 PCR was performed to amplify IFI16 incorporating the c-myc tag. PCR was performed in a 
final	volume	of	50	µl	consisting	of	5	µl	10x	Buffer,	200	µM	of	each	dNTP,	0.5	µM	of	each	primer,	
2,5 U Pwo polymerase (Roche), 2.5 mM MgCl2 and 10 ng of pCMV-SPORT6-IFI16B (NM_005531) 
(IRATp970A0119D, Source Bioscience)	as		template	DNA.	PCR	conditions	used	for	amplification	of	
IFI16 were as follows: initial denaturation at 95°C for 5 min (1 cyle), denaturation at 95°C for 30 sec, 
Table M2. Primary and secondary antibodies used for immunofluorescence 
analysis. The commercial source or the academic lab that provided the 
antibody are listed.
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annealing at 55°C for 1 min, extension at 68°C	for	6	min	(25	cycles)	and	final	extension	at	68°C for 
10 min. PCR product was run on a 1% agarose gel.
Primer 5’-3’ sequence
IFI16 forward CGG GAT CCG CCA CCA TGG GAA AAA AAT ACA AGA ACA TTG
IFI16 reverse c-myc G CTG CGG CCG CTA CAG ATC TTC TTC AGA AAT AAG TTT TTG TTC GGT ACC GAA GAA AAA GTC TGG TGA AG
Agarose gel electrophoresis
 Gels were made using 100 ml TAE buffer, 1 g agarose and 3 µl ethidium bromide. Prior to 
electrophoresis, samples were mixed with DNA loading buffer and loaded onto the gel for electrophoresis 
at 100 V. Gels were visualized using UV light.
Gel	purification	of	DNA	fragments
	 DNA	 fragment	 of	 interest	 was	 gel	 purified	 using	 QIAquick® Gel Extraction kit (Qiagen) 
according to manufacturer’s instructions.
Digestion and ligation of DNA fragments
 DNA fragments were digested with the restriction enzymes BamHI and NotI (New England 
Biolabs) and cloned into the corresponding site of pHR-SIN cPPT-SGW vector (Demaison, Parsley et 
al. 2002) a gift of Dr. Paul Lehner (Cambridge Institute for Medical Research, Department of Medicine, 
University of Cambridge). Ligation of DNA fragments was carried out by incubation of the linearised 
and pre-digested vector with the DNA insert at a 1:4 ratio, 5 U of T4 DNA ligase (New England 
Biolabs)	and	T4	DNA	ligase	buffer	in	a	final	volume	of	10µl	for	2	h	at	RT.	
Transformation 
 Competent bacteria (Escherichia coli strain XL1 blue) were incubated with the plasmid of 
interest for 30 min on ice. Bacteria were heat-shocked at 37°C for 3 min and transferred to ice for 
further 2 min. Following the addition of SOB broth, the bacteria were incubated at 37°C on a shaker 
for 1h and spread onto agar plates containing ampicillin antibiotic.  After overnight incubation at 37°C 
single colonies were picked and placed into LB culture medium containing 100µg/ml ampicillin for 8 
h at 37°C on a shaker.
Plasmid	purification
 Plasmids were isolated using QUIAprep® Spin Miniprep kit (Qiagen) according to 
manufacturer’s	instructions.	The	construct	was	verified	by	digesting	and	sequencing.
DNA sequencing
	 Sequencing	was	carried	out	by	Parque	Científico	de	Madrid	and	the	analysis	of	the	sequence	
was performed using DNASTAR Lasergene 8 software.
Table M3. Primers designed to amplify the target sequence.
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Transfections
 Plasmids were transfected with jetPEI™ (Polyplus transfection) in OptiMEM® medium 
(GIBCO) following manufacturer’s instructions.
Plasmids Supplier
pHR-SIN-IFI16 Described in this thesis
pWZL hygro (empty vector) Dr. M Serrano
pWZL hygro hp53 wt Dr. M Serrano
pWZL hygro hp53 175H Dr. M Serrano (Serrano, Lin et al. 1997)
GFP-UL37 Dr. Colin Crump
GFP-UL37_N-terminus Dr. Colin Crump
GFP-UL37_∆N-terminus Dr. Colin Crump
Table M4. Plasmids used in this study. 
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1. Study of IFI16 protein in HSV-1 infection:
 As described in the introduction, host cells have developed mechanisms to detect and restrict 
viral infections, but in response, viruses have also evolved a large variety of strategies to evade these 
immune processes. Several viruses including herpesviruses use viral factors that are similar to E3 
ubiquitin ligases to inactivate the host cell defenses. The HSV-1 immediate-early protein ICP0 is an 
example of these viral factors, and previous studies have shown that, by acting as an E3 ubiquitin 
ligase, ICP0 promotes the degradation or dissociation of several cellular proteins to counteract the 
antiviral responses (reviewed in (Boutell and Everett 2013; Lanfranca, Mostafa et al. 2014)).
 Among the diverse range of proteins targeted by ICP0 is IFI16, which acts as a nuclear DNA 
sensor during HSV-1 infection (Orzalli, DeLuca et al. 2012; Li, Diner et al. 2012a; Johnson, Chikoti et 
al. 2013) to induce the expression of type I IFNs (Unterholzner, Keating et al. 2010; Orzalli, DeLuca 
et	al.	2012)	and	the	maturation	of	IL-1β	(Johnson,	Chikoti	et	al.	2013).	In	addition	to	its	roles	in	IFN-β	
induction	and	activation	of	the	inflammation	response,	IFI16	is	also	involved	in	the	silencing	of	the	
HSV-1 genome, promoting the assembly of heterochromatin on viral DNA (Orzalli, Conwell et al. 
2013) and reducing the association of important transcription factors with promoters of several HSV-1 
genes (Johnson, Bottero et al. 2014), therefore limiting the viral replication and viral gene expression.
1.1.	 Analysis	of	IFI16	levels	after	HSV-1	infection:	Effect	of	ICP0	expression	
on IFI16 stability.
 Orzalli et al.	were	the	first	to	report	a	marked	reduction	in	the	levels of IFI16 in human foreskin 
fibroblasts	(HFF)	infected	with	HSV-1	and	to	demonstrate	that	ICP0	promoted	the	IFI16	degradation	
in	a	proteasome-	and	RING	finger	domain-dependent	mechanism	(Orzalli,	DeLuca	et	al.	2012).
	 To	 confirm	 their	 findings	 regarding	 the	 ICP0-induced	 decrease	 in	 IFI16	 levels,	 human	
telomerase reverse transcriptase (hTERT) immortalized HFF cells were mock infected (uninfected) 
or infected at multiplicity of infection (m.o.i.) 10 with an ICP0 deletion mutant HSV-1 (dl1403), the 
control revertant virus (dl1403R)	and	a	mutant	HSV-1	deficient	in	all	the	immediate	early	(IE)	genes	
except ICP0 (dh1f) (Table R1). The dl1403 mutant expresses a truncated form of ICP0 that has been 
shown to be inactive. The virus used as wild type (wt) is the revertant of the dl1403 mutant in which the 
ICP0 deleted sequences have been restored (Stow and Stow 1986). Whole cell lysates were prepared 
24 hours post infection (hpi) and western blot analysis performed with antibodies to ICP4 as a control, 
ICP0,	IFI16	and	β-actin	(Fig.	R1).
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HSV-1 virus Mutation
dl1403 ICP0-
dl1403R dl1403 revertant
dh1a gH-
dh1b gH-,ICP4-
dh1c gH-,ICP4-,ICP22/47-
dh1f gH-,ICP4-,ICP22/47-,ICP27-
 
Like Orzalli et al, the levels of IFI16 protein in HFF cells were observed to decrease dramatically after 
infection with the revertant HSV-1 (dl1403R)	and	the	mutant	deficient	in	all	the	IE	genes	except	ICP0	
(dh1f), but not after the infection with the ICP0 deletion mutant virus (dl1403).	Staining	for	β-actin	
confirmed	similar	loading	of	both	mock	and	infected	cell	lysates	(Fig.	R1).
Table R1. HSV-1 viruses used in this study.
Figure R1. HSV-1 infection induces a decrease in IFI16 levels in an ICP0-dependent 
manner.  HFFs were uninfected or infected with a control revertant HSV-1 (dl1403R), a 
mutant HSV-1 that expresses ICP0 but not additional IE genes (dh1f) or an ICP0 deletion 
mutant virus (dl1403) at 10 pfu/cell. Total cell lysates were prepared at 24 hpi and 50 
µg were analyzed by western blot with antibodies to ICP4 as a control, ICP0, IFI16 and 
β-actin.
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	 These	data	confirm	the	findings	of	Orzalli	et al. regarding the reduction in the levels of IFI16 
after HSV-1 infection in HFFs when ICP0 is expressed. 
 Given that the effect of HSV-1 infection on IFI16 levels had only been studied in HFFs (Orzalli, 
DeLuca et al. 2012), it was interesting to test whether this decrease in IFI16 levels was cell type-
dependent. To analyze if this result was consistent in other human cell lines permissive for HSV-1 
infection, human osteosarcoma (U2OS) cells were infected with the mutant virus defective in ICP0 
(dl1403), the revertant virus (dl1403R) and a mutant virus defective in the glycoprotein H (dh1a) as 
a control (Table R1) (all infections were done using a m.o.i. of 10). Since the dh1 mutant virus series 
derived from gH-null HSV-1 (dh1b, dh1c and dh1f), used in the following experiments, cannot express 
ICP4, an antibody for VP16 (an HSV-1 tegument protein) was used as a control of infection, unless 
otherwise indicated. Lysates were prepared at 24 hpi and western blot analysis performed (Fig. R2).
The result obtained in U2OS cells was consistent with the previous data from HFF infection studies 
since IFI16 levels were only diminished after infection with those viruses that express ICP0, which 
are the revertant virus dl1403R and the mutant dh1a (Fig. R2). However, the HSV-1 induced decrease 
in	IFI16	levels	was	less	marked	than	in	HFF	cells.	Given	that	ICP0	is	not	required	for	efficient	HSV-1	
replication in U2OS (Yao and Schaffer 1995), it is perhaps possible that ICP0 is not as functionally 
important during infection of U2OS cells and that it cannot counteract the effect of IFI16 with the same 
efficiency	as	in	HFF	cells.
Figure R2. HSV-1 infection induces a decrease in IFI16 levels in an ICP0-dependent 
manner. U2OS cells were uninfected or infected with a mutant deficient in gH (dh1a), 
the mutant deficient in ICP0 (dl1403) or the control revertant virus (dl1403R) at 10 pfu/
cell. Total cell lysates were prepared at 24 hpi and 50 µg were analyzed by western blot 
with antibodies to VP16 as a control of infection, IFI16, ICP0 and β-actin.
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 During the course of this work, another paper was published reporting that HSV-1 infection in 
HFFs induced IFI16 degradation in an ICP0- and proteasome-dependent mechanism (Johnson, Chikoti 
et	al.	2013).	This	study	confirmed	the	data	of	Orzalli	et	al.	and	our	results	showing	that	HSV-1	infection	
of HFFs produced a decrease in IFI16 levels in an ICP0-dependent manner.
 However a third study, from Roger Everett’s group, presented data that are in apparent contrast, 
since	they	indicated	that	ICP0	is	neither	sufficient	nor	necessary	for	the	degradation	of	IFI16	during	
the course of HSV-1 infection (Cuchet-Lourenco, Anderson et al. 2013). They suggested that IFI16 
degradation was dependent on viral progression independently of ICP0 expression, but they did not 
discard an indirect effect of ICP0 in IFI16 degradation.
 To resolve this discrepancy, and to clarify whether the loss of IFI16 expression was an ICP0-
independent consequence of the progression of viral infection, HFF and U2OS cells were infected with 
mutants	of	HSV-1	deficient	for	the	expression	of	a	range	of	IE	proteins,	but	which	express	ICP0	(dh1b,	
dh1c and dh1f) (Table R1).
 The mutants dh1b, dh1c and dh1f express ICP0, but are unable to complete a normal cycle of 
viral replication due to the absence of the major transcriptional activator ICP4, thus analysis of IFI16 
levels in cells infected with these viruses allows discrimination between the effects of ICP0 expression 
and those of the progression of viral infection. In these experiments the levels of IFI16 expression 
were dramatically lower in the HFFs infected with all the mutants that express ICP0 (dh1a, dh1b, dh1c 
and dh1f) than in those cells infected with the mutant in ICP0 (dl1403) (Fig. R3-A). Thus these data 
confirm	that	ICP0	is	a	key	factor	that	governs	IFI16	stability	in	HFFs.
 IFI16 levels were also decreased in U2OS infected with the mutants that express ICP0 (dh1a, 
dh1b, dh1c and dh1f) (Fig. R3-B), but consistent with our previous data, the effect was less marked 
than in HFF cells. However, in this experiment the loss of IFI16 during the control revertant (dl1403R) 
infection of U2OS cells was more similar to that in HFF cells (compare Figs. 3A and 3B) than in 
previous	experiments	(compare	Figs.	R1	and	R2).	Cuchet-Lourenço	et al. also observed less IFI16 
degradation in U2OS infected with the wt virus than in other cells examined, including HFs (human 
diploid	fibroblasts)	and	HepaRG	cells	(a	human	hepatocellular	carcinoma	cell	line).	Although	in	our	
experiments more IFI16 degradation was observed in the U2OS cells infected with the control virus 
than	that	seen	by	Cuchet-Lourenço	and	colleagues.	This	may	be	explained	because	here	the	expression	
of	IFI16	was	analysed	after	24	hpi	whereas	Cuchet-Lourenço	et al. assayed for IFI16 12 hpi. Moreover, 
they	observed	only	a	slight	decrease	in	the	amounts	of	IFI16	after	the	infection	with	the	virus	deficient	
in ICP0 in U2OS cells whereas in HepaRG cells they noted that the rate of IFI16 loss was equivalent in 
the infection with the wt and with the mutant in ICP0 when progression of infection was equivalent in 
both	infections.	From	these	studies	they	concluded	that	the	efficiency	of	IFI16	degradation	in	response	
to HSV-1 infection is different depending on the cell type and therefore the cellular factors that govern 
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the IFI16 degradation could be defective in U2OS cells. As explained before, another possibility is 
that the lesser degradation of IFI16 in the U2OS cells infected with the wt virus compared to other 
cell	lines	is	because	the	pathways	targeted	by	ICP0	are	defective/inefficient	in	U2OS	cells	(Yao	and	
Schaffer 1995; Hancock, Cliffe et al. 2010). This hypothesis is consistent with the observation that 
the U2OS cells infected with the mutants defective in the rest of the IE genes but express ICP0 (dh1b, 
dh1c and dh1f) showed less IFI16 loss than HFF cells. Although ICP0 may play an important role since 
the U2OS cells infected with the ICP0 mutant virus which expresses the rest of the IE genes (dl1403) 
showed less IFI16 degradation than the mutant that only expresses ICP0 (dh1f).
	 To	 test	 the	 hypothesis	 of	Cuchet-Lourenço	 et al. regarding the different IFI16 degradation 
according to the cell type, the stability of IFI16 was analysed in another cell line, the Vero cell line, 
derived from the kidney of an African green monkey, which is unable to synthesize interferon (Desmyter, 
Melnick et al. 1968; Emeny and Morgan 1979) and hence highly permissive to viral infection (Rhim, 
Schell et al. 1969).
 In Vero cells the levels of IFI16 maintained the same pattern (Fig. R3-C) as seen in U2OS cells 
when infected with the different HSV-1 viruses, although the loss of IFI16 was lower than in U2OS 
cells (Figs. R2 and R3-B). However it is important to note that Vero cells differ from the previous cell 
lines analysed in that Vero cells only expressed one of the three IFI16 isoforms (Fig. 3C).
 These results showed that the expression of IFI16 displayed a similar trend in HFF, U2OS 
and	Vero	cells	after	HSV-1	infection,	thus	reconfirming	the	necessity	of	ICP0	for	IFI16	degradation.	
Furthermore,	these	data	suggest	that	the	rate	of	IFI16	degradation	does	not	correlate	with	an	efficient	
viral progression, because although the mutants dh1b, dh1c and dh1f are unable to complete a normal 
cycle of viral replication, the cells infected with these mutant viruses showed a decrease in IFI16 
levels. However, the degree of IFI16 reduction in cells infected with the mutant dh1f did not reach 
that observed in control virus infection, indicating that IFI16 degradation depends on other factors in 
addition to ICP0. Nevertheless, a control for ICP0 expression and viral progression of infection would 
have	been	required	to	allow	more	confident	interpretation	of	the	data.	
 
 Therefore, it was necessary to reexamine whether ICP0 was the main factor that orchestrates 
the loss of IFI16 or whether it was an indirect effect, as according to Cuchet-Lourenço	 et al. the 
degradation of IFI16 correlates with infection progression. And given that the mutant viruses that 
lack functional ICP0 show a replication defect (Everett, Boutell et al. 2004), the absence of IFI16 
degradation in cells infected with the ICP0-null mutant virus could be explained due to the delay in the 
infection progression rather than due to the absence of ICP0 per se.
	 Therefore,	to	further	explore	the	hypothesis	of	Cuchet-Lourenço	et al. and discard the possibility 
69
Results
that the observed absence of IFI16 loss in cells infected with the ICP0-null mutant was due to a delay in 
the viral progression, the IFI16 levels were analysed in cells infected with the mutant in ICP0 (dl1403) 
at higher m.o.i. than that of the control virus (dl1403R).	This	experiment	was	performed	firstly	with	
U2OS	because	if	ICP0	is	not	required	for	efficient	HSV-1	replication	in	U2OS	cells	(Yao	and	Schaffer	
1995), the infections with the control virus and the ICP0-null mutant virus would be expected to 
progress	equally	efficiently.	However	Cuchet-	Lourenço	et al. found that the viral gene expression 
during ICP0-null mutant infection of U2OS cells was a bit delayed; therefore the experiment was 
performed using the control virus at an m.o.i of 20 and the mutant in ICP0 at an m.o.i. of 45. The 
other mutants were infected using an m.o.i. of 20 (Fig. R4). As expected, the levels of IFI16 were 
not decreased during ICP0-null mutant virus (dl1403) infection, although it seems, as judged by the 
different	rates	of	gD	expression,	that	this	infection	did	not	progress	equally	efficiently	as	the	control	
Figure R3. ICP0 is necessary for the 
decrease in IFI16 levels during HSV-
1 infection. (A) HFF, (B) U2OS and (C) 
Vero cells were infected with different 
mutants in gH (dh1a), IE genes (dh1b, 
dh1c, dh1f and dl1403) and the ICP0 
rescued virus (dl1403R) at 10 pfu/cell. 
Total cell lysates were prepared at 24 
hpi and 20 µg were analyzed by western 
blot with antibodies to IFI16 and β-actin.
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(dl1403R) infection (Fig. R4). gD glycoprotein is incorporated into the viral particle and part of the 
gD detected represents glycoprotein persisting from the input virus used for the infection. Given that 
gD staining was not the most appropriate control for viral progression, we decided to use another viral 
protein synthesized de novo as a control of viral progression. The expression of UL42, a protein that 
is early expressed during HSV-1 infection, was used to compare the rates of viral progression (Fig. 
R4). As can be observed from the UL42 expression levels, the infection with the mutant in ICP0 did 
not	progress	as	efficiently	as	the	control	infection,	even	using	2.25	more	pfu/cell.	On	the	other	hand,	
another observation that supports our hypothesis is that the cells infected with the mutants dh1b, dh1c 
and dh1f present a defective progression of infection (observe UL42 staining) due to the absence of 
ICP4, however, they still did show IFI16 degradation (Figs. R3 and R4).
 To further explore the previous result and ensure that the infection with the ICP0-null mutant 
virus	progressed	equally	efficiently,	U2OS	cells	were	infected	with	a	greater	difference	of	m.o.i	using	
the mutant dl1403 virus at 20 pfu/cell and the revertant virus dl1403R at 4 pfu/cell (Fig. R5).
Figure R4. ICP0 is necessary for the decrease in IFI16 levels during HSV-1 infection. 
U2OS were infected with the mutant dl1403 at 45 pfu/cell, and with the revertant 
virus (dl1403R) and the mutant virus dh1a, dh1b, dh1c and dh1f at 20 pfu/cell. Total 
cell lysates were prepared at 24 hpi and 20 µg were analyzed by western blot with 
antibodies to IFI16, UL42, gD and β-actin.
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 Even in this condition, the result obtained in U2OS was consistent with our previous data since 
IFI16 levels were once again dramatically diminished after infection with the control virus comparing 
with the ICP0 mutant virus infection (Fig. R5). However, despite the mutant virus being used at higher 
multiplicity,	this	infection	still	progressed	slightly	less	efficiently	than	the	control	infection	as	judged	
by the UL42 levels. The levels of gD detected in cells infected with the mutant might be expected 
to be similar than those observed after control infection since the mutant virus was used at higher 
multiplicity and part of the gD detected represents glycoprotein persisting from the input virus used 
for the infection. Moreover, the mutant infection progressed similarly to control infection. However, 
the levels of gD after mutant infection were much lower than those from control infection. This may 
indicate that the differences in the progression rate were more pronounced at late stages of viral 
expression.
 To extend this result, the levels of IFI16 were examined in HFFs infected with the control 
virus at m.o.i of 10 or 20 and with the mutant in ICP0 at much higher multiplicity, m.o.i of 200 
or 250, because HFFs are less permissive for the mutant infection (Fig. R6). IFI16 levels were still 
Figure R5. IFI16 levels are slightly decreased in U2OS cells infected with the ICP0 
mutant when the viral infection progress efficiently. U2OS were infected with the 
mutant dl1403 at 20 pfu/cell and with the corresponding rescued virus dl1403R at 
4 pfu/cell. Total cell lysates were prepared at 24 hpi and 20 µg were analyzed by 
western blot with antibodies to IFI16, UL42, gD and β-actin.
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slightly diminished in the cells infected with the ICP0 mutant virus (dl1403) even though the infection 
progressed	with	almost	comparable	efficiency	to	the	control	infection	in	the	HFF	cells	of	the	left	panel,	
as shown by the UL42 expression levels. However, the mutant virus infection still progressed less 
efficiently	than	the	control	virus	infection.	
 Altogether,	these	data	confirm	that	ICP0	plays	a	role	in	IFI16	degradation.	The	involvement	
of	 ICP0	was	confirmed	 from	results	obtained	by	study	of	 three	 independent	cell	 lines:	 two	human	
cell lines, normal (HFFs) and tumoral (U2OS), and a monkey cell line (Vero). Despite their different 
origins, all of them displayed the same pattern of IFI16 destabilization in an ICP0-dependent manner.
 During the writing of this work, another study has observed that ICP0 is necessary but 
not	 sufficient	 for	 IFI16	degradation	 (Diner,	Lum	et	 al.	2015b),	 suggesting	another	viral	or	 cellular	
mechanism, different from other ICP0 targets, that contributes to IFI16 degradation.
	 In	view	of	the	findings	from	other	groups	and	our	own	results,	it	is	tempting	to	conclude	that	
ICP0	is	essential	for	an	efficient	IFI16	degradation,	although	the	degree	of	IFI16	loss	varies	between	
different cell lines, implying that other factors still unknown are involved in IFI16 degradation.
Figure R6. IFI16 levels are slightly or not decreased in HFF cells infected with 
the ICP0 mutant virus when the viral infection progress efficiently. HFF were 
infected with the mutant dl1403 at 200 pfu/cell (left panel) or 250 pfu/cell (right 
panel) and with the corresponding rescued virus dl1403R at 10 pfu/cell (left 
panel) or 20 pfu/cell (right panel). Total cell lysates were prepared at 24 hpi and 
30 µg were analyzed by western blot with antibodies to IFI16, UL42 and β-actin.
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1.2. Analysis of the stability of IFI16-interacting proteins after HSV-1 
infection:
 As explained in the introduction, in addition to its role as a sensor for pathogen DNA in the 
innate immune response, IFI16 has also been implicated in the DNA damage response (DDR) due to its 
physical interaction with the tumor suppressor proteins p53 and BRCA1 (Johnstone, Wei et al. 2000; 
Aglipay, Lee et al. 2003; Song, Alimirah et al. 2008; Liao, Lam et al. 2011).
The	HIN-A	domain	of	 IFI16	binds	 the	C-terminus	of	p53,	 likely	preventing	nonspecific	p53-DNA	
interactions, whereas the HIN-B domain of IFI16 recognizes the core domain of p53 stabilizing p53 
binding to DNA (Liao, Lam et al. 2011). On the other hand, the PYRIN domain of IFI16 interacts with 
BRCA1 promoting p53-dependent apoptosis in presence of cellular damage or oncogenic stimuli. 
Indeed, IFI16 is a component of the DNA repair multi-protein complex known as BASC (BRCA1-
associated genome surveillance complex) (Aglipay, Lee et al. 2003). In turn, both p53 and BRCA1 are 
proteins known to interact with the HSV-1 genome (Wilcock and Lane 1991; Maul, Jensen et al. 1998; 
Lilley, Chaurushiya et al. 2011; Hsieh, Kuta et al. 2014).
 The tumor suppressor p53 is critical for antiviral defense by inducing apoptosis and enhancing 
type I IFN responses (reviewed in (Rivas, Aaronson et al. 2010)). In the context of HSV-1 infection, 
an early study showed that p53 is recruited to nuclear HSV-1 DNA replication compartments (Wilcock 
and Lane 1991) and	more	 recently	 two	 p53	 responsive	 elements	 (p53RE)	 have	 been	 identified	 in	
the HSV-1 genome, where p53 binds both in vitro and in vivo suggesting a mechanism of viral gene 
regulation by p53 (Hsieh, Kuta et al. 2014).
 BRCA1 plays a central role in DNA repair controlling the cellular responses to DNA damage 
(Scully, Chen et al. 1997a; Scully, Chen et al. 1997b). Like other DNA repair proteins, the incoming 
HSV-1 genomes affect BRCA1 protein since BRCA1 accumulations are dispersed from nuclear 
domains after wild type HSV-1 infection (Maul, Jensen et al. 1998), leading to a redistribution of 
BRCA1 in accumulations very close to incoming viral genomes, but this early response to HSV-1 
infection is inhibited by ICP0 (Lilley, Chaurushiya et al. 2011). 
 Whether IFI16 recognizes foreign DNA together with other proteins such as p53 and BRCA1 
is unknown. Knowing that there are direct interactions between IFI16 protein with BRCA1 and p53, 
the expression levels of these proteins were analysed after HSV-1 infection.  Our hypothesis was that 
as IFI16 is degraded during HSV-1 infection, the levels of these proteins could also decrease after 
HSV-1 infection if they are interacting directly with IFI16 in the same complex to bind HSV-1 DNA. 
However, the degradation of p53 and/or BRCA1 would not necessarily imply that they interact with 
IFI16 to bind the viral DNA, and vice versa the absence of p53 and/or BRCA1 degradation would not 
necessarily mean that these proteins do not participate with IFI16 in the early recognition of HSV-1 
genome.
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1.2.1. Study of p53 stability after HSV-1 infection:
 The tumor suppressor p53 is a short-lived protein whose levels are maintained low in normal 
cells mainly by the action of Mdm2 (double minute 2 protein), a cellular ubiquitin ligase (Haupt, 
Maya et al. 1997). However, after stress stimuli p53 is stabilized and activated by post-translational 
modifications	that	affect	its	interaction	with	Mdm2	(reviewed	in	(Lavin	and	Gueven	2006)).	Therefore	
the	stabilization	of	p53	is	crucial	to	initiate	an	efficient	response	to	cellular	stress.
 Viral infections represent an important cellular stress and, as mentioned before, p53 is critical 
for the antiviral defense. The transcription of the p53 gene is induced by type I IFNs due to the presence 
of ISREs (IFN-stimulated response elements) in its promoter (Takaoka, Hayakawa et al. 2003). 
Moreover, p53 is activated indirectly by type I IFNs to induce apoptosis in the infected cells (Takaoka, 
Hayakawa et al. 2003; Townsend, Scarabelli et al. 2004; Ding, Lee et al. 2006; Pampin, Simonin et 
al. 2006) and in turn p53 enhances type I IFN signaling and production because several IFN-inducible 
genes (IRF9, IRF5, ISG15 and TLR3) are direct transcriptional targets of p53 (Hummer, Li et al. 
2001; Mori, Anazawa et al. 2002; Munoz-Fontela, Macip et al. 2008; Taura, Eguma et al. 2008). To 
overcome the proapoptotic and antiviral activities of p53, some viruses have evolved mechanisms to 
counteract the p53 responses, for example leading to p53 degradation (Scheffner, Werness et al. 1990; 
Moore, Horikoshi et al. 1996; Querido, Marcellus et al. 1997; Steegenga, Riteco et al. 1998; Querido, 
Blanchette et al. 2001; Pampin, Simonin et al. 2006).
 During HSV-1 infection, previous studies have demonstrated that although ICP0 promotes 
the ubiquitination of p53 (Boutell and Everett 2003), p53 levels were actually stabilized in HSV-
1 infection of HFF-2 cells, a nontransformed human primary cell line derived from foetal foreskin 
fibroblasts,	and	this	stabilization	occurred	independently	of	ICP0	(Boutell	and	Everett	2004;	Boutell,	
Canning et al. 2005). 
 However the stabilization of p53 by HSV-1 infection was cell type dependent since the wt p53 
expressed by U2OS cells was not stabilized during HSV-1 infection, in fact the total levels of p53 were 
reduced independently of the presence or absence of ICP0 (Boutell and Everett 2004).
 To extend these previous results, the p53 levels were examined after HSV-1 infection in the 
HFF and U2OS cell lines used in our previous experiments (Figs. R1 and R2).
 In HFFs the p53 levels were stabilized after infection with the control HSV-1 (dl1403R) 
(Fig. R7), in agreement with the previous results from Boutell and colleagues (Boutell and Everett 
2004; Boutell, Canning et al. 2005), while infection with dl1403, at elevated m.o.i. to overcome the 
requirement for ICP0-mediated transactivation, resulted in levels of p53 that were only somewhat 
lower than those observed in control virus infection (Fig. R7). Infection with a mutant virus that 
expresses ICP0 but no additional IE gene products (dh1f) showed no increase in p53 stabilization 
compared to mock cells (Fig. R7). These results suggest that p53 stabilization in HFF cells does not 
depend exclusively on ICP0, although its expression helps p53 stabilization. As Boutell et al. proposed 
it is possible that p53 stabilization requires the ability of ICP0 to induce viral gene expression (Boutell 
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and Everett 2004).
The data obtained in U2OS cells were also consistent with previously published results from Boutell 
and Everett (Boutell and Everett 2004) since p53 levels were not stabilized after HSV-1 infection 
independently of ICP0 expression (Fig. R8). 
Figure R7. HSV-1 infection of HFF cells induces 
an increase in p53 levels in an ICP0-independent 
manner.  HFFs were uninfected or infected with a 
control revertant HSV-1 (dl1403R), a mutant HSV-
1 that expresses ICP0 but not additional IE genes 
(dh1f) or an ICP0 deletion mutant virus (dl1403) at 
10 pfu/cell. Total cell lysates were prepared at 24 
hpi and 50 µg were analyzed by western blot with 
antibodies to ICP4, ICP0 IFI16, p53 and β-actin.
Figure R8. HSV-1 infection of U2OS cells induces a 
slight decrease in p53 levels in an ICP0-independent 
manner. U2OS cells were uninfected or infected 
with a mutant deficient in gH (dh1a), the mutant 
deficient in ICP0 (dl1403) or the control revertant 
virus (dl1403R) at 10 pfu/cell. Total cell lysates 
were prepared at 24 hpi and 50 µg were analyzed 
by western blot with antibodies to IFI16, ICP0, p53, 
VP16 and β-actin.
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	 In	 conclusion,	 these	 results	 support	 previous	 published	findings	 and	 confirmed	 that	HSV-1	
infection does not reduce p53 stability in an ICP0-dependent manner, arguing against the idea that 
HSV-1 ICP0 targets IFI16 complexed with p53. However, this result does not necessarily imply that 
p53 does not interact with IFI16 to bind the HSV-1 DNA.
1.2.2.	 Study	of	BRCA1	stability	after	HSV-1	infection:
 As stated in the introduction, infection by many viruses induces the activation of the DNA 
damage signaling pathways through the same cellular cascades that are activated by genomic DNA 
damage. And in turn, viruses have developed complex mechanisms to inactive or activate these 
pathways in order to facilitate viral replication (reviewed in (Turnell and Grand 2012)).
 HSV-1 has a complex relationship with the DNA damage and repair machinery. During HSV-
1 infection, DNA repair proteins are activated and accumulated at sites of viral genomes (Lilley, 
Chaurushiya	et	al.	2011).	Some	of	them	are	beneficial	for	HSV-1	replication	(Taylor	and	Knipe	2004;	
Lilley, Carson et al. 2005; Mohni, Livingston et al. 2010; Placek and Berger 2010) while others are 
detrimental to HSV-1 replication (Parkinson, Lees-Miller et al. 1999; Taylor and Knipe 2004; Lilley, 
Chaurushiya et al. 2011). However, the antiviral activity of the proteins deleterious for the viral infection 
is	overcome	in	part	through	the	E3	ubiquitin	ligase	activity	of	ICP0.	Specifically	ICP0	ubiquitinates	
and directs the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein 
kinase (DNA-PKcs) (Lees-Miller, Long et al. 1996; Parkinson, Lees-Miller et al. 1999) and the DNA 
damage E3 ubiquitin ligases RNF8 and RNF168 (Lilley, Chaurushiya et al. 2010).
 As described in the introduction, DNA-PK plays a central role in DNA double-strand break 
repair via non-homologous end-joining (NHEJ) pathway and in V(D)J recombination. In addition it 
plays newly emerging roles in mitosis, transcription, maintenance of telomeres and in viral infections 
(reviewed in (Jette and Lees-Miller 2015)). In fact, it has been shown that DNA-PK acts as a DNA 
sensor that induces the production of type I IFN, cytokines and chemokines in an IRF-3-dependent 
manner during infection with DNA viruses, such as HSV-1 (Ferguson, Mansur et al. 2012). RNF8 
and RNF168 are key mediators in the ATM-dependent signaling pathway. They are cellular RING 
finger	E3	ubiquitin	ligases	that	play	a	central	role	in	the	DNA	double-strand	break	response	by	poly-
ubiquitinating histones, a signal that promotes the accumulation of the downstream effectors such as 
53BP1 and BRCA1 to the damaged chromatin (Huen, Grant et al. 2007; Kolas, Chapman et al. 2007; 
Mailand, Bekker-Jensen et al. 2007; Wang and Elledge 2007; Doil, Mailand et al. 2009). Similarly, 
RNF8 and RNF168 coordinate the recruitment of DNA repair factors to viral genomes during HSV-1 
infection; therefore identifying both proteins as components of the host antiviral defense against HSV-
1 (Lilley, Chaurushiya et al. 2011).
 The tumor suppressor BRCA1 is a 220-KDa protein that plays roles in several pathways that 
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maintain genomic stability, including protein ubiquitination (reviewed in (Wu, Koike et al. 2008)), 
chromatin remodeling (Bochar, Wang et al. 2000), transcriptional regulation (reviewed in (Rosen, 
Fan et al. 2006)), apoptosis (Shao, Chai et al. 1996; Harkin, Bean et al. 1999) and the DNA-damage 
response pathways through DNA damage-induced cell cycle checkpoint activation (Xu, Kim et al. 
2001; Yarden, Pardo-Reoyo et al. 2002) and DNA damage repair, particularly dsDNA breaks, via NHEJ 
(Zhong, Chen et al. 2002a; Zhong, Boyer et al. 2002b; Bau, Fu et al. 2004; Wang, Chou et al. 2006; 
Zhuang, Zhang et al. 2006) and homologous recombination (HR) (Moynahan, Chiu et al. 1999; Stark, 
Pierce et al. 2004). Like other DNA repair proteins, BRCA1 relocates to DNA damage sites forming 
nuclear foci (Scully, Chen et al. 1997b). As mentioned previously, what is known about BRCA1 during 
HSV-1 infection is that BRCA1 accumulations are dispersed from its nuclear domains in the initial 
phases of HSV-1 infection (Maul, Jensen et al. 1998) and redistributed proximal to incoming viral 
genomes, but this early response to HSV-1 infection is inhibited by ICP0 (Lilley, Chaurushiya et al. 
2011). 
 Given that ICP0 induces the degradation of some proteins involved in DNA damage responses 
including the DNA sensor IFI16, which is known to interact with BRCA1 in the BASC complex, we 
wondered if ICP0 could also affect BRCA1 stability during HSV-1 infection. 
 To test the effect of ICP0 on BRCA1 levels, HFF and U2OS cells were infected with either the 
ICP0-null HSV-1 (dl1403) or the control revertant HSV-1 (dl1403R) at m.o.i. of 20. Lysates prepared 
from these cells 24 hpi were analysed by western blot using an antibody against BRCA1 (Santa Cruz 
I-20) (Fig. R9).
Figure R9. HSV-1 infection induces a marked 
increase in the levels of a 120-KDa protein 
reactive with an antibody specific for BRCA1 in 
an ICP0-independent manner in HFF and U2OS 
cells. HFF and U2OS cells were infected with the 
mutant deficient in ICP0 (dl1403) or the revertant 
virus (dl1403R) at 20 pfu/cell. Total cell lysates 
were prepared at 24 hpi and 25 µg were analyzed 
by western blot with antibodies to BRCA1 (I-20), 
IFI16, VP16 and β-actin.
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 Unlike IFI16 levels, which are decreased after infection with the control revertant virus but 
are maintained after infection with the ICP0 deletion mutant  virus, HSV-1 infection with both the 
revertant and the mutant virus provoked a marked increase of an approximately 120-KDa protein 
reactive with the antibody for BRCA1 (Fig. R9), hereafter referred to as the 120 kDa protein.
 Given that canonical BRCA1 protein has an apparent molecular weight on SDS-PAGE of 
around 220-230 KDa, this 120-KDa protein could be a potential variant of BRCA1, a product of 
BRCA1 cleavage induced by HSV-1 or another protein. In any case, it can be concluded from these 
data that ICP0 is not involved in the up-regulation of this protein. However, it is important to note that 
this conclusive data relating to the ability of HSV-1 to regulate BRCA1 expression levels could not be 
validated since detection of a protein at the previously reported molecular weight was not observed in 
our western blot analysis. 
 As described in the introduction, HSV-1 promotes a partial activation of the ATM-dependent 
signaling pathways, since infection induces the activation of ATM and downstream targets including 
Nbs1, Chk2 and p53 (Lilley, Carson et al. 2005; Shirata, Kudoh et al. 2005; Li, Baskaran et al. 2008), 
however ICP0 mediates the degradation of RNF8 and RNF168 (Lilley, Chaurushiya et al. 2010), which 
are key mediators in this DDR pathway. Therefore, this suggests that HSV-1 has evolved to modulate 
components of the same DDR pathway temporally and differentially to ensure its own replication. 
Given that BRCA1 is an important downstream target in the ATM-dependent pathway, our result was 
intriguing because while proteins repressive for the viral infection seem to be degraded, proteins that 
facilitate the infection are retained (Lilley, Chaurushiya et al. 2011). Therefore, as this unknown protein 
could be advantageous for the virus a more detailed characterization of the 120-kDa protein revealed 
by	a	BRCA1	specific	antibody	on	western	blot	was	undertaken.
79
Results
2.	Study	of	the	120	KDa-protein,	reactive	with	an	antibody	specific	for	
BRCA1,	induced	after	HSV-1	infection:
2.1. Analysis of the induction of the 120 KDa-protein after viral infection of 
a range of cell lines.
 
 Given that we had observed a marked increase in the levels of a potential BRCA1 variant in 
HFF and U2OS cells infected with HSV-1 (Fig. R9), it was of interest to ascertain whether this result 
was consistent in a range of cells susceptible to infection by HSV-1 or whether this response was 
specific	to	HFF	and	U2OS	cells.	To	address	this	question,	the	breast	epithelial	cancer	cell	lines,	MCF7	
and MDA-MB-231, were infected with the control revertant HSV-1 (dl1403R) or with vaccinia virus 
(VACV, another DNA virus belonging to the poxvirus family) at m.o.i.s of 10. These experiments 
showed that infection with HSV-1, but not VACV, led to an upregulation of the 120 kDa-protein in 
MCF7 and MDA-MB-231 cells (Fig. R10-A). Both infected cell lines were collected at 24 hpi because 
HSV-1 and VACV have similar kinetics of infection (Fields 1990). The absence of upregulation of 
the	120	KDa-protein	in	HFFs	after	VACV	infection	was	confirmed	in	experiments	where	HFFs	were	
infected with HSV-1 (dl1403R) and VACV at m.o.i. 10 (Fig. R10-B). Consistent with the previous 
data, HFFs infected with VACV did not show an increase in the expression of the 120 KDa-protein.
Figure R10. HSV-1 infection, but not VACV infection, induces a marked increase in the levels 
of a 120-KDa protein reactive with an antibody specific for BRCA1 in MCF-7, MDA-MB-231 
and HFF cells. (A) MCF-7 and MDA-MB-231 cells were infected with either HSV-1 (dl1403R) or 
VACV (WR strain) at 10 pfu/cell. Total cell lysates were prepared at 24 hpi and 50 µg of total 
protein were analysed by western blot with antibodies to BRCA1 (I-20) and β-actin. (B) HFF 
cells were infected with either HSV-1 (dl1403R) or VACV (WR strain) at 10 pfu/cell. Total cell 
lysates were prepared at 24 hpi and 50 µg of total protein were analysed by western blot with 
antibodies to BRCA1 (I-20) and β-actin.
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 Although VACV is a large DNA virus, like HSV-1, VACV replicates in the cytoplasm of host 
cells whereas HSV-1 replicates in the nucleus. To test whether this difference could explain the absence 
of the 120 KDa-protein after VACV infection, HFFs were infected with human cytomegalovirus 
(HCMV),	 a	 β	 herpesvirus	 that	 also	 replicates	 in	 the	 nucleus.	 Since	HCMV	 replicates	with	 slower	
kinetics than HSV-1 (Fields 1990), HFFs infected with HCMV at m.o.i. of 10 were harvested at 48 
h.p.i. We found that HCMV infection did not induce the expression of the 120 KDa-protein,	confirming	
that	the	appearance	of	this	protein	was	specific	for	HSV-1	infection	(Fig.	R11).
A time course experiment was also performed to analyse the kinetics of the induction of expression 
of the 120 KDa-protein after HSV-1 expression, because in previous experiments the expression of 
this protein was only analysed at 24 h.p.i. HSV-1 (dl1403R) infection was done using 10 pfu/cell (Fig. 
R11).	This	time	course	experiment	revealed	that	upregulation	of	the	120	kDa-protein	was	first	detected	
at 4 hours of HSV-1 lytic infection and increased as HSV-1 infection proceeded (Fig. R11).
	 From	these	data	it	can	be	concluded	that	the	upregulation	of	the	120	KDa-protein	is	specific	
to HSV-1 infection because, at least VACV and HCMV infections did not induce expression of this 
protein. Although an extensive cytopathic effect was observed when infected cells were collected, a 
western	blot	control	for	VACV	and	HCMV	infection	would	have	been	a	better	control	for	efficient	
infection with both viruses. Furthermore, the upregulation occurred in all the cells lines analysed. 
 It is important to note that in many of the western blot analyses, a weak band around 80 KDa 
appeared together with the 120 KDa band in the lane corresponding to the HSV-1-infected cells. But 
we decided to focus on the strong 120 KDa-protein, which was consistently expressed. Moreover, a 
Figure R11. HCMV does not induce the 120 KDa-protein expression and its 
upregulation during HSV-1 infection increases as infection progresses in HFF 
cells. HFF cells were infected with HCMV (strain AD169) at 10 pfu/cell and 
harvested at 48 hpi. HHF cells were infected with HSV-1 at 10 pfu/cell and the 
expression of the 120 KDa-protein was monitored over the time. 50 µg of total 
protein were analysed by western blot with antibodies to BRCA1 (I-20) and 
β-actin.
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very weak band (more intense in MCF7 cells) can be seen in the mock cells but its molecular weight 
was a bit higher than the 120 KDa band observed on infected cells. One possibility to explain that 
was that the band on mock cells was the same 120 KDa protein but at a different post-translational 
modification	status.
2.2.	 Evaluation	of	the	possible	involvement	of	viral	genes	in	the	upregulation	
of the 120 KDa-protein during HSV-1 infection:
 Given that preliminary experiments showed that ICP0 is not a key factor in the increase of the 
120 KDa-protein levels (Fig. R9), a different panel of HSV-1 mutant viruses (Table R2) was used to 
study which viral proteins could have a role in the upregulation of the 120 KDa-protein.
VP16	is	a	tegument	protein,	released	into	host	cell	upon	virus	entry,	that	is	essential	for	efficient	viral	
replication because it is the transcriptional activator of the IE genes (Campbell, Palfreyman et al. 1984) 
and that also plays a role during virion assembly (Ace, Dalrymple et al. 1988; Weinheimer, Boyd et al. 
1992). To assay whether VP16 was involved in induction of the 120 KDa-protein, HFFs were infected 
with the HSV-1 mutant in1814  (derived from HSV-1 strain 17 ) (Table R2 ), which contains a 12-base-
pair insertion in the gene encoding VP16 that compromises its transactivating function (Ace, McKee 
et al. 1989) (Fig. R12). 
HFFs	were	also	infected	with	a	mutant	deficient	in	the	viral	glycoprotein	E	(∆gE)	(Table	R2)	to	check	
if this mutant could also provoke the upregulation of the 120 KDa-protein (Fig. R12). This mutant 
was	tested	because	we	had	planned	to	do	immunofluorescence	experiments	to	study	the	localization	
of the 120 KDa-protein and the complex of the viral glycoproteins gE/gI is well known to form a 
receptor for the Fc domain of immunoglobulin G (IgG) (Baucke and Spear 1979; Johnson and Feenstra 
1987; Johnson, Frame et al. 1988). This Fc-receptor (FcR) has a strong capacity to bind human IgGs, 
decreasing	affinity	for	rabbit,	goat	and	sheep	and	not	affinity	for	murine	IgGs	(reviewed	in	(Dubin,	
Fishman	et	al.	1992)).	Therefore,	to	avoid	non-specific	signals	due	to	the	binding	of	gE/gI	to	the	Fc	
portion of the rabbit and goat primary and secondary antibodies, it was convenient to use a virus 
deficient	in	gE.	The	mutant	in	gE	was	preferred	over	an	HSV-1	mutant	lacking	gI	alone,	because	gE	
alone	can	bind	IgG	(although	with	lower	affinity	than	the	Fc	binding	observed	with	gE	and	gI	together)	
whereas gI alone does not bind IgG (Bell, Cranage et al. 1990; Dubin, Frank et al. 1990; Hanke, 
Graham et al. 1990).
Furthermore, to test whether the observed band was induced by an unexpected effect of the BHK 
(baby hamster kidney cells) debris present in the viral stocks, HFFs were exposed to concentrated 
supernatants	from	uninfected	BHKs	and	were	also	infected	with	purified	HSV-1	viruses	(MP,	medium-
purified	viruses)	in	addition	to	the	cell-associated	viruses	(CA)	(Fig.	R12).	
Lysates prepared from HFFs 24 h.p.i with wt (strain 17)  or the different mutant HSV-1 virus at a m.o.i. 
of 20, were analysed by western blot with the previously used rabbit polyclonal anti-BRCA1 antibody 
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(Santa Cruz I-20) together with a mouse monoclonal antibody anti-gD (LP14) as a control of infection 
and a mouse monoclonal antibody anti-actin as a loading control (Fig. R12).
Mutant
Protein 
mutated
Description
∆gE gE LacZ insertion within the gene 
encoding gE (US8)
in1814 VP16 12-base-pair insertion in the gene 
encoding VP16 
tsk ICP4 Temperature sensitive mutation in the 
gene encoding ICP4
in1382 VP16
ICP4 
ICP0
12-base-pair insertion in the gene 
encoding VP16
Temperature sensitive mutation in the 
gene encoding ICP4
Deletion	within	the	RING	finger	of	
ICP0
As shown in Fig. R12, infection with all the different HSV-1 viruses, either cell-associated (CA) or 
medium-purified	stocks	(MP),	led	to	the	upregulation	of	the	120	KDa-protein,	in	contrast	no	increased	
expression of this protein was noted in HFFs exposed to BHK debris. The different conditions used 
for the western blot analysis (primary antibodies were incubated with 5% skimmed milk 1h at RT, for 
more	specifications	see	Materials	and	Methods)	might	explain	why	the	120	kDa	band	was	less	marked.
 To further explore these data, HFFs were next infected with the mutant tsK (isolated from 
Table R2. HSV-1 mutants used in this study.
Figure R12.  Infection with wt HSV-1 
and different HSV-1 mutants induces 
an increase in the levels of the 120-
KDa protein reactive with the anti-
BRCA1 antibody I-20. HFF cells were 
infected with wt HSV-1 (strain 17 CA 
stock), the mutant deficient in gE 
(strain SC16 CA and MP stocks) and 
the mutant in1814 (strain 17 CA and 
MP stocks) at 20 pfu/cell. HFFs were 
also exposed to BHK debris. Total cell 
lysates were prepared at 24 hpi and 
were analysed by western blot with 
antibodies to BRCA1 (I-20), gD and 
β-actin.
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HSV-1	 strain	17+)	 (Table	R2)	 at	m.o.i.	 20	 (Fig.	R13).	This	mutant	 carries	 a	 temperature	 sensitive	
mutation in the DNA binding domain of ICP4, allowing virus replication to proceed at 31°C but not at 
37-38°C (Preston 1979; Davison, Preston et al. 1984). HFFs infected with this virus were incubated at 
37°C and harvested 24 h.p.i. Lysates prepared from these cells were analysed by western blot using the 
antibody against BRCA1 (Santa Cruz I-20).
This experiment showed that even in the absence of functional ICP4 the band of 120 KDa still appeared 
(Fig. R13), although the induction was less marked. As might be expected, gD staining showed that 
infections	with	the	ICP4	mutant	tsK	seem	to	progress	less	efficiently	than	with	wt	strain	17	virus.
 It is important to note that previous publications showed that the defect in IE gene transactivation 
of the mutant in1814 was observed at low m.o.i., however, IE gene transinduction by VP16 was not 
essential for viral growth at high m.o.i. (at m.o.i. 1 the viral gene expression in in1814 relative to that 
observed in wt HSV-1 was reduced by 33-fold, at m.o.i. 10 it was reduced by 6-fold but in1814 was 
not detectably impaired at m.o.i. 100) (Ace, McKee et al. 1989). Since we infected at m.o.i. 20, IE gene 
expression,	and	hence	the	viral	growth	should	not	be	severely	affected	(as	reflected	by	gD	staining	in	
Figs. R12 and R13).
Moreover, the mutant tsk carries a lesion in ICP4 that affects its normal functions at non-permissive 
temperatures, including the capacity of ICP4 to repress IE gene expression, thus, in infection with tsk 
virus the other IE proteins are over-produced (Watson and Clements 1978; Preston 1979; DeLuca, 
McCarthy et al. 1985).
Therefore to reduce further viral gene expression, HFFs were infected with the mutant in1382 (Preston 
Figure R13. Infection with different mutants of HSV-1 induces expression of the 120-
KDa protein reactive with the anti-BRCA1 antibody I-20. HFF cells were infected with 
wt HSV-1 (strain 17 CA and MP stock), the mutant in1814 (CA), the mutant deficient in 
gE (CA stock) and the mutant TSK (CA and MP stocks) at 20 pfu/cell. Total cell lysates 
were prepared at 24 hpi and were analysed by western blot with antibodies to BRCA1 
(I-20), gD and β-actin.
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and McFarlane 1998; Preston, Rinaldi et al. 1998), which contains the insertion in the VP16 coding 
sequence derived from in1814, the temperature sensitive mutation in the ICP4 coding sequence 
derived	from	tsK	and	additionally,	a	deletion	within	the	RING	finger	domain	of	ICP0	rendering	it	non-
functional	(Table	R2)	(Fig.	R14).	Furthermore,	to	further	study	if	this	effect	was	specific	to	HSV-1,	
HFFs were infected with HSV-2, another member of the genus Simplexvirus which is closely related 
to HSV-1 (Fig. R14). In this experiment all the infections were carried out at m.o.i. of 3 instead of the 
previously used of 10-20 in order to study if the same result is observed at lower multiplicities, because 
as stated previously when cells are infected with low number of these mutant viruses (with mutations 
in VP16 or ICP0), viral replication and gene expression are greatly reduced comparing to wt infections 
(Ace, McKee et al. 1989; Everett 1989). 
All the infected HFFs were incubated at 37 °C and harvested 24 h.p.i. Lysates prepared from these 
HFFs were analysed by western blot using the antibody against BRCA1 (Santa Cruz I-20).
Cells infected with in1382 could induce expression of the 120 KDa-protein, but at much lower levels 
than	that	observed	for	the	wt	or	∆gE	viruses	(Fig.	R14).	Infection	with	the	wt	and	∆gE	viruses	triggered	
the	increased	expression	of	the	120	KDa-protein	levels	even	at	low	m.o.i.,	confirming	the	previous	
experiments and showing that this effect was not m.o.i.-dependent. Surprisingly, the levels of gD 
detected in cells infected with the in1382 virus were not very different from those observed after 
infection with the other HSV-1 viruses used. Given that this mutant, in1382,	has	difficulties	in	initiating	
a lytic cycle of viral replication due to the absence of functional VP16, ICP4 and ICP0, the three major 
transactivator proteins, it is possible that the gD detected in these experiments represents glycoprotein 
persisting from the input virus used for infection. Infection with HSV-2 was not associated with the 
induction of expression of the 120 KDa-protein (Fig. R14).
 
Figure R14.  Infection with different 
mutants of HSV-1 induces the increase 
in the levels of the 120-KDa protein 
reactive with the anti-BRCA1 antibody 
I-20. HFF cells were infected with wt 
HSV-1 (strain 17 CA), the mutant in1382 
(CA), the mutant deficient in gE (CA 
stock) and HSV-2 (CA stock) at 3 pfu/
cell. HFFs were also exposed to BHK 
debris. Total cell lysates were prepared 
at 24 hpi and were analysed by western 
blot with antibodies to BRCA1 (I-20), 
gD and β-actin.
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 Altogether these data (Figs. R12-13 and 14) showed that infection with all the different HSV-1 
mutants,	either	as	cell-associated	(CA)	or	medium-purified	stocks	(MP),	triggered	upregulation	of	the	
120-kDa protein. In contrast, neither exposure to BHK debris, nor infection with HSV-2 virus led to 
expression of the 120 kDa-protein. Therefore it can be concluded that the presence of the 120 kDa band 
is	specific	for	HSV-1	infection.
2.3.	 Assessment	 of	 the	 reactivity	 of	 the	 N-terminal	 D20	 BRCA1	 specific	
antibody with the 120 KDa-protein.
 The band observed after HSV-1 infection with the BRCA1 I-20 antibody has a molecular 
weight of 120 KDa approximately; however, the size of the canonical sequence of BRCA1 protein 
in SDS-PAGE is 220-230 KDa. Multiple different splice variants of BRCA1 have been described 
(Lu, Conzen et al. 1996; Thakur, Zhang et al. 1997; Wilson, Payton et al. 1997; Xu, Chambers et al. 
1997), but none of them is detected at 120 KDa. However, a BRCA1 variant lacking most of exon 11 
(BRCA1-∆exon11b)	seems	to	encode	a	protein	of	110	kDa	(Wilson,	Payton	et	al.	1997).	Moreover	the	
band of approximately 220 KDa corresponding to the full length molecule was not observed in our 
experiments	with	the	I-20	antibody,	raised	by	immunization	with	a	specific	peptide	of	the	C-terminal	
region of the human BRCA1.
Given this discrepancy between the consensus molecular weights of BRCA1 species and our 
observations,	another	antibody	against	BRCA1	was	used	to	confirm	the	upregulation	of	this	protein	
following HSV-1 infection, and discard any possible I-20 antibody crossreactivity. Given that the 
antibody I-20 used was raised against a peptide mapping near the C-terminus of human BRCA1, we 
used an antibody designed against the N-terminus of the molecule: the rabbit polyclonal D-20 antibody 
(Santa Cruz Biotechnology). 
Some of the lysates used in the previous experiments (Figs. R12, 13 and 14) were subjected to western 
blotting using the N-terminal D-20 antibody (Figs. R15, 16 and 17). This antibody recognized mainly 
a protein of about 80-90 KDa in HSV-1 infected cells, but it did not detect the previously seen 120 
KDa protein or the canonical 220 KDa form of BRCA1. Moreover Figure R17 also showed that D-20 
antibody detected numerous bands from 60 to 120 kDa approximately even in uninfected cells, cell 
exposed to BHK debris and HSV-2 infected cells.
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Figure R15. Infection with different mutants of HSV-1 induces an increase in the 
levels of an 80-KDa protein reactive with the N-terminus anti-BRCA1 antibody 
D-20. HFF cells were infected with wt HSV-1 (strain 17 CA stock), the mutant 
deficient in gE (strain SC16 CA and MP stocks) and the mutant in1814 (CA and 
MP stocks) at 20 pfu/cell. HFFs were also exposed to BHK debris. Total cell lysates 
were prepared at 24 hpi and were analysed by western blot with antibodies to 
BRCA1 (D-20), gD and β-actin.
Figure R16.  Infection with different mutants of HSV-1 induces an increase in the 
levels of an 80-KDa protein reactive with the N-terminus anti-BRCA1 antibody 
D-20. HFF cells were infected with wt HSV-1 (strain 17 CA and MP stock), the 
mutant in1814 (CA), the mutant deficient in gE (CA stock) and the mutant TSK 
(CA and MP stocks) at 20 pfu/cell. Total cell lysates were prepared at 24 hpi and 
were analysed by western blot with antibodies to BRCA1 (D-20), gD and β-actin.
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 In our experiments the I-20 and D-20 antibodies detected different sets of proteins induced 
after	HSV-1	infection,	but	not	a	protein	that	can	be	unambiguously	identified	as	the	canonical	form	of	
BRCA1.	However,	it	is	well	known	that	it	is	difficult	to	detect	endogenous	BRCA1	expression	using	
immunoprecipitation and western blot analysis, as described below. Therefore, the presence of the 
bands observed not at the proper molecular weight could represent the same target with different post-
translational	modifications,	splice	variants,	breakdown	products,	or	different	proteins.	
	2.4.	 Study	about	BRCA1	antibodies	in	the	literature:
 In the light of these results, an extended literature research about antibodies against BRCA1 
was	performed,	 and	a	 controversy	 in	 this	field	was	 found,	 indicating	a	 lack	of	 antibodies	with	 the	
required	specificity:
 In the middle of the nineties, some reports using the commercially available C-20 antibody 
(Santa Cruz Biotechnology) showed that BRCA1 encodes a 180-190 KDa protein (Gudas, Nguyen et 
al. 1995) with sequence homology and biochemical analogy to the granin family of secretory proteins. 
Therefore BRCA1 was considered to be secreted from breast epithelial cells (Jensen, Thompson et 
al. 1996). However, it was later concluded by Wilson et al. in 1996 that the C-20 antibody cross-
reacted with the epidermal growth factor receptor (EGFR, also called HER1), which migrated in 
SDS-PAGE with a size about 190 kDa, and the human epidermal growth factor receptor 2 (HER2), 
which migrated at 205 kDa approximately (Wilson, Payton et al. 1996). Later in the same year another 
publication reported that the C-20 antibody, in addition to the 220 KDa protein, also recognized a 180 
Figure R17.  Infection with 
different mutants of HSV-1 
induces an increase in the levels 
of an 80-KDa protein reactive 
with the N-terminus anti-BRCA1 
antibody D-20. HFF cells were 
infected with wt HSV-1 (strain 
17 CA), the mutant in1382 (CA), 
the mutant deficient in gE (CA 
stock) and HSV-2 (CA stock) at 3 
pfu/cell. HFFs were also exposed 
to BHK debris. Total cell lysates 
were prepared at 24 hpi and 
were analysed by western blot 
with antibodies to BRCA1 (D-20), 
gD and β-actin.
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Kda protein in total lysates from human breast cancer cell line MDA-MB-468 that was no detected 
by other antibodies against BRCA1. And they suggested that this protein was EGFR (Thomas, Smith 
et	al.	1996).	Next	year	an	additional	report	confirmed	the	cross-reactivity	of	the	C-20	antibody	to	the	
EGFR and they also reported cross-reaction of this antibody with EGF (Bernard-Gallon, Crespin et 
al. 1997). One year later a new report showed another cross-reactivity of the C-20 antibody because it 
detected smooth muscle cells, although the exact epitope that this antibody recognized is not clear yet 
(Imakado, Hoashi et al. 1998).
The C-20 antibody is raised against residues 1843-1862 at the carboxy terminus of the BRCA1 protein. 
The aminoacid sequence alignment between the peptide used to generate this antibody and the members 
of the type I tyrosine kinase receptor family revealed a similarity with EGFR consisting of six identical 
amino acids, including the tyrosine autophosphorylation site at position 992 of EGFR, as well as three 
conservative substitutions. Similar matches were observed with the homologous autophosphorylation 
sites in HER2 and HER4 (Wilson, Payton et al. 1996). 
 The I-20 antibody (Santa Cruz Biotechnology) that we had been using is also a C-terminal 
antibody, but it is raised against residues 1823-1842.  Although I-20 did not cross-react with type I 
receptor tyrosine kinase receptors (Wilson, Payton et al. 1996) and it did not stain smooth muscle cells 
as did C-20 (Imakado, Hoashi et al. 1998), it was found by Wilson and coworkers (the same group 
that discovered the crossreaction of the C-20) that in cytoplasmic, nuclear and total cell extracts from 
simian Cos-7 kidney cells transfected with full length BRCA1, the I-20 antibody recognized, besides 
the 230 KDa over-expressed protein, an unknown abundant, predominantly cytoplasmic protein 
slightly smaller than BRCA1. It was suggested that this protein was not BRCA1 because it was not 
detected with other antibodies against BRCA1 (Wilson, Payton et al. 1997).
Wilson	and	colleagues	further	evaluated	the	specificity	and	utility	of	19	antibodies	against	different	
epitopes of BRCA1 and revealed that the C-20, D-20 and I-20 antibodies recognized additional proteins 
in human SK-OV3 extracts, which were probably not products of alternative splicing because they 
were not observed with other antibodies against overlapping BRCA1 sequences. Furthermore, the I-20 
was the only antibody that was unable to identify the BRCA1 220 kDa protein in both human epithelial 
HBL-100 and SK-OV3 cell lines extracts  (Wilson, Ramos et al. 1999). The same year another report 
suggested that some C-terminal antibodies, among them C-20 and I-20, cross-reacted with a protein(s) 
different from BRCA1 because they showed false-positive immunostaining in BRCA1-associated 
cancer cells that had a BRCA1 protein-truncating mutation and in BRCA1-deficient	cell	line	HCC1937	
that	lacks	the	C-terminus	of	the	BRCA1	protein	(Yoshikawa,	Honda	et	al.	1999).	The	specificity	of	
I-20 was questioned again years later since this antibody showed predominantly cytoplasmic staining 
in immunohistochemical analyses with no differences in staining between tumoral and non-tumoral 
mammary epithelial cells as would be expected (Perez-Valles, Martorell-Cebollada et al. 2001). 
Moreover, another study discarded I-20 and also C-20 antibodies for further analysis of BRCA1 
expression	due	 to	 the	non-specificity	of	 these	antibodies	 in	western	blot	and	 immunohistochemical	
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staining controls (Bogdani, Teugels et al. 2002).
	 Therefore,	the	C-terminal	antibodies,	such	as	C-20	and	I-20,	were	found	to	produce	non-specific	
additional staining patterns. With respect to the I-20 antibody, it has been reported that this antibody 
may recognize other proteins besides BRCA1 or products of alternative splicing of the gene, thus, the 
possibility	that	the	results	obtained	using	the	I-20	antibody	were	influenced	by	cross-reactive	binding	
to non BRCA1 proteins was carefully evaluated.
 Firstly, the possibility that the protein around 120 KDa recognized by the I-20 antibody was 
some form of EGFR was tested, since the predicted molecular weight of EGFR is 134 KDa, although it 
is	usually	detected	around	180	KDa	in	western	blot	analysis	due	to	its	post-translational	modifications.	
To address this issue, lysates from two cell lines with different levels of EGFR expression, HFF and 
MCF7, mock infected and infected with HSV-1 were subjected to western blot analysis using an antibody 
specific	for	EGFR	together	with	the	I-20	antibody	(Fig.	R18).	We	used	these	cell	lines	because	it	is	
known	 that	fibroblasts	 express	EGFR	(40,000-100,000	 receptors/cell)	 (Hollenberg	and	Cuatrecasas	
1973; Carpenter, Lembach et al. 1975; Hollenberg and Cuatrecasas 1975) while MCF-7 have low levels 
of EGFR expression (~4,000 receptors/cell) (Davidson, Gelmann et al. 1987; Goldenberg, Masui et al. 
1989; Kaplan, Jaroszewski et al. 1990; Kute and Quadri 1991; Sharma, Horgan et al. 1994).
Our result showed that EGFR banding pattern was completely different from that observed with I-20, 
indicating	that	the	band	around	120	KDa	did	not	correspond	to	EGFR.	Therefore	we	confirmed	previous	
findings	showing	that	immunoblot	analysis	with	an	EGFR	antibody	of	I-20	immunoprecipitates	did	not	
detect EGFR (Wilson, Payton et al. 1996). 
Figure R18. The antibody anti-BRCA1 I-20 does not cross-react with EGFR. HFF 
and MCF-7 cells were infected with HSV-1 (dl1403R) at 10 pfu/cell. Total cell 
lysates were prepared at 24 hpi and 30 µg were analysed by western blot with 
antibodies to EGFR and BRCA1 (I-20).
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Given that our observations raised concern about the identity of the proteins recognized by the I-20 
antibody, lysates from infected HFF cells were subjected to immunoprecipitation with the I-20 
antibody for subsequent analysis of the immunoprecipitated proteins by mass spectrometry to resolve 
the	 identity	 of	 the	 proteins	 recognized	 in	western	 blot	 analysis,	 specifically	 the	most	 intense	 band	
around 120 KDa (section 2.6). While proteomic analysiswas underway, we examined in parallel 
another hypothesis about the identity of the 120 KDa-protein. The pattern of bands observed could be 
product of a BRCA1 cleavage during HSV-1 infection. If the protein was cleaved, the epitopes of the 
I-20 and D-20 antibodies might become more accessible; thereby, the N-terminus fragment around 90 
KDa could be recognized by the D-20 antibody and the C-terminal fragment around 120 KDa could be 
recognized by the I-20 antibody (section 2.5).
2.5.	 Study	 of	 a	 possible	 cleavage	 in	 full-length	 BRCA1	 during	 HSV-1	
infection.
 If HSV-1 infection led to a cleavage of full-length BRCA1 protein, the resulting BRCA1 
fragments could be predicted to have different patterns of subcellular localization. Given the 
distribution	of	 the	nuclear	 localization	signals	 (NLS)	and	 the	RING	finger	domain	of	BRCA1,	 the	
N-terminal fragment around 90 Kda, recognized by D-20 antibody, would be predicted to be retained 
in the nucleus while the C-terminal fragment of approximately 120 KDa, recognized by I-20 antibody, 
would be expected to be located in the cytoplasm (Fig. R19). 
Figure R19. Schematic 
representation of the 
hypothetical cleavage of full-
length BRCA1 mediated by HSV-
1.  BRCA1 contains two main 
functional domains, a RING finger 
domain and the BRCA1 C-terminal 
(BRCT) domains. The RING 
domain, responsible for BARD1 
binding, the nuclear export signals 
(NESs), the exon 11, the nuclear 
localization signals (NLSs) and the 
BRCT domains are indicated. If 
HSV-1 infection led to a cleavage 
of full-length BRCA1 protein, the 
resulting BRCA1 fragments around 
80 and 120 kDa, recognized by D-20 
and I-20 antibodies respectively, 
would be expected  to be retained 
in the nucleus and the cytoplasm 
respectively.
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 The subcellular distribution of BRCA1 has been studied by numerous groups, however there 
are many discrepancies between these different studies in the literature. 
Generally, BRCA1 has been considered to be a predominantly nuclear protein involved in multiple 
nuclear located functions. BRCA1 has two nuclear localization signals (NLS1 and NLS2) located 
within exon 11, the largest of the exons in the BRCA1 gene. Two mechanisms for BRCA1 nuclear 
import	 have	 been	 described;	 the	 classical	 importin	 α/β	 pathway,	 in	which	NLS1	 interacts	 directly	
with	importin	α,	which	in	turn	interacts	with	importin	β.	And	the	second	pathway	involves	a	NLS-
independent mechanism, in which BRCA1 binds to BRCA1-associated RING domain protein 1 
(BARD1)	via	their	RING	finger	domains,	and	then	this	BRCA1:BARD1	complex	binds	to	the	importin	
machinery	interacting	first	with	importin	α.	However,	BRCA1	can	also	be	exported	from	the	nucleus.	
BRCA1 has two nuclear export signals (NES), at amino acid residues 81-99 and 22-30, which bind 
to the nuclear export receptor CRM1 (chromosome region maintenance 1; also known as exportin1) 
to translocate BRCA1 out of the nucleus. Therefore BRCA1 can shuttle between the nucleus and the 
cytoplasm. However, it has been suggested that the interaction of BRCA1 with BARD1 inhibits the 
nuclear export of BRCA1 because BARD1 masks the BRCA1 NESs, since these sequences are located 
within	the	RING	finger	domain	of	BRCA1	(aa	1-109).	All	these	observations	indicate	an	important	
role of BARD1 for both nuclear import and export of BRCA1 and in aggregate explain why BRCA1 
is predominantly detected in the nucleus (reviewed in (Thompson 2010)).
 In order to explore the hypothesis of HSV-1-induced cleavage of BRCA1, localization studies 
by	immunofluorescence	analysis	were	carried	out.	HFF	cells	were	mock	infected	or	infected	with	∆gE	
HSV-1	using	the	previously	used	m.o.i	of	20	and	subjected	to	immunofluorescence	analysis	7-8	h.p.i	
using different anti-BRCA1 antibodies. 
The	cells	were	infected	with	the	∆gE	virus	in	order	to	avoid	non-specific	signal	due	to	the	binding	of	
gI/gE to the Fc portion of the primary and secondary antibodies, as explained before. And they were 
fixed	7-8	h.p.i	because	we	observed	in	the	time	course	that	the	marked	increase	in	expression	of	the	
120 kDa-protein was clear 6 h.p.i (Fig. R11) and at this time the cells are not massively damaged due 
to the infection.
The panel of anti-BRCA1 antibodies comprised the previous C-terminal I-20 (rabbit polyclonal 
Santa Cruz Biotechnology) and the N-terminal D-20 (rabbit polyclonal Santa Cruz Biotechnology) 
antibodies;	as	well	as	a	mouse	monoclonal	antibody	specific	for	BRCA1,	MS110	(Millipore),	raised	
against the N-terminus.
Since the I-20 and D-20 antibodies have been suggested to cross-react with proteins other than BRCA-
1 (Wilson, Payton et al. 1997; Wilson, Ramos et al. 1999; Yoshikawa, Honda et al. 1999), we also 
used the MS110 antibody, also called Ab-1 in the literature and generated by the Livingston’s group 
(Scully, Ganesan et al. 1996), to corroborate our previous results. This N-terminal antibody has been 
widely used for detection of BRCA1 and has been considered one of the best antibodies for BRCA1 
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detection, even though previous studies also indicated potential non-BRCA1 reactivities of the MS110 
antibody (Yoshikawa, Honda et al. 1999; Perez-Valles, Martorell-Cebollada et al. 2001; Fraser, Reeves 
et	al.	2003;	Mangia,	Chiriatti	et	al.	2009).	Specifically,	recent	mass	spectrometry	analyses	have	shown	
that MS110 clearly binds two proteins different from BRCA1, Sec16A and PCM1, in lysates of HeLa 
cells.	Moreover,	three	other	bands	of	lower	molecular	size	were	also	identified	as	possible	additional	
non-specific	interactions	(Milner,	Wombwell	et	al.	2013).	In	spite	of	these	data,	this	antibody	has	been	
considered to produce the most reliable and consistent results mainly in immunohistochemical analysis 
(Wilson, Ramos et al. 1999; Yoshikawa, Honda et al. 1999; Perez-Valles, Martorell-Cebollada et al. 
2001; Al-Mulla, Abdulrahman et al. 2005; Alamshah, Springall et al. 2008; Milner, Wombwell et al. 
2013). 
 As shown in Fig. R20 ΔgE HSV-1 infection of HFF cells led to a marked increase in staining 
with I-20 and this signal was homogeneous in intensity in both nucleus and cytosol. Moreover, the 
immunofluorescence	 staining	 intensity	directly	 correlated	with	 the	amount	of	 the	120	KDa-protein	
detected by our western blot analyses.
Figure R20. Staining with the I-20 
antibody shows an increased signal, in 
both nucleus and cytosol, after HSV-1 
infection of HFF cells. HFF cells were 
mock or infected with ∆gE (20 p.f.u/
cell). 7 h.p.i  uninfected and infected 
cells were fixed in 2% paraformaldehyde 
and stained with anti-BRCA1 I-20 plus 
goat anti-rabbit Alexa Fluor 488 (green, 
left panel) and anti-gD LP2 plus donkey 
anti-mouse Alexa Fluor 568 (red, 
middle panel) as a control of infection. 
Nuclei were stained with DAPI (blue, 
right panel). 
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 Staining with the D-20 antibody showed no differences in intensity or localization between 
non-infected and infected cells, with signal observed in both the cytoplasm and nucleus (Fig. R21).
Since the marked cell damage produced by infection using an m.o.i. of 20 complicated the analysis 
of	the	immunofluorescence	data,	for	staining	with	MS110	antibody	the	infection	was	carried	out	at	an	
m.o.i of 3 instead of the usual 20. The cells stained with MS110 exhibited different pattern of staining 
compared to that observed with the previous antibodies. The non-infected cells showed a faint and 
principally cytoplasmic staining (Fig. R22). This result was in apparent contrast with data from other 
groups	that	showed	a	predominantly	nuclear	staining	pattern,	specifically	a	punctate	nuclear	signal,	
using this antibody (Scully, Ganesan et al. 1996; Hsu and White 1998; Wilson, Ramos et al. 1999; 
Yoshikawa, Honda et al. 1999; Tulchin, Chambon et al. 2010). HSV-1 infection led to an increased 
staining with MS110 that was homogeneous in both cytoplasm and nucleus.
Figure R21.  Staining with the D-20 
antibody shows no differences 
between noninfected and infected 
HFF cells. HFF cells were mock or 
infected with ∆gE (20 p.f.u/cell). 7 
h.p.i  uninfected and infected cells 
were fixed in 2% paraformaldehyde 
and stained with anti-BRCA1 D-20 
plus goat anti-rabbit Alexa Fluor 
488 (green, left panel) and anti-gD 
LP2 plus donkey anti-mouse Alexa 
Fluor 568 (red, middle panel) as a 
control of infection. Nuclei were 
stained with DAPI (blue, right 
panel).
94
Results
 Taken together, the data obtained with the three BRCA1 antibodies did not exhibit the 
characteristic nuclear localization of BRCA1, predominantly in nuclear speckles, previously reported 
(Scully, Ganesan et al. 1996; Hsu and White 1998; Wilson, Ramos et al. 1999; Yoshikawa, Honda et 
al. 1999; Tulchin, Chambon et al. 2010) and they did not show a consistent change in the localization 
of BRCA1 staining between uninfected and HSV-1 infected cells as we had hypothesized.  
 To determine whether the data obtained on analysis of the HFF cells were consistent in other 
cells susceptible to HSV-1 infection, the highly permissive VERO cell line was mock infected or 
infected	with	HSV-1	at	m.o.i.s	of	3	or	1,	as	indicated,	and	subjected	to	immunofluorescence	analysis	8	
h.p.i using I-20, D-20 and MS110 antibodies. 
The pattern of staining observed in Vero cells using I-20 (Fig. R23) was very similar to that observed 
in HFF cells (Fig. R20). However, the signal in the HSV-1 infected Vero cells was much more intense, 
so much so that the exposure had to be reduced to be able to discern properly the pattern of staining.
 
Figure R22. Staining with the 
MS110 antibody shows faint 
cytoplasmic localization in 
noninfected cells and increased 
signal in both cytoplasm and 
nucleus during HSV-1 infection 
of HFF cells. HFF cells were 
mock or infected with ∆gE (3 
p.f.u/cell). 8 h.p.i  uninfected 
and infected cells were fixed 
in 2% paraformaldehyde 
and stained with anti-BRCA1 
MS110 plus goat anti-mouse 
IgG1 Alexa Fluor 633 (grey, left 
panel) and anti-gD LP2 plus 
goat anti-mouse IgG2a Alexa 
Fluor 488 (green, middle panel) 
as a control of infection. Nuclei 
were stained with DAPI (blue, 
right panel). 
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Staining with D-20 showed no differences in intensity or localization between uninfected and 
infected Vero cells (Fig. R24), being consistent with that observed in HFF cells (Fig. R21). 
Figure R23.  The staining with I-20 shows an increased signal, in both nucleus and cytosol, during HSV-
1 infection of VERO cells. VERO cells were mock or infected with ∆gE (1 p.f.u/cell). 8 h.p.i  uninfected 
and infected cells were fixed in 2% paraformaldehyde and stained with anti-BRCA1 I-20 plus goat 
anti-rabbit Alexa Fluor 488 (green, left panel) and anti-gD LP2 plus donkey anti-mouse Alexa Fluor 568 
(red, middle panel) as a control of infection. Nuclei were stained with DAPI (blue, right panel).
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The uninfected Vero cells showed no staining using MS110. As stated above, this result was in contrast 
with previous reports that showed a predominantly nuclear staining using this antibody. During HSV-1 
infection cells displayed a predominantly nuclear staining with less marked cytoplasmic signal (Fig. 
R25). This pattern of labeling was completely different from that observed in HFF cells, although in 
both cell lines HSV-1 infection led to an increased staining (Fig. R22). Indeed, during infection of Vero 
cells the staining was more intense at higher m.o.i.. Moreover, at m.o.i. 1 the signal was mainly nuclear 
but at m.o.i. 3 the cytoplasmic staining was considerably increased. 
Figure R24. The staining with D-20 shows no differences between non-infected and infected 
VERO cells. VERO cells were mock or infected with ∆gE (1 p.f.u/cell). 8 h.p.i  uninfected and 
infected cells were fixed in 2% paraformaldehyde and stained with anti-BRCA1 D-20 plus goat 
anti-rabbit Alexa Fluor 488 (green, left panel) and anti-gD LP2 plus donkey anti-mouse Alexa 
Fluor 568 (red, middle panel) as a control of infection. Nuclei were stained with DAPI (blue, 
right panel).
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 Taken together, the data obtained in HFF and Vero cells using the BRCA1 antibodies I-20, 
D-20 and MS110 did not exhibit the characteristic nuclear dot staining pattern of BRCA1 previously 
reported. Moreover, these experiments did not show a change in the localization of BRCA1 staining 
during HSV-1 infection as we had hypothesized that might happen if BRCA1 was cleaved (Fig. R19). 
Figure R25. MS110 staining 
shows no labeling in 
non-infected cells and a 
predominantly nuclear staining 
with faint cytoplasmic signal 
during HSV-1 infection of VERO 
cells. VERO cells were mock 
or infected with ∆gE (1 p.f.u/
cell). 8 h.p.i  uninfected and 
infected cells were fixed in 2% 
paraformaldehyde and stained 
with anti-BRCA1 MS110 plus goat 
anti-mouse IgG1 Alexa Fluor 488 
(green, left panel) and anti-gD 
LP2 plus goat anti-mouse IgG2a 
Alexa Fluor 568 (red, middle 
panel) as a control of infection. 
Nuclei were stained with DAPI 
(blue, right panel).  
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 Since the predominantly nuclear localization of full-length BRCA1 previously described was 
not	observed	in	our	immunofluorescence	analyses	of	HFF	and	Vero	cells,	and	levels	of	this	220	KDa	
protein appeared non-detectable in our immunoblot analyses, a positive-control system using cells 
transfected to express full-length BRCA1 was employed to test the hypothesis of the BRCA1 cleavage 
during	HSV-1	infection.	Specifically,	a	U2OS	cell	line	that	stably	expressed	full-length	BRCA1	fused	
in its N-terminal region to GFP (J. Lukas, personal communication) (GFP-BRCA1 Flag-BARD1), 
kindly provided by Steve Jackson’s lab (The Gurdon Institute, University of Cambridge) (Mailand, 
Bekker-Jensen et al. 2007; Galanty, Belotserkovskaya et al. 2009), was used. These cells also express 
BARD1 to avoid the mislocalization of BRCA1 as explained before. This is of particular importance 
because deregulation of nuclear transport pathways can cause not only the mislocalization of the 
proteins, but also the alteration of their functions (reviewed in (Hung and Link 2011)). 
The amount of bright GFP positive cells was low (around 20% of positive cells as measured by 
fluorescence	microscopy	using	anti-GFP	and	anti-FLAG	antibodies)	complicating	the	analyses.	Thus	
initially, while we tried to enrich the positive population by single-cell cloning, an anti-GFP antibody 
was	used	to	enhance	the	signal	in	immunofluorescence	analysis.
To evaluate how HSV-1 infection affected the subcellular localization of full-length BRCA1, the stably 
transfected	U2OS	cells	were	either	mock	infected	or	infected	with	HSV-1	∆gE	and	immunofluorescence	
analysis was done using antibodies to GFP and gD as a control of infection (Fig. R26).
Using this system, the characteristic punctate nuclear staining of full-length BRCA1 was seen in the 
uninfected cells, but after HSV-1 infection most BRCA1 accumulations were dispersed throughout 
the nucleus (Fig. R26). This result was consistent with previous reports, which indicated that wt HSV-
1 infection dispersed BRCA1 from its nuclear accumulations and redistributed BRCA1 diffusely in 
the nucleus (Maul, Jensen et al. 1998; Lilley, Chaurushiya et al. 2011). No shift in the subcellular 
localization of BRCA1 was observed after HSV-1 infection, but this could be explained due to the 
detection of GFP fused to the N-terminus of full-length BRCA1, which is the region predicted to 
remain in the nucleus, if the molecule is proteolysed (Fig. R19).
 
The availability of this cell line expressing GFP-BRCA1 allowed a better characterization of the signal 
recognized	by	the	BRCA1	antibodies	I-20,	MS110	and	D-20	in	immunofluorescence	analysis.	
Immunofluorescence	using	 the	I-20	antibody	showed	a	predominantly	nuclear	staining	in	cells	 that	
overexpressed GFP-BRCA1 full-length, which overlapped with the GFP signal. In cells with lower 
levels of GFP-BRCA1 expression, as judged by the GFP staining, the I-20 antibody yielded an apparent 
nuclear dot staining (Fig. R27). Therefore, in cells overexpressing full-length BRCA1, I-20 staining 
showed the expected nuclear pattern, indicating that this antibody is able to recognize transfected full-
length BRCA1. 
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Figure R27. I-20 recognized 
full-length BRCA1 in 
the nucleus. U2OS 
stably expressing BRCA1 
cells were fixed in 2% 
paraformaldehyde and 
stained with anti-BRCA1 
I-20 plus goat anti-rabbit 
Alexa Fluor 568 (red, left 
panel) and anti-GFP (clone 
JL-8) plus goat anti-mouse 
Alexa Fluor 488 (green, 
middle panel). Nuclei were 
stained with DAPI (blue, 
right panel). 
Figure R26. Full-length BRCA1 resides in the nucleus and in nuclear dots in uninfected cells, but it is 
redistributed diffusely in the nucleus during HSV-1 infection. U2OS stably expressing BRCA1 cells were mock 
or infected with ∆gE (0,5 p.f.u/cell). 8 h.p.i uninfected and infected cells were fixed in 2% paraformaldehyde 
and stained with anti-GFP plus goat anti-rabbit Alexa Fluor 488 (green, left panel) and anti-gD LP2 plus 
donkey anti-mouse Alexa Fluor 568 (red, middle panel) as a control of infection. Nuclei were stained with 
DAPI (blue, right panel). 
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	 Once	the	ability	of	the	I-20	antibody	to	bind	full-length	BRCA1	was	confirmed,		the	effects	
of HSV-1 infection on the pattern of staining were studied. These experiments were performed using 
a new batch of cells with stronger GFP-BRCA1 signal obtained by single cell cloning of the stable 
U2OS	cell	line.	This	enabled	us	to	do	the	immunofluorescence	analysis	without	the	anti-GFP	antibody.	
These	cells	were	mock	infected	or	infected	with	∆gE	HSV-1,	and	the	infection	was	checked	using	the	
LP2 anti-gD antibody (Fig. R28). 
Figure R28. I-20 staining does not reveal any change in subcellular localization signal during HSV-1 
infection of U2OS stably expressing full-length BRCA1. U2OS stably expressing BRCA1 cells were mock 
or infected with ∆gE (1 p.f.u/cell). 8 h.p.i uninfected and infected cells were fixed in 2% paraformaldehyde 
and stained with I-20  plus goat anti-rabbit Alexa Fluor 568 (red) and anti-gD LP2 plus goat anti-mouse 
Alexa Fluor 633 (grey) as a control of infection. GFP fluorescence was visualized directly (green). Nuclei 
were stained with DAPI (blue). Magnification 40X.
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These	 experiments	 showed	 that	 no	 significant	 changes	 in	GFP-BRCA1	 localization	were	 detected	
during HSV-1 infection of U2OS stably expressing full-length BRCA1 using the I-20 antibody (Fig. 
R28).
 This experiment was then repeated with single cell cloned cells expressing full-length BRCA1, 
isolated using Fluorescence Activated Cell Sorting (FACS) and replated to generate a monoclonal 
lineage (Fig. R29). Although we could see stronger GFP-BRCA1, the staining with I-20 again failed 
to	show	significant	changes	in	localization	during	HSV-1	infection.
The staining of these sorted cells with MS110 (Fig. R30) gave a nuclear pattern which was consistent 
with the GFP signal. This result indicated that MS110 antibody recognized transfected full-length 
BRCA1.	HSV-1	infection	did	not	lead	to	significant	changes	in	the	localization	of	full-length	BRCA1,	
however, if the molecule is fractionated, the N-terminal region recognized by this antibody would be 
expected to be retained in the nucleus.
Figure R29. I-20 staining does not reveal any change in subcellular localization signal during HSV-1 infection 
of sorted U2OS stably expressing full-length BRCA1. U2OS stably expressing BRCA1 cells were mock or 
infected with ∆gE (1 p.f.u/cell). 8 h.p.i uninfected and infected cells were fixed in 2% paraformaldehyde and 
stained with I-20 plus goat anti-rabbit Alexa Fluor 568 (red) and anti-gD LP2 plus goat anti-mouse Alexa 
Fluor 633 (grey) as a control of infection. GFP fluorescence was visualized directly (green). Nuclei were 
stained with DAPI (blue).
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 Since the D-20 antibody did not recognize full-length BRCA1 in the stably transfected U2OS 
cells (Fig. 34) we did not study further the pattern of staining during HSV-1 infection with this antibody. 
This result pointed out the unreliability of this antibody.
Figure R30. MS110 recognized BRCA1 in the nucleus but MS110 staining does not reveal any change in 
subcellular localization signal during HSV-1 infection of sorted U2OS stably expressing full-length BRCA1. 
U2OS stably expressing BRCA1 cells were mock or infected with ∆gE (1 p.f.u/cell). 8 h.p.i uninfected and 
infected cells were fixed in 2% paraformaldehyde and stained with MS110 plus goat anti-mouse IgG1 Alexa 
Fluor 633 (grey) and anti-gD LP2 plus goat anti-mouse IgG2a Alexa Fluor 568 (red) as a control of infection. 
GFP fluorescence was visualized directly (green). Nuclei were stained with DAPI (blue).
Figure R31. D-20 does not 
recognize full-length BRCA1. 
U2OS stably expressing 
BRCA1 cells were fixed in 2% 
paraformaldehyde and stained 
with anti-BRCA1 D-20 plus goat 
anti-rabbit Alexa Fluor 568 (red, 
left panel) and anti-GFP (clone 
JL-8) plus goat anti-mouse Alexa 
Fluor 488 (green, middle panel). 
Nuclei were stained with DAPI 
(blue, right panel). 
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These	data	verified	that	I-20 and MS110, but not D-20, recognized full-length transfected BRCA1 
within	 the	 nucleus	 in	 immunofluorescence	 analysis,	 but	 the	 staining	with	 these	 antibodies	 did	 not	
reveal	significant	changes	in	localization	during	HSV-1	infection	as	we	had	hypothesized	(Fig.	R19).
	 Since	no	significant	changes	 in	BRCA1	localization	were	observed	by	 immunofluorescence	
analysis, immunoprecipitation-immunoblot analyses of the cells that stably expressed BRCA1 at high 
levels were performed simultaneously. GFP molecular weight is 27KDa, so, if BRCA1 full-length was 
cleaved during HSV-1 infection originating the 120KDa fragment observed with the I-20 antibody, a 
band	around	100	KDa	(80+27)	would	be	also	expected	using	an	antibody	against	GFP	or	antibodies	
which recognized an epitope in the N-terminus part of the molecule (D-20, MS110) (Fig. R32).
 
For this experiment, the stably transfected U2OS cells were either mock infected or infected with the 
∆gE	virus	at	m.o.i	of	5.	24	h.p.i	cell	lysates	from	uninfected	and	infected	cells	were	immunoprecipitated	
with a rabbit polyclonal antibody anti-GFP and then subjected to immunoblotting using a mouse 
monoclonal	antibody	anti-GFP.	Figure	R33	shows	that	a	specific	band	could	be	detected	running	above	
the 230-KDa marker, consistent with the expression by these cells of the tagged full-length BRCA1, 
higher than 220-230 KDa due to the fusion to the GFP tag. However, the smaller band of around 100 
KDa expected in the lane of the infected cells was not observed. The full-length BRCA1 band was not 
seen	in	the	total	lysates,	but	this	might	reflect	that	the	lysates	were	too	dilute.
Figure R32. Schematic representation of the hypothetical cleavage of GFP-BRCA1 mediated 
by HSV-1.  A cleavage of GFP-BRCA1 protein mediated by HSV-1 infection would originate 
a fragment of 120 kDa, recognized by the I-20 antibody, respectively. originating the 120KDa 
observed	with	the	I-20	antibody,	a	band	around	100	KDa	(80+27)	would	be	also	expected	using	
an antibody against GFP or antibodies which recognized an epitope in the N-terminus part of the 
molecule (D-20, MS110)
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Also, lysates of the positive control cells, uninfected and infected, were immunoprecipitated with anti-
GFP antibodies followed by  immunoblotting with I-20 and D-20, as well as GFP antibodies, to check if 
I-20 and D-20 were able to recognise immunoprecipitated full-length BRCA1 and to test if any smaller 
bands appeared in the lane of the infected cells using these antibodies (Fig. R34). MS110 was not used 
in the immunoprecipitation/immunoblotting analysis because in our previous experiments MS110 did 
not work in western blot. Moreover, despite its success detecting BRCA1 in immunohistochemistry 
analysis,	previous	findings	indicated	its	lack	of	specificity	in	western	blot	analysis	(Fraser,	Reeves	et	
al. 2003; Milner, Wombwell et al. 2013).
These experiments were performed using FACS sorted cells for higher GFP-BRCA1 expression and 
they were infected with a reduced m.o.i of 1 pfu/cell that still achieved a good infection.
 As shown in Figure R34 the I-20 and D-20 antibodies recognised immunoprecipitated full-
length BRCA1, but no differences were observed between mock and infected cells. In particular, the 
smaller band of 100 KDa expected after HSV-1 infection using anti-GFP and D-20 antibodies (which 
would recognized the N-terminal fraction of BRCA1) was not detected. Moreover, the band around 
80kDa previously detected by the D-20 antibody in total lysates of infected cells (Figs. R15, R16, R17) 
was not clearly observed.
Figure R33. BRCA1 from U2OS stably transfected with full-length GFP-BRCA1 
construct was detected by immunoprecipitation and immunoblot analysis using anti-
GFP antibodies. U2OS stably expressing BRCA1 cells were mock infected or infected 
with ∆gE virus (5 pfu/cell). 24 h.p.i cell lysates were immunoprecipitated with a rabbit 
polyclonal antibody anti-GFP and immunoblotted with a mouse monoclonal antibody 
anti-GFP (clone JL-8).
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 The fact that the 120 kDa band was not observed by immunoblot analysis with I-20 of anti-
GFP immunoprecipitates from HSV-1 infected cells (Fig. R34) could be consistent with our cleavage 
hypothesis. As the region precipitated by GFP is the N-terminal, if a cleavage of BRCA1 took place, 
the C-terminal region recognized by the I-20 antibody would not be precipitated. If this was the case, 
immunoprecipitation of the unbound fraction from the previous immunoprecipitation (Fig. R34) using 
the	I-20	antibody	should	show	the	120	KDa-protein.	This	experiment	confirmed	this	prediction	(Fig.	
R35). However, while it is possible that this band represent a 120 KDa fragment produced by BRCA1 
cleavage, the fact that full-length BRCA1 could not be detected by the I-20 antibody in total lysates 
leaves	open	the	possibility	that	this	120	KDa	band	could	be	another	target	(inespecificity).	
	 Overall,	these	data	confirm	that I-20 and D-20 antibodies recognize the transfected GFP-
BRCA1 fusion protein in anti-GFP immunoprecipitates, but the smaller band around 100KDa expected 
with the N-terminal antibodies was not seen. Moreover these immunoprecipitation-immunoblot 
analyses	correlated	with	the	immunofluorescence	stainings	of	the	U2OS	stably	expressing	full-length	
BRCA1, suggesting that the full-length molecule was not cleaved during HSV-1 infection. However, 
it could not be excluded that the cleavage might be prevented by the presence of the GFP fusion. For 
Figure R34. I-20 and D-20 detect overexpressed full-length BRCA1 in FACS sorted U2OS 
cells stably expressing GFP-BRCA1 by immunoprecipitation with anti-GFP and immunoblot 
analysis using I-20 and D-20. U2OS stably expressing BRCA1 were mock infected or infected 
with ∆gE virus (1 pfu/cell). 24 h.p.i cell lysates were immunoprecipitated with a polyclonal 
antibody anti-GFP and immunoblotted with the monoclonal antibody anti-GFP (clone JL-8), 
the I-20 antibody or the D-20 antibody.
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example, due to the GFP tagged to the BRCA1, a possible blocking accessibility for cellular or viral 
proteins to correctly bind and adequately cleave BRCA1 could explain these results. 
	 All	the	previous	data,	both	immunofluorescence	and	immunoprecipitation	analyses,	indicated	
that	the	I-20	antibody	efficiently	recognized	full-length	BRCA1	protein	fused	to	GFP,	but	they	suggested	
that full-length BRCA1 was not cleaved during HSV-1 infection, as although the 120 KDa protein can 
be found in total lysates of infected GFP-BRCA1 cells, the 100 KDa protein was not detected. Thus, 
the identity of the 120KDa protein recognized by the I-20 antibody was still an incognita.
 
Figure R35. I-20 immunoprecipates the 120 KDa-protein in the unbound fraction 
from an immunoprecipitation using anti-GFP. The unbound fraction from the 
previous immunoprecipitation was immunoprecipitated with I-20 antibody and 
immunoblotted with the same antibody. Total cell lysates were also immunoblotted 
with I-20.
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2.6.	 Identification	of	the	120	KDa-protein	by	proteomic	analysis.
	 Given	that	the	immunofluorescence	staining	with	I-20	was	so	intense	in	Vero	cells	(Fig.	R23),	
presumably	reflecting	a	higher	level	of	expression	of	the	I-20	reactive	material,	we	decided	to	carry	
out an immunoprecipitation with I-20 from mock and HSV-1 infected vero cells lysates to try to obtain 
sufficient	material	to	allow	a	proteomic	identification	of	the	120	KDa	protein	(Fig.	R36).	
 Given that the 120 KDa-protein was successfully immunoprecipitated (Fig. R36), the 
immunoprecipitated proteins were again separated by SDS-PAGE and the resulting gel was stained 
with Coomassie dye. The 120 KDa band was visualized in the Coomassie-stained gel together with 
other bands in the infected cells, especially one around 150 KDa as well as the one at 80 KDa which 
had been observed in some of our previous western blot analysis using the I-20 antibody (Fig. R37). 
These	proteins	(150,	120	and	80	KDa)	were	then	processed	for	MALDI	Fingerprinting	identification.	
 
Figure R36.  I-20 immunoprecipates the 120 KDa-protein in HSV-1 
infected VERO cells. VERO cells were mock infected or infected with 
∆gE virus (1 pfu/cell). 24 h.p.i cell lysates were immunoprecipitated 
with I-20 antibody and immunoblotted with the same antibody. 
Total cell lysates were also immunoblotted with I-20.
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The	mass	spectrometry	analysis	identified	the	120 KDa-protein (band number 2) as the viral tegument 
protein UL37 from human herpesvirus 1 (also called Capsid assembly protein UL37) with 55 peptides 
corresponding to 57.8 % sequence coverage (Fig. R38). The predicted molecular weight of UL37 is 
120 KDa (http://www.ncbi.nlm.nih.gov/protein/222478368/). 
The	other	two	proteins	were	also	identified	as	viral	proteins:
• Band 1: major capsid protein (human herpesvirus 1) (also called Capsid protein VP5), which has 
a predicted molecular weight of 149 kDa.
• Band 3: tegument protein VP13/14 (human herpesvirus 1) (also called tegument protein UL47), 
which has a predicted molecular weight of 74 kDa.
 The antigen used to generate the anti-BRCA1 antibody I-20 is the sequence between 1823-
1842 aminoacids located within the BRCT2 domain: AIGQMCEAPVVTREWVLDSV. Alignment 
between the peptide used to generate the anti-BRCA1 antibody I-20 and HSV-1 UL37 protein revealed 
a similarity of six consecutive identical amino acids at the N-terminus region of UL37 (Fig. R38).
 
Figure R37. Coomassie stained SDS-PAGE gel showing the three 
immnunoreactive bands which were subjected to mass spectrometry 
analysis. Bands of interest are indicated by red boxes. 
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Moreover, the mass spectrometry result was complemented by another proteomic approach called 
Off	Gel.	This	technique	does	not	identify	a	specific	protein	but	enriches	the	protein	of	interest	in	a	
sample	and	identifies	the	proteins	present	in	the	sample.	Our	result	showed	that	the	first	HSV-1	protein	
identified	with	 the	 highest	 score	was	UL37.	The	 best	 scored	 protein	was	UL37,	 25	 peptides	were	
recognized with a 28.3 %.coverage of UL37. 
	 The	mass	 spectrometry	data	were	confirmed	by	 immunoprecipitation	 from	Vero	cells	using	
I-20	followed	by	western	blot	with	a	specific	primary	antibody	targeting	UL37	(Klupp,	Granzow	et	al.	
2001) (Fig. 39A). The results showed a clear band of the relevant molecular size for its target protein, 
which had the same molecular mass as the band recognized by I-20. These data suggest that I-20 
preferentially binds UL37.
The	cross-reactivity	of	I-20	was	further	confirmed	by	infection	of	VERO	cells	with	an	HSV-1	deficient	
in	UL37	(ΔUL37	HSV-1)	(Fig.	39B).	This	experiment	showed	that	I-20	did	not	detect	the	120	KDa-
Figure R38. The anti-BRCA1 antibody I-20 recognizes UL37 from HSV-1. A) Mass spectrometry 
analysis identified the reactive band at 120 kDa as the HSV-1 UL37 protein. The sequence 
coverage observed is 57.8 %, calculated by dividing the number of amino acids in all found 
peptides (indicated in red) by the total number of amino acids in the entire protein sequence. B) 
The peptide used to generate the anti-BRCA1 antibody I-20 shares six identical amino acids with 
the HSV-1 UL37 protein at the N-terminal part of the molecule. 
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protein	in	the	lane	corresponding	to	the	cells	infected	with	the	virus	deficient	in	UL37.
Also, the cross-reactive binding of I-20 to the N-terminus of UL37 was further analysed by transfection 
of 293T cells with 1) a plasmid containing a GFP-UL37 construct, 2) a plasmid containing only the 
N-terminus of UL37, which contains the potential cross-reacting motif (the six aminoacid shared with 
the BRCA1 I-20 antigenic molecule), and 3) a plasmid lacking the N-terminus of UL37 (Fig. 39C). 
These experiments showed that I-20 recognized the full-length and N-terminal fusion proteins of 
UL37,	but	not	the	fusion	protein	lacking	the	N-terminus.	Thus,	these	data	confirmed	that	I-20	binds	
specifically	to	the	N-terminus	region	of	UL37	as	predicted	from	the	epitope	mapping.
 Taken together, the above data demonstrated that the I-20 antibody crossreacts with the 
tegument protein UL37 from HSV-1, which is the 120 KDa protein recognized after HSV-1 infection. 
Figure 39. The cross-reactivity 
of I-20 with HSV-1 UL37 was 
validated in three ways: (A) by 
immunoprecipitation of mock 
infected and ΔgE HSV-1-infected 
VERO cells using I-20 followed 
by western blot with specific 
anti-UL37 or anti-BRCA1 I-20 
antibodies. Total lysates (input) 
were also immunobloted with the 
same antibodies; (B) by infection 
of VERO cells with an HSV-1 
deficient in UL37, a wt HSV-1 or 
ΔgE HSV-1. Lysates from these 
cells were immunobloted with 
specific anti-UL37, anti-BRCA1 
I-20 and anti-gD LP14; (C) by 
transfection of 293T cells with 
a plasmid containing the GFP-
UL37 construct, another plasmid 
containing only the N-terminus of 
UL37 which contains the potential 
motif and a plasmid lacking the 
N-terminus of UL37. Lysates from 
these cells were immunobloted 
with anti-GFP, specific anti-UL37 
or anti-BRCA1 I-20 antibodies.
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3. Study of IFI16 expression in human cancer cells of different p53 
genotypes 
3.1.	 Expression	of	IFI16	in	the	wild	type	and	p53	deficient	HCT116	colorectal	
carcinoma cell line.
	 As	described	in	the	introduction,	in	addition	to	the	role	in	anti-viral	defense,	IFI16	was	first	
suggested	to	be	linked	to	tumour	suppression.	Although	it	cannot	be	classified	as	a	conventional	tumour	
suppression	protein	it	satisfies	several	important	criteria.	For	example,	IFI16	has	been	associated	with	
reduced cell proliferation, cell cycle arrest and cellular senescence. Moreover, it has been observed to 
interact with several tumour suppressor proteins such as pRb, p53 and BRCA1. Also, IFI16 expression 
is lost in several human tumours such as breast and prostate cancer cells (Johnstone, Wei et al. 2000; 
Aglipay, Lee et al. 2003; Xin, Curry et al. 2003; Fujiuchi, Aglipay et al. 2004; Raffaella, Gioia et al. 
2004; Xin, Pereira-Smith et al. 2004; Kim, Park et al. 2005).
 Regarding the relationship of IFI16 with p53 it is known that IFI16 and p53 associate with each 
other and that the binding of IFI16 to p53 is important for p53 binding to DNA (Johnstone, Wei et al. 
2000).	Specifically,	the	HIN-A	domain	of	IFI16	binds	the	C-terminus	of	p53,	likely	preventing	p53	
from	nonspecific	DNA	interactions;	whereas	the	HIN-B	domain	recognizes	the	core	domain	of	p53	
stabilizing the p53-DNA binding (Liao, Lam et al. 2011).
A variety of evidence suggests that the IFI16-p53 interaction enhances p53 transcriptional activity 
(Johnstone, Wei et al. 2000; Fujiuchi, Aglipay et al. 2004; Xin, Pereira-Smith et al. 2004; Gugliesi, 
Mondini et al. 2005; Duan, Ponomareva et al. 2011). Moreover, it is also likely that IFI16 is involved 
in recruitment of additional factors to the p53-binding sites via its PYRIN domain. Indeed, the BRCA1 
protein interacts with the PYRIN domain of IFI16 and promotes p53-dependent apoptosis (Aglipay, 
Lee et al. 2003).
 Although a role for IFI16 in modulating p53 activity has been suggested, whether p53 regulates 
IFI16 expression or activity is still unclear. There is only one report stating that functional activation 
of	p53	can	stimulate	the	transcription	of	the	IFI16	gene	in	normal	human	fibroblasts	and	the	human	
osteosarcoma Saos2 cell line (Song, Alimirah et al. 2008).
To better understand how p53 could regulate IFI16, lysates from HCT116 cells (colorectal carcinoma) 
expressing wt p53 and HCT116 p53-/- were analysed by western blot using antibodies anti-IFI16, 
anti-p53	and	anti-β-actin	as	a	loading	control.	Surprisingly	a	marked	decrease	in	IFI16	protein	levels	
was	observed	in	the	p53	deficient	cells	compared	to	those	in	wt	HCT116	cells	(Fig.	R40).
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	 As	 described	 in	 the	 introduction,	 IFI16	 protein	was	 firstly	 considered	 as	 a	 nuclear	 protein,	
specifically	nucleolar,	due	to	the	presence	of	a	nuclear	localization	sequence.	However,	several	studies	
have reported that IFI16 can be found in the nucleus, cytoplasm or both compartments depending on 
the cell type and several other factors (reviewed in (Veeranki and Choubey 2011)). Given that IFI16 
protein can associate with other proteins including p53, it is likely that these interactions contribute to 
the subcellular localization of IFI16. Since p53 has been considered mainly a nuclear protein, although 
it can also localize in the cytoplasm (reviewed in (O’Brate and Giannakakou 2003)), the interaction 
between p53 and IFI16 could contribute to the main nuclear localization of IFI16 in some cell types. 
However, in the absence of p53, IFI16 could be mislocalized to the cytoplasm leading to a reduction 
in IFI16 stability. To test this hypothesis HCT116 wt and p53-/- cells were subjected to subcellular 
fractionation and immunoblotting analysis for IFI16 (Fig. R41). The validity of the cell fractionation 
procedure	was	confirmed	by	assay	for	lamin	A/C	(a	nuclear	protein)	and	MEK1/2	(cytosolic	protein).	
IFI16 was mainly concentrated in the nuclear fraction with relatively lower levels in the cytoplasmic 
fraction in wt HCT116 cells. As previously observed in p53-null HCT116 cells IFI16 was barely 
expressed, however, IFI16 was slightly more abundant in the cytoplasmic fraction. This result was 
consistent with the hypothesis that the association of p53 might affect IFI16 stability.
 
Figure R40.  IFI16 is hardly expressed in HCT116 p53-/- cells. 
50 µg of total lysates from HCT116 cells, wt and p53-/-, were 
analysed by western blot with antibodies to IFI16, p53 and 
β-actin.
Figure R41. IFI16 is mainly nuclear in wt HCT116 but it is 
barely expressed in HCT116 p53-/- cells. HCT116 wt and 
p53-/- cells were subjected to subcellular fractionation. 
Equal amounts (15µg) of total protein were loaded in 
each lane and were analysed by western blot with an 
antibody to IFI16. Lamin A/C was used as a nuclear (N) 
marker, and MEK 1/2 was used as a cytoplasmic (C) 
marker.
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 In spite of the fact that HCT116 cells are tumour-derived cells, they express wt p53. Therefore, 
the reduced expression of IFI16 in HCT116 p53-/- cells was consistent with the possibility that wt p53 
was involved in regulating the stability of IFI16 protein or that wt p53 could regulate IFI16 expression 
at either a transcriptional or translational level. 
 If the absence of p53 protein was associated with the marked decrease of IFI16 protein expression 
due to a role of p53 on IFI16 expression or stability then, the reconstitution of p53 expression could 
restore IFI16 expression. To test this hypothesis, HCT116 p53-/- cells were transfected with a plasmid 
containing p53 wt or a plasmid containing a p53 mutant sequence (R175H, an arginine to histidine 
mutation at residue 175). The R175H mutation is a hotspot mutation in the DNA-binding core domain 
of	p53,	classified	as	a	p53	structural	mutation,	 i.e	 it	greatly	perturbs	 the	conformation	of	 its	DNA-
binding region (reviewed in (Sigal and Rotter 2000; Joerger and Fersht 2007)). As with all hotspot 
mutations, it abolishes the wild type tumor suppression function of p53, but this mutant has also 
acquired new oncogenic functions in promoting tumorigenesis (Liu, Song et al. 2010). Lysates from 
transfected HCT116 p53-/- cells were analysed by western blot with antibodies to IFI16, p53 and 
β-actin	(Fig.	R42).	As	shown	in	Figure	R42	no	re-expression	of	IFI16	protein	was	observed	after	p53	
reconstitution with wt or mutant p53. 
Figure R42. IFI16 expression is not reconstituted in HCT116 p53-/- cells after p53 restoration. 
HCT116 p53-/- were plated into a 6 well-plate and transfected with 3 µg of empty vector or 
expression vector for p53 wt or the mutant p53-R175H using jetPEI. HCT116 p53-/- cells were also 
exposed to jetPEI reagent (no vector) as another negative control. Total cell lysates were prepared 
at 44 hours after transfection and 25 µg of protein lysates from these cells and from HCT116 wt, as 
a positive control of IFI16 and p53 expression, were analysed by western blot using antibodies to 
IFI16, p53 and β-actin.
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This result was consistent with a previously published report where the expression of tranfected wt p53 
did not affect the expression levels of transfected IFI16 (Johnstone, Wei et al. 2000). 
 It is well known that p53 regulates the expression of different genes, mainly involved in cell 
cycle arrest and apoptosis, in response to various forms of cellular stress (reviewed in (Laptenko and 
Prives 2006; Kruse and Gu 2009)). Moreover, the single report about IFI16 up-regulation by p53 
showed that activation of p53, for example in response to certain DNA-damaging agents, stimulated 
the transcription of the IFI16 gene (Song, Alimirah et al. 2008). 
 Therefore to ascertain if activation of p53 was required for regulating IFI16 expression the 
previous transfections were repeated and 24 hours after transfection cells were subjected to different 
DNA-damaging agents: short wave ultraviolet radiation (254nm) during 15 minutes as a non-ionizing 
radiation (Fig. R43) or gamma radiation (Cesium 137,10Gy) as an ionizing radiation (Fig. R44). Total 
cell lysates were prepared at 4 hours post-irradiation and were analysed with antibodies to IFI16, p53 
and	β-actin.	The	cells	were	collected	at	this	time	point	because	according	to	Fujiuchi	et al. in cells 
in which IFI16 expression is reduced the maximal activation and, in consequence, stabilization of 
p53 occurred at 2-4 hours post-irradiation (10Gy) (Fujiuchi, Aglipay et al. 2004). Therefore, if IFI16 
expression levels were regulated by p53 activation, an IFI16 upregulation might be expected when p53 
was maximally activated.
Moreover to assess whether p53 activation could also affect the expression levels of a transfected 
IFI16, IFI16 isoform B was cloned and transfected together with wt or mutant p53.
 As shown in Figure R43, after exposure to gamma radiation IFI16 levels were similar to those 
of non-irradiated cells in wt HCT116, non-transfected HCT116 p53-/- and p53-transfected cells. 
Similarly, no differences were found in IFI16 expression levels between non-transfected and p53-
transfected HCT116 p53-/-cells after exposure to gamma radiation. Moreover, when IFI16 and p53 
were co-expressed in these experiments, the presence of p53 does not seem to increase the levels of 
transfected IFI16 since they were equivalent between wt and mutant p53-transfected cells. However, 
in the experiments shown in Figure R43 a control for IFI16 transfection alone would be required to be 
able to compare the IFI16 expression levels properly. This control was included when UV radiation 
was used as the DNA-damaging agent (Fig. R44) and it was observed that cotransfection of p53 with 
IFI16 did not increase the levels of the transfected IFI16 compared to those seen in cells transfected 
with IFI16 alone. Moreover, after exposure to UV IFI16 levels of cells transfected with p53 were 
similar to those from non-transfected and non-irradiated p53 null cells. Although in this experiment a 
control of non-transfected but UV-exposed p53-null cells, as included in Figure R43, would have been 
required	to	allow	more	confident	interpretation	of	the	data.
These results indicate that p53 seems not to induce the up-regulation of IFI16 expression after exposure 
to ionizing and non-ionizing radiation. 
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Figure R43. IFI16 expression is not reconstituted in HCT116 p53-/- when p53 is restored and activated 
after gamma irradiation. HCT116 p53-/- were plated in duplicates into 6 well-plates and transfected 
with 3 µg of expression vector for p53 wt or the mutant p53-R175H or 1.5 µg of each plasmid in the 
double transfections (IFI16 full-length plus p53 wt or the mutant p53-R175H) using jetPEI. 24 hours 
after transfection plates were exposed or not to ionizing radiation (gamma irradiation; source Cesium 
137; 10 Gray). 4 hours after irradiation total cell lysates were prepared and 25 µg of protein lysates were 
analysed by western blot using antibodies to IFI16, p53 and β-actin.
Figure R44. IFI16 expression is not reconstituted in HCT116 p53-/- when p53 is restored and activated 
after UV radiation. HCT116 p53-/- were plated in duplicate into 6 well-plates and transfected with 3 µg of 
expression vector for IFI16 full-length, p53 wt or the mutant p53-R175H or 1.5 µg of each plasmid in the 
double transfections (IFI16 plus p53 wt or the mutant p53-R175H) using jetPEI. 24 hours after transfection 
plates were exposed or not to UV radiation (254 nm) during 15 minutes. 4 hours after irradiation total cell 
lysates were prepared and 30 µg of protein lysates from these cells and from HCT116 wt, as a positive control 
of IFI16 and p53 expression, were analysed by western blot using antibodies to IFI16, p53 and β-actin.
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 In conclusion, these results suggested that on activation in response to DNA-damaging 
agents, p53 was not able to induce the expression of IFI16. However, inclusion of a control for p53 
activation by both types of radiation, for example p53-phosphorylated on Serine15, would provide 
more	confidence	in	this	conclusion.	Even	though	gamma	(ionizing	radiation)	and	UV	(non-ionizing	
radiation) exposure induce different types of DNA damage (ionizing radiation induces DNA strand 
breaks whereas UV light provokes pyrimidine dimers), and distinct signalling pathways are triggered 
following exposure to these different types of radiation (reviewed in (Ljungman 2000; Ljungman and 
Lane 2004)), phosphorylation of Serine15 is a major focal point in the activation of p53 during both 
DNA	damage	responses	(Loughery,	Cox	et	al.	2014).	Specifically,	this	residue	is	phosphorylated	in	an	
ATM/ATR-dependent manner in response to IR, and in an ATR-dependent manner in response to UV 
(reviewed in (Lakin and Jackson 1999)).
 Thus, although these preliminary data do not allow rejection of the hypothesis that p53 could 
have	a	role	in	IFI16	expression	in	HCT116	cells,	it	seems	that	p53	activation	is	not	sufficient	to	activate	
IFI16 expression. 
 We had also planned to measure the IFI16 mRNA levels of wt and p53-null HCT116 cells by 
quantitative real-time PCR (qRT-PCR) to assess if the regulation of IFI16 by p53 could be at mRNA 
or protein level. For example, if the expression of the corresponding IFI16 mRNA was not affected 
in the p53 knockout cells compared to that from wt cells, any IFI16 protein up-regulation observed in 
wt cells might be a result of protein accumulation through IFI16 stabilization by p53 or p53 could be 
involved in IFI16 translation. On the other hand, if the levels of IFI16 mRNA were down-regulated in 
the p53-null cells, this could indicate that p53 could stimulate the IFI16 transcription. Nevertheless, it 
would be essential to verify the integrity of IFI16 gene in HCT116 p53-null cells. 
However, it proved impossible to continue doing more experiments with the HCT116 cells because 
both wt and p53 knockout cells, started to grow as spheroids instead of as a monolayer. For as yet 
unknown reasons, when the wt cells formed these spheroids they did not express IFI16 anymore. 
Intriguingly, no other batches of HCT116 cells supplied by other groups expressed IFI16 protein.  
3.2.	 Expression	of	IFI16	protein	in	human	mammary	cell	lines
 We next wanted to extend the analysis of IFI16 expression in other cell lines of known p53 
genotype. As mentioned before it is known that levels of IFI16 mRNA and/or protein are frequently 
decreased in many breast cancer cell lines  and tissues from breast cancer patients (Fujiuchi, Aglipay et 
al. 2004), suggesting a potential link between loss of IFI16 and breast cancer development. Although 
other factors apart from p53 could affect IFI16 expression in these cells, we wanted to take advantage 
of the extensive knowledge of p53 genotype in breast cancer cells to study its possible relation with 
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IFI16 expression.
 Therefore to relate the genotype of p53 to the IFI16 expression levels, lysates from different 
human mammary cell lines (normal and tumoral) (Table R3) were analyzed by western blot with 
antibodies to IFI16 and p53 (Fig. R45). 
In order to establish the p53 mutations in the breast cell lines used in our study, we compared the 
information among different databases which describe the p53 status in cell lines: the p53 database 
that was originally developed by T. Soussi at the Institut Curie in Paris, France (http://p53.free.fr/) 
and the International Agency for Research on Cancer TP53 database (http://p53.iarc.fr/) maintained 
and curated in Lyon, France. In addition, we contrasted the previous information with the Catalogue 
of Somatic Mutations in Cancer (COSMIC) database of the Sanger Institute, England (http://cancer.
sanger.ac.uk/cosmic).	 This	 database	 is	 not	 specific	 to	 p53	mutations	 but	 it	 does	 tabulate	 multiple	
somatic mutations and related published information relating to human cancers and cancer cell lines.
During the last years there has been an extraordinary increase in the information about DNA sequence 
mutations and in particular there is a vast amount of information about p53 mutations, which are the 
genetic defects most frequently reported in human cancers (reviewed in (Levine and Oren 2009; Olivier, 
Hollstein et al. 2010)). For this reason different databases registering all published p53 mutations have 
been established. Although the different databases show slight differences in some cell lines due to 
a lack of homogeneous data in the literature, to our knowledge the IARC online resource claims to 
track reported p53 mutations and performs updated data retrieval as well as reviewing and editing the 
database contents. Moreover this database contains the full reference of all publications describing the 
p53 mutations in each cell line. In addition, the p53 mutations registered in the IARC database are in 
concordance with our results (Fig. R45). Therefore, we used mainly the data of p53 mutations from the 
IARC database (Table R4) in order to relate IFI16 expression to the p53 genotype.
Wild type p53 Mutant p53
MCF10A (Normal) MDA-MB-468 (Tumoral)
HB4a (Normal) (n/a) BT-474 (Tumoral)
MCF7 (Tumoral) SK-BR-3 (Tumoral)
MDA-MB-361 (Tumoral)
MDA-MB-453 (Tumoral)
T-47D (Tumoral)
Hs578T (Tumoral)
BT-549 (Tumoral)
MDA-MB-157 (Tumoral)*
MDA-MB-231 (Tumoral)*
Table R3. p53 status of the breast 
cell lines used in this study. 
Although there is no information 
available about the status of 
p53 genotype in HB4a, it was 
classified in the wt p53 group 
because it is a nontumorigenic 
and nontransformed breast cell 
line. n/a: not available. (*) MDA-
MB-157 and MDA-MB-231 cell 
lines were later shown to be 
actually the colon cell line SW480.
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 Note that although the MDA-MB-231 and MDA-MB-157 cell lines appear in Table R3 and 
Figure R45-C, the provenance of these cancer cell lines was not clear and they actually turned out to 
be the colon cell line SW480 when cell genotyping was performed. For this reason the p53 mutations 
of these cells do not appear in Table R4.
Cell line Nucleotide change Aminoacid change
MDA-MB-468 c.818G>A p.R273H
BT-474 c.853G>A p.E285K
SK-BR-3 c.524G>A p.R175H
MDA-MB-361 c.166G>T p.E56*
MDA-MB-453 c.1101_1130del30 / c.991-1182del192 p.?
T47D c.580C>T p.L194F
Hs-578T c.469G>T p.V157F
BT-549 c.747G>C / c.108G>A p.R249S / p.P36P
 It is important to note that the breast cancer cell lines analysed which possess a missense 
mutation (MDA-MB-468, BT-474, SK-BR-3, T-47D, Hs578T and BT-549), in contrast to cell lines 
with deletion (MDA-MB-453) and nonsense (MDA-MB-361) mutations, displayed elevated levels of 
p53	protein	as	compared	to	the	wt	protein	(Figure	R45).	As	mentioned	in	the	first	section	of	Results,	in	
normal cells p53 has a very short half-life because wt p53 is degraded by MDM2-mediated proteolysis. 
However, mutated p53 often has an extended half-life due to its defect in MDM2 transactivation and 
binding. Missense mutations are the most frequent genetic alterations in p53 and most of them expand 
p53 half-life producing an accumulation of the full-length protein (reviewed in (Brosh and Rotter 
2009)). For this reason accumulation of mutant p53 is a common characteristic of human cancer, 
including breast tumours (Bartek, Bartkova et al. 1991). Therefore our result agreed with previous 
reports showing that many human breast tumours accumulated high levels of a missense mutant p53 
(Bartek, Bartkova et al. 1990; Bartek, Iggo et al. 1990; Davidoff, Humphrey et al. 1991).
 Unlike wt HCT116, not all the breast cell lines that have wt p53 (MCF10A, HB4a and MCF7) 
express IFI16; only the normal cell lines MCF10A and HB4a expressed IFI16 (although note that 
HB4a only expressed one of the three IFI16 isoforms), whereas the tumoral MCF7 did not express 
IFI16. However, the p53 molecule expressed in MCF7 ran slightly slower than the p53 protein from 
MCF10A (Fig. R45 A-B).
 On the other hand, most of the breast cancer cell lines that have a mutant p53 showed no IFI16 
expression, except Hs578T, which expressed IFI16 levels comparable to MCF10A, and BT-549, which 
expressed slight levels of IFI16 (Fig. R45 A,B and C).
Table R4. p53 mutations of the breast cancer cell lines used in this study according to the 
International Agency for Research on Cancer (IARC) TP53 Database. (*) means STOP codon.
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 These results were consistent with the previous report indicating a frequent loss of IFI16 
in many human breast cancer cells (Fujiuchi, Aglipay et al. 2004), thus reinforcing the idea of an 
involvement of IFI16 in tumour suppressor functions in breast cancer.
 Although these results were consistent with the previously published data, no direct correlation 
between the presence of functional p53 and the expression of IFI16 in breast cell lines as shown in 
HCT116 was observed. It seems that the expression of IFI16 may be more dependent on the cellular 
phenotype (normal or tumoral) in breast cells.
Figure R45. Analysis of IFI16 expression based on p53 status in human breast cells. (N) Normal breast cell 
lines and (T) tumor breast cell lines. 50 µg of total lysates from different breast cells lines were analysed by 
western blot with antibodies to IFI16, p53 and β-actin. (*) MDA-MB-157 and MDA-MB-231 cell lines were later 
shown to be actually the colon cell line SW480. 
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 Taken together, these results suggested that IFI16 function could be lost in breast cancer 
development. 
3.3.	 Expression	of	IFI16	expression	in	human	bladder	cell	lines
 As mentioned previously, several studies and our own work have demonstrated that loss or 
reduced expression of IFI16 is often associated with breast cancer (Fujiuchi, Aglipay et al. 2004), and 
other human cancers such as prostate cancer (Xin, Curry et al. 2003). 
 To study if the reduction of IFI16 expression was consistent in other epithelial cancer cell 
lines not yet studied for IFI16 expression, lysates from a panel of different bladder tumour cell lines 
(Table R5) that have different mutational status of p53 (Table R6) were analysed by western blot using 
antibodies to IFI16 and p53 (Fig. R46). 
Wild type p53 Mutant p53
RT4 RT-112
J82
UM-UC-3
T-24
Cell line Nucleotide change Aminoacid change
RT-112 c.548C>G / c.743G>A p.S183* / p.R248Q
J82 c.811G>A p.E271K
UM-UC-3 c.338T>G p.F113C
T24-A c.378C>G p.Y126*
 It is important to note that according to the three databases that we checked for p53 mutational 
status, p53 could contain different mutations in the J82 cell line due to a controversy between 
publications. Moreover, there are two sublines of the T24 cell line which seem to contain a different 
p53 mutation. In these experiments we have assumed that the p53 mutations in both cell lines (shown 
in	Table	R6)	were	the	ones	defined	in	a	mutational	analysis	carried	out	by	the	group	that	provided	us	
with these cells (Lopez-Knowles, Hernandez et al. 2006).
Table R5. p53 status of the bladder tumor cell lines used in this study.
Table R6. p53 mutations of the bladder cancer cell lines used in this study according to the 
International Agency for Research on Cancer (IARC) TP53 Database and/or Lopez-Knowles et 
al. (*) means STOP codon.
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 As shown in Fig. R46 IFI16 expression was detected in all the bladder tumour cell lines 
independently of the p53 status. Indeed, the RT4 cell line that contains wt p53 expressed lower 
levels of IFI16 than the other cell lines. Unlike the majority of the breast cancer cell lines analysed, a 
direct correlation between the absence or reduction of IFI16 expression and tumoral phenotype was 
not observed in the bladder cancer cell lines studied. Moreover, a relation between the presence of 
functional p53 and the expression of IFI16, as we observed in HCT116 cells, was not found in these 
bladder tumour cells.
 Altogether, the results shown here demonstrated that IFI16 is never expressed in the absence 
of p53 in HCT116 cells. This is consistent with the hypothesis that p53 expression is required but 
not	sufficient	for	the	expression	of	IFI16	in	HCT116	cells,	because	the	transfection	with	p53	was	not	
sufficient	to	activate	IFI16	expression.	The	nature	of	the	other	factors	required	for	IFI16	expression	
remains unclear. When the expression of IFI16 protein in eleven breast cell lines  was analyzed, it was 
apparent that the majority of the cells that have a mutant p53 (all except Hs578T) did not express or 
slightly expressed IFI16, however this correlation was not observed in the bladder cancer cell lines 
studied. 
 All in all, these results suggest that IFI16 expression regulation by p53 could be tissue-
dependent.
Figure R46. Analysis of IFI16 expression based on p53 status in bladder tumour cell 
lines. 40 µg of total lysates from different bladder tumour cell lines were analysed by 
western blot with antibodies to IFI16, p53 and β-actin.
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	 The	 importance	of	 innate	 immune	system	 in	 response	 to	viral	 infections	 is	 reflected	by	 the	
complexity of the interactions between the virus and host. Infection with viruses leads to the release 
of viral DNA into the cellular cytoplasm or nucleus. The cascade of signals activated by microbial 
DNA	sensors	not	 only	 stimulates	 the	 recruitment	of	 immune	cells	 to	 the	 site	 of	 inflammation,	 but	
also could induce changes in the infected cell to facilitate direct immune recognition of the infected 
cell (Hamerman, Ogasawara et al. 2004; Kloss, Decker et al. 2008). Therefore it is not surprising that 
viruses have developed strategies to evade the recognition and signaling by DNA sensors. Several 
DNA	sensors	have	been	identified,	among	them	IFI16,	which	on	recognition	of	viral	DNA	induces	
the	production	of	type	I	IFN	and	the	assembly	of	the	inflammasome	complex	leading	to	maturation	
of	 inflammatory	cytokines	(Unterholzner,	Keating	et	al.	2010;	Kerur,	Veettil	et	al.	2011).	Recently,	
IFI16 has been shown to play an additional role in antiviral defense by silencing herpesvirus genomes, 
specifically	HSV-1	and	HCMV	genomes	(Orzalli,	Conwell	et	al.	2013)	(Gariano,	Dell’Oste	et	al.	2012;	
Johnson, Bottero et al. 2014).
 During experiments involving virus infection it was observed that HSV-1 infection led to a 
loss of IFI16 expression. An initial hypothesis was that the reduced expression of these molecules 
reflected	a	general	inhibition	of	synthesis	of	cellular	proteins	associated	with	virus	infection,	however	
other observations suggesting that IFI16 has a long half-life in the cell (data not shown) indicated that 
this hypothesis was not correct and suggested the existence of viral strategies to evade the immune 
response	promoted	by	 this	molecule	via	 specific	 inhibition	of	 its	 expression.	 Indeed,	Orzalli	et al. 
concluded	that	ICP0	promoted	the	IFI16	degradation	in	a	proteasome-	and	ICP0	RING	finger	domain-
dependent	mechanism.	However,	conflicting	data	have	been	published	on	the	role	of	ICP0	in	mediating	
destabilization of the DNA sensor protein IFI16 after HSV-1 infection. Thus, the impact of ICP0 on 
IFI16 remains to be fully understood. In this thesis this phenomenon has been re-examined and these 
data	confirm	that	infection	with	HSV-1	leads	to	a	marked	reduction	in	IFI16	expression	levels,	although	
the extent of the loss of IFI16 varies somewhat between different cell lines. These data also show that 
IFI16 levels are slightly reduced after infection with ICP0 mutant virus, but that the reduction in IFI16 
expression is markedly enhanced if the HSV-1 expresses ICP0 and that this loss of IFI16 can occur 
even	in	the	absence	of	efficient	viral	replication.
 The existence of an ICP0-dependent regulation of IFI16 stability after HSV-1 infection was 
first	suggested	by	the	observation	that	the	decrease	in	IFI16	seen	after	infection	with	wt	HSV-1	(strain	
KOS) or a virus which expresses ICP0 but not additional IE gene products (d106) is markedly greater 
than that observed after infection with a virus which expresses no IE proteins (d109) (Orzalli, DeLuca 
et al. 2012; Johnson, Chikoti et al. 2013). However, a third paper, from a group with considerable 
expertise	in	the	biology	of	ICP0,	concluded	that	ICP0	was	neither	necessary	nor	sufficient	to	trigger	a	
loss of IFI16 (Cuchet-Lourenco, Anderson et al. 2013). They argued that ICP0 controls the likelihood 
of	progression	of	viral	 infection	(Everett,	Boutell	et	al.	2004)	and	 that	 the	efficient	entry	 into	 lytic	
replication, rather than ICP0 expression per se, regulates IFI16 stability (Cuchet-Lourenco, Anderson 
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et al. 2013). This argument was supported by experiments showing that IFI16 can be degraded 
normally	in	the	absence	of	ICP0	as	long	as	the	lytic	cycle	is	progressing	efficiently	(Cuchet-Lourenco,	
Anderson et al. 2013). We could not achieve the same infection progression in both ICP0-null and 
control	virus	 infections,	as	did	Cuchet-Lourenço	and	colleagues,	 to	compare	properly	the	levels	of	
IFI16 between the two infections, and this could be explained due to the differences in the moi used, 
since	 variations	 in	 the	 multiplicity	 could	 provoke	 modifications	 in	 the	 results.	 However,	 the	 key	
observation	of	this	thesis	is	that	infections	with	a	set	of	mutant	viruses	deficient	for	expression	of	one	
or more IE genes including ICP4 but excluding ICP0, and thus unable to complete a normal cycle 
of	viral	replication(DeLuca,	McCarthy	et	al.	1985),	as	judged	by	UL42	expression,	are	sufficient	to	
produce a marked decrease in IFI16 (Fig. R4). These viruses will express only very low levels, if any, 
of HSV-1 viral gene products other than ICP0 and so these data clearly show that ICP0 expression, 
even	in	the	context	of	a	non-productive	viral	infection,	can	be	sufficient	to	trigger	a	marked	reduction	
of IFI16 expression levels. It is not clear why expression of ICP0 during a viral infection, but not by 
transfection,	should	be	sufficient	to	trigger	IFI16	loss	but	this	might	be	related	to	the	levels	of	ICP0	
expression. ICP0 has been reported to be expressed at higher than normal levels in cells infected with 
ICP4 mutant viruses (DeLuca, McCarthy et al. 1985), while the levels of ICP0 achieved in the induced 
cells	used	by	Cuchet-Lourenço	et al,	although	sufficient	to	trigger	PML	degradation,	were	lower	than	
those obtained after infection with wt HSV-1 strain 17 (Cuchet-Lourenco, Anderson et al. 2013). 
Specifically,	the	levels	of	ICP0	induced	in	the	cell	system	employed	by	these	authors	were	equivalent	
to those at early stages of infection. These data suggested that the amount of ICP0 needed to degrade 
IFI16 was higher than that for PML degradation. Therefore, further quantitative studies comparing the 
expression levels of ICP0 between cell lines and their impact on IFI16 levels would be an important 
area for further investigation. In this context, a control for ICP0 expression in all of our western blot 
analyses would have been convenient. The differences between PML and IFI16 degradations might 
also	reflect	the	use,	by	ICP0,	of	distinct	mechanisms	to	target	both	proteins.	Since	ICP0	uses	a	variety	
of	mechanisms	to	target	different	substrates	for	degradation,	elucidation	of	the	specific	mechanism	
employed by ICP0 to target IFI16 would be an interesting area of study. 
Viral proteins that enter the cells as part of the virion might interact with ICP0 to produce the reduction 
in IFI16, but this explanation seems unlikely since cells exposed to the d109 virus that contains 
mutations	in	the	five	IE	genes	ICP0,	ICP4,	ICP22,	ICP27,	and	ICP47,	effectively	blocking	all	viral	
gene expression during infection (Samaniego, Neiderhiser et al. 1998) does not trigger a loss of IFI16 
expression, although this virus lacks ICP0 (Orzalli, DeLuca et al. 2012). 
 The simplest model that can be advanced to reconcile these observations is that the turnover 
of IFI16 protein depends on cellular factors, but that this process is enhanced in the presence of 
ICP0. In this model HSV-1 infection, for example by shutting-off host-protein synthesis, will lead to 
a reduction in IFI16 expression at a rate that depends on the stability of IFI16 in that particular cell. 
However expression of ICP0 acts to “catalyze” this loss of IFI16. 
	 The	idea	that	cellular	factors	influence	the	loss	of	IFI16	after	HSV-1	infection	is	mainly	based	
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on the observation that the degree to which IFI16 expression is reduced after infection varies between 
cell	lines.	For	example,	in	both	our	experiments	and	those	of	Cuchet-Lourenço	et	al	(Cuchet-Lourenco,	
Anderson et al. 2013) infection of the U2OS osteosarcoma cell line was associated with lower levels of 
IFI16 loss than seen after HSV-1 infection of HFFs. Although in our experiments a more pronounced 
loss of IFI16 was observed in U2OS cells infected with the control virus than that described by Cuchet-
Lourenço	and	colleagues.	Some	of	this	variation	may	reflect	differences	in	experimental	conditions;	in	
our experiments IFI16 expression was analysed 24 hpi whereas they analysed IFI16 12 hpi (Cuchet-
Lourenco, Anderson et al. 2013). Although cell death may contribute to the decreased IFI16 levels 
at	24	hpi,	 analysis	of	 the	 expression	of	other	 cellular	proteins	would	have	confirmed	 that	 IFI16	 is	
specifically	targeted	for	degradation	during	HSV-1	infection.	However,	other	published	studies	have	
determined the kinetics of IFI16 degradation showing a progressive loss of IFI16 that directly depends 
on the time of infection (Orzalli, DeLuca et al. 2012; Cuchet-Lourenco, Anderson et al. 2013; Johnson, 
Chikoti et al. 2013), with little or no IFI16 staining by 24 hpi (Johnson, Chikoti et al. 2013).
 An interesting observation is that IFI16 degradation during infection of HFF, U2OS and Vero 
cells with the replication-defective mutant viruses deleted for the regulatory IE genes except ICP0 
correlates with the number of IFI16 isoforms observed in each cell line (Fig. R3). One hypothesis to 
explain this observation could be that expression of the cellular factors that regulate the expression of 
the different IFI16 isoforms or their turnover might vary among different cell lines, thereby affecting 
the	efficiency	of	IFI16	degradation	mediated	by	ICP0.
	 Indeed,	inspection	of	data	from	a	number	of	other	authors	confirms	that	there	is	considerable	
variation in the effect of HSV-1 infection on IFI16 between different cell lines. HSV-1 infection of HEp-
2 cells (derived from an epithelial carcinoma) produced a loss of IFI16 expression that was moderately 
more marked than that observed after HSV-1 infection of HEL cells (human embryonic lung cells) 
(Kalamvoki and Roizman 2014). However, when STING, an interaction partner of IFI16, was deleted, 
the pattern of IFI16 expression was completely different in both cell lines. Infection of the human 
mammary epithelial cell line 184B5 leads to an almost complete loss of IFI16 expression after only 4 
hpi, whereas infection of another breast cancer cell line, HCC1937, actually leads to accumulation of 
IFI16 (Dutta, Dutta et al. 2015). The simplest interpretation of all these data is that the stability of IFI16 
is regulated by cellular factors differentially expressed between these different cell lines. The identity 
of these factors is as yet unknown, but IFI16 protein is known to interact with multiple cellular proteins 
including BRCA1, p53 and cGAS  (Johnstone, Wei et al. 2000; Aglipay, Lee et al. 2003; Song, Alimirah 
et al. 2008; Liao, Lam et al. 2011; Orzalli, Broekema et al. 2015; Diner, Li et al. 2015a). Interestingly, 
the breast cancer cell line HCC1937 expresses a truncated BRCA1 protein (Chen, Silver et al. 1998; 
Tomlinson, Chen et al. 1998). Given that BRCA1 has E3 ubiquitin ligase activity, the absence of the 
wt BRCA1 protein could prevent the ubiquitination of IFI16 leading to its accumulation during HSV-1 
infection.	Moreover,	since	the	HCC1937	cells	are	also	deficient	in	functional	p53	(Tomlinson,	Chen	
et al. 1998), speculatively, the lack of IFI16 degradation during HSV-1 infection could also be due to 
the absence of wt p53. It is known that the absence of cGAS is associated with a decreased stability 
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of IFI16 (Orzalli, Broekema et al. 2015). As Sun and colleagues suggested (Sun, Wu et al. 2013) it is 
possible that not all cell types express the same repertoire of DNA sensors. Thus cell types with lower 
expression of cGAS could show a decreased stability of IFI16. Although it has been demonstrated that 
cGAS promotes the stability of IFI16 in HFF cells, the mechanism by which cGAS enhances IFI16 
stability has not been described. As Orzalli et al proposed the interaction of cGAS with IFI16 could 
affect the conformation of IFI16 preventing the binding of an E3 ubiquitin ligase or facilitating the 
binding of a deubiquitinase (Orzalli, Broekema et al. 2015). IFI16 is also known to undergo multiple 
post-translational	modifications,	including	acetylation	and	phosphorylation	(Li,	Diner	et	al.	2012)	that	
regulate	the	intracellular	localisation	of	this	protein,	but	the	effects	of	these	modifications	on	IFI16	
stability, nor how they vary between cell lines, are not yet clear. Thus, in addition to the well known 
cell-type	dependent	restriction	of	replication	of	ICP0	deficient	viruses	the	nature	of	the	cell	line	used	
can profoundly affect the experiment, presumably via variation in the expression of other factors that 
modify or interact with ICP0. Indeed during the writing of this thesis a recent study has also proposed 
that	ICP0	is	necessary	but	not	sufficient	for	IFI16	degradation,	suggesting	that	in	addition	to	the	ICP0	
ubiquitin ligase activity other viral or cellular mechanisms contribute to IFI16 stability (Diner, Lum 
et al. 2015b). Finally, in this context, it is interesting to note that STING, which interacts with IFI16, 
is stable in cancer-derived HEp-2 and HeLa cells infected with wt HSV-1, but degraded when cells 
are infected with ICP0-null mutants (Kalamvoki and Roizman 2014). Curiously, however, in normal 
tissue-derived HEL or HEK293T cells, STING is stable throughout infection with either wt or ICP0 
mutant viruses. The degradation of STING does not appear to be related to the effects of viral infection 
on IFI16 degradation in neither case (Kalamvoki and Roizman 2014). Kalamvoki et al. concluded that 
HSV-1 has not evolved the capacity to make STING dysfunctional or to degrade it because STING 
is not only detrimental for the infection but also necessary for optimal viral replication. Another 
example of this double functionality related to the IFN pathway would be NF-κB, which could be both 
deleterious and essential for HSV-1 replication (Taddeo, Luo et al. 2003; Taddeo, Zhang et al. 2004). 
ICP0	in	particular	can	inhibit	NF-κB	activation	by	promoting	the	degradation	of	the	p50	component	
of	NF-κB	(Zhang,	Wang	et	al.	2013),	but	on	the	other	hand,	ICP0	also	ubiquitinates	IκBα,	which	is	
complexed	with	NF-κB,	leading	to	the	activation	of	NF-κB,	thereby	stimulating	the	transcription	of	
NF-κB	target	genes	(Diao,	Zhang	et	al.	2005).	Curiously,	NF-κB	has	been	shown	to	be	recruited	to	
ICP0 promoter, enhancing the transcription of ICP0 (Amici, Rossi et al. 2006). However, it seems that 
this is not case for IFI16, which is degraded in almost all the cell lines analyzed, although the degree 
of loss of IFI16 varies considerably between different cell lines.
	 In	view	of	these	findings,	it	is	tempting	to	conclude	that	ICP0 is necessary for efficient IFI16 
degradation,	and	depending	on	the	cell	type	it	could	also	be	sufficient	to	induce	IFI16	loss.	However,	
further experiments would be necessary in order to clarify this issue. Although it has been established 
numerous associations of IFI16 with viral and cellular proteins during HSV-1 infection (Diner, Lum et 
al. 2015b), further studies will be required to determine the important factors regulating IFI16 stability.
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	 The	fact	that	IFI16	can	recognize	the	presence	of	viral	DNA,	specifically	during	KSHV	(Kerur,	
Veettil et al. 2011; Singh, Kerur et al. 2013), EBV (Ansari, Singh et al. 2013), HCMV (Cristea, Moorman 
et al. 2010; Li, Chen et al. 2013) and HSV-1 (Unterholzner, Keating et al. 2010; Orzalli, DeLuca et al. 
2012; Li, Diner et al. 2012a; Johnson, Chikoti et al. 2013) infections, and exerts antiviral functions also 
in this compartment  has challenged the model in which the presence of DNA in the cytosol is the only 
factor that determines the difference between self and exogenous DNA (reviewed in (Unterholzner and 
Bowie 2011; Paludan and Bowie 2013) and has raised the question of how IFI16 distinguishes between 
viral and cellular DNA. Specially, the recognition of herpesviruses, dsDNA viruses that replicate in the 
nucleus of infected cells, is of particular interest.
It	 has	 long	 been	 known	 that	 IFI16	 binds	DNA.	Specifically,	 IFI16	 can	 recognize	 ssDNA,	 dsDNA	
and also RNA (Dawson and Trapani 1995b; Johnstone, Kerry et al. 1998a; Yan, Dalal et al. 2008). 
Additionally,	IFI16	was	suggested	to	bind	nonspecifically	to	GC-rich	ssDNA	(Yan,	Dalal	et	al.	2008)	
and GC-rich dsDNA (Luu and Flores 1997). It also bound to the G-rich fragment in the p53 and cMYC 
gene promoters. Moreover these fragments possessed non-B DNA structures (Egistelli, Chichiarelli et 
al. 2009). In addition to binding GC-rich regions, some reports have demonstrated a strong preference 
of IFI16 protein binding to cruciform structure and supercoiled (sc) DNA (Brazda, Coufal et al. 2012). 
And the crystal structures of the HIN domains from IFI16 in complex with the B-form dsDNA, derived 
from	the	vaccinia	virus	genomic	repeat	sequences,	revealed	a	non-sequence-specific	DNA	recognition	
through electrostatic attraction between the positively charged HIN domain residues and the dsDNA 
sugar-phosphate backbone (Jin, Perry et al. 2012). Given that the DNA-sensing activity of IFI16 seems 
to be independent of the DNA sequence (Unterholzner, Keating et al. 2010; Jin, Perry et al. 2012), an 
alternative explanation proposed by Johnson et al. is that during the circularization of the dsDNA genome 
of HSV-1 in the host nucleus, a DNA structure that resembles cruciform or supercoiled is recognized 
by IFI16 (Johnson, Chikoti et al. 2013). Since during lytic infection, HSV-1 genome associates with 
histones but not in regular repeating nucleosomes as cellular DNA (Kent, Zeng et al. 2004), another 
possibility could be that HSV-1 genome is more accessible for IFI16 binding. If this were true, IFI16 
recognition of viral DNA should mainly occur at late times postinfection since it has been reported that 
early in infection HSV-1 genome associates with histones but the proportion of viral DNA associated 
with histones decreases at later times postinfection (Cliffe and Knipe 2008; Oh and Fraser 2008). 
However, IFI16 actually responds very quickly to the invasion of HSV-1 genomes (Horan, Hansen 
et al. 2013; Johnson, Chikoti et al. 2013; Everett 2015). Alternatively, IFI16 may recognize the viral 
genome	as	damaged	DNA.	As	stated	in	the	introduction,	prior	to	its	identification	as	an	innate	immune	
sensor of pathogenic DNA, IFI16 had been shown to interact with components of the DNA damage 
response (DDR) such as BRCA1 and p53 (Johnstone, Wei et al. 2000; Aglipay, Lee et al. 2003; Song, 
Alimirah	et	al.	2008;	Liao,	Lam	et	al.	2011).	Specifically,	IFI16	is	known	to	associate	with	BRCA1	at	
sites of genomic DNA damage to induce p53-dependent apoptosis (Aglipay, Lee et al. 2003). Many 
viruses induce the same DDR pathways as those stimulated by abnormalities in genomic DNA. Some of 
these viruses including HSV-1 have evolved mechanisms to inhibit, circumvent or exploit the DDR for 
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example by activation of certain repair proteins or by targeting others for degradation or mislocalization 
(reviewed by (Lilley, Schwartz et al. 2007)). Consistent with the proposed link between the DDR and 
innate immune responses to viral DNA, UV-mediated DNA damage promoted the nuclear export of 
IFI16 (Costa, Borgogna et al. 2011), similar to the IFI16 translocation to the cytoplasm that occurs 
during certain viral infections (Kerur, Veettil et al. 2011; Ansari, Singh et al. 2013; Johnson, Chikoti et 
al. 2013; Dutta, Dutta et al. 2015). Moreover, some crucial components of the DDR pathways, such as 
DNA-PK and MRE11, have also been involved in STING-dependent responses to cytoplasmic or viral 
DNA (Zhang, Brann et al. 2011a; Ferguson, Mansur et al. 2012; Kondo, Kobayashi et al. 2013). It is 
also known the antiviral role of p53 by enhancing type I IFN responses (reviewed in (Rivas, Aaronson 
et al. 2010)) and it has also been shown that the DDR can induce the production of IFN (Brzostek-
Racine, Gordon et al. 2011).
Since	firstly	IFI16	and	later	PML	respond	very	rapidly	to	the	invasion	of	HSV-1	(Everett	2015),	and	
in turn IFI16 is related to BRCA1 and p53 during the DDR, this could indicate that IFI16 links the 
responses against HSV-1 infection: the recruitment of ND10 proteins and the recruitment of DDR 
proteins. And this highlights the connection between the functions of IFI16.
In the light of these various lines of evidences, it was possible that IFI16 might interact with HSV-1 
genome through other DDR proteins such as BRCA1 and p53 as proposed by Johnson et al. Since 
IFI16 is degraded by ICP0, the levels of these proteins could also be hypothesized to decrease during 
HSV-1 infection, if they are interacting directly with IFI16 in the same complex to bind HSV-1 DNA. 
Therefore, the expression levels of these proteins were analysed after HSV-1 infection.  
Our results show that HSV-1 infection does not induce a decrease in p53 levels via ICP0. Previous 
publications have demonstrated that in spite of p53 ubiquitination mediated by ICP0, p53 levels were 
stabilized during HSV-1 infection of HFF-2 cells (Boutell and Everett 2003; Boutell and Everett 2004; 
Boutell,	Canning	et	al.	2005).	Consistent	with	these	findings,	we	observed	that	in	HFF	cells	the	p53	
levels were stabilized after HSV-1 infection in a manner that was not exclusively dependent on ICP0, 
although its expression could have an impact on p53 stabilization (Fig. R7). Probably the requirement 
for ICP0 is related to its ability to induce viral gene expression, which triggers cellular responses that 
inhibit ubiquitination and turnover of p53, as proposed by the group of Roger Everett (Boutell and 
Everett 2004). Therefore, although HSV-1 infection can lead to the phosphorylation and stabilization 
of p53 in ATM-dependent (Shirata, Kudoh et al. 2005) and ATM-independent pathways (Boutell and 
Everett 2004), the ubiquitination of p53 mediated by ICP0 could prevent p53 downstream signaling 
reducing the levels of Mdm2 and p21, thereby blocking the main mechanism for apoptosis and ensuring 
the progression of infection, as Shirata and colleagues have suggested (Shirata, Kudoh et al. 2005).
 The p53 stabilization was cell-dependent since the work in this thesis showed, as has previously 
been observed (Boutell and Everett 2004), that p53 was not stabilized during HSV-1 infection of U2OS 
cells; indeed the total levels of p53 were reduced independently of ICP0 (Fig. R8). 
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 Analysis of the effect of ICP0 on BRCA1 levels during HSV-1 infection revealed that 
infection with both the ICP0-null virus and the control revertant virus induced a marked increase of an 
approximately 120-KDa protein reactive with an antibody for BRCA1 (I-20, Santa Cruz Biotechnology) 
(Fig. R9). This result was surprising since full-length BRCA1 protein has an apparent molecular weight 
on SDS-PAGE of around 220-230 KDa, however, no protein of this molecular weight was observed in 
our western blot analysis. Therefore, the ability of HSV-1 to regulate BRCA1 expression levels could 
not be validated.
 These experiments were performed to assay the effects of HSV-1 infection on IFI16, p53 and 
BRCA1	expression,	however,	it	should	be	noted	that	this	approach	does	not	allow	definition	of	whether	
IFI16 binds DNA alone or in complex with other proteins, or whether the DNA-binding activity of 
IFI16 is involved in the recruitment of other proteins that interact with IFI16 to sites associated with 
HSV-1 genomes. The degradation of IFI16-interacting proteins, such as p53 and BRCA1, would 
not have necessarily implied that these proteins participate with IFI16 in the recognition of HSV-1 
genomes	and	vice	versa.	To	examine	that	issue	would	require	the	use	of	immunofluorescence	assays	
to observe any possible colocalization among the proteins of interest and the incoming viral DNA, or 
chromatin immunoprecipitation assays. Indeed, it has recently been reported that BRCA1 regulates 
the	herpesviral	DNA	nuclear	 sensing	by	 IFI16	and	 the	 induction	of	 inflammasome	and	 type	 I	 IFN	
responses. These authors reported that BRCA1 is complexed with IFI16 in the nucleus of host cells, 
and after herpesviral genome recognition BRCA1 translocates into the cytosol together with the IFI16 
inflammasome	(Dutta,	Dutta	et	al.	2015).	This	observation	is	similar	to	the	movement	of	BRCA1	to	
the cytosol after DNA damage in a p53-dependent manner (Feng, Kachnic et al. 2004; Jiang, Yang 
et al. 2011), indicating once more the analogy between the responses against DNA damage and viral 
infections.
 As described in the introduction, HSV-1 has evolved to regulate components of the same 
pathway differentially to promote its own replication. For example, HSV-1 infection results in the 
activation of ATM and downstream targets including Chk2 and p53 (Lilley, Carson et al. 2005; Shirata, 
Kudoh et al. 2005; Li, Baskaran et al. 2008), however ICP0 prevents full activation of the ATM-
dependent pathway by inducing the degradation of RNF8 and RNF168, which are key mediators in 
this signalling pathway (Lilley, Chaurushiya et al. 2010). Given that BRCA1 is an important mediator 
in the ATM-signalling pathway and the 120 KDa-band was reactive with an antibody for BRCA1, 
the upregulation of the 120 kDa protein was intriguing. Since this band could be a potential splice 
variant of BRCA1, a product of BRCA1 cleavage induced by HSV-1 or another protein, a detailed 
characterization of this 120 KDa protein was undertaken.
	 From	these	data	it	can	be	concluded	that	the	upregulation	of	the	120	KDa-protein	was	specific	
to HSV-1 infection because, at least VACV, HCMV and HSV-2 infections did not alter the levels of this 
protein (Figs. R10, R11 and R14). 
 Upregulation of the 120 KDa-protein during HSV-1 infection was also observed in all the cell 
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lines analyzed, independently of their origin (Figs. R9, R10 and R36).
 Furthermore, the 120 KDa-protein was up-regulated during the infection with all the HSV-1 
mutants used, even during the infection with replication-defective mutant viruses; therefore, productive 
viral replication was not necessary to stimulate the up-regulation of the 120 KDa-protein, although 
infection with the mutants with a more restrictive phenotype (tsK and in1382) was associated with 
lower levels of induction of the protein (Figs. R13 and R14).
 It is important to note that in some immunoblot analyses the antibody I-20 recognized another 
protein of around 80 KDa in lysates of HSV-1 infected cells. Moreover, when lysates of uninfected 
cells were analysed another band appeared, but its molecular weight was a bit higher than the 120 KDa 
band observed on infected cells. 
 Since a band of approximately 220-230 kDa corresponding to full-length BRCA1 was not 
observed in our experiments with the I-20 antibody, another antibody against BRCA1 was used to 
assess the up-regulation of the putative BRCA1 related 120 kDa-protein during HSV-1 infection, 
and discard any possible I-20 antibody crossreactivity. Given that the I-20 antibody was raised by 
immunization with a peptide of the C-terminal region of the human BRCA1, the D-20 antibody (Santa 
Cruz Biotechnology) that was raised by immunization with a peptide from the N-terminus of the 
molecule	was	used.	However,	 this	 antibody	 showed	 extensive	 cross-reactivity	 and	poor	 specificity	
for BRCA1 making interpretation of these data problematic. The D-20 antibody recognized mainly 
a protein of 80-90 kDa in HSV-1 infected cells, but it did not recognize the 120 kDa protein or full-
length BRCA1 (Figs. R15, R16 and R17).
 Different proteins were detected by the I-20 and D-20 antibodies, and a protein that can be 
unequivocally	 identified	 as	 full-length	 BRCA1	 was	 not	 recognized	 by	 these	 antibodies,	 as	 other	
authors	 stated	 previously	 (Wilson	1996).	Moreover,	 the	 difficulty	 to	 detect	 endogenous	 full-length	
BRCA1 by different techniques including western blot analysis is widely known (Thomas, Smith et 
al. 1996; Wilson, Payton et al. 1996; Bernard-Gallon, Crespin et al. 1997; Wilson, Payton et al. 1997; 
Imakado, Hoashi et al. 1998; Wilson, Ramos et al. 1999; Yoshikawa, Honda et al. 1999; Perez-Valles, 
Martorell-Cebollada et al. 2001; Bogdani, Teugels et al. 2002; Milner, Wombwell et al. 2013). Thus, 
the presence of the bands observed not at the proper molecular weight could represent splice variants, 
cleavage products, or cross-reactive binding to non BRCA1 proteins. These concerns prompted us to 
investigate the identity of the 120 kDa protein more deeply.
 An initial hypothesis to explain the observation of bands of 120 kDa and 80-90 kDa instead of 
full-length BRCA1 (220-230 kDa) was a possible cleavage of BRCA1 induced by HSV-1 infection. 
Proteolysis of the full-length molecule might render the epitopes of the I-20 and D-20 antibodies more 
“accessible”; therefore, the N-terminus fragment around 90 KDa could be recognized by the D-20 
antibody and the C-terminal fragment around 120 KDa could be recognized by the I-20 antibody. As 
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well as I-20 and D-20 antibodies, we used the N-terminal MS110 antibody to study our hypothesis. 
However,	our	 immunoprecipitation-immunoblot	 and	 immunofluorescence	analyses	of	U2OS	stably	
expressing full-length BRCA1 suggested that the full-length molecule was not cleaved during HSV-1 
infection (Figs. R28, R29 and R34).  
 One issue that complicated all these analyses was the lack of consistency between the antibodies 
used. This has been a general problem in studies of the cell biology of BRCA1; indeed there has been 
much controversy with regard to the size and localization of BRCA1 protein explained largely by 
differences	in	the	specificity	of	the	antibodies	used	in	the	various	studies.	The	specificity	of	several	
BRCA1	 antibodies	 has	 been	 extensively	 debated	 previously	 and	 this	 issue	 is	 exemplified	 by	 the	
crossreactivity of the C-terminal C-20 antibody (Santa Cruz Biotechnology) with EGFR. Initial reports 
using	the	C-20	antibody	identified	BRCA1	as	approximately	a	190	kda	protein	which	functioned	as	
a secreted growth inhibitor (Gudas, Nguyen et al. 1995; Gudas, Li et al. 1996; Holt, Thompson et al. 
1996; Jensen, Thompson et al. 1996). However, subsequent studies revealed that the band of 190 kDa 
recognized by this antibody corresponded to EGFR. This antibody was also found to crossreact with 
HER2,	another	member	of	the	type	I	tyrosine	kinase	receptor	family,	and	with	as	yet	undefined	antigen	
expressed by smooth muscle cells (Thomas, Smith et al. 1996; Wilson, Payton et al. 1996; Bernard-
Gallon, Crespin et al. 1997; Imakado, Hoashi et al. 1998).
 The I-20 antibody is also a C-terminal antibody but the epitope is adjacent to that of the C-20 
antibody. Although other published data (Wilson 1996) and our own work (Fig. R18) showed that the 
I-20	antibody	does	not	crossreact	with	EGFR,	the	specificity	of	this	antibody	has	been	questioned	in	
several publications (Wilson, Payton et al. 1996; Wilson, Payton et al. 1997; Wilson, Ramos et al. 1999; 
Yoshikawa, Honda et al. 1999; Perez-Valles, Martorell-Cebollada et al. 2001; Bogdani, Teugels et al. 
2002). In particular, it was found that this antibody recognized other proteins different from BRCA1 
in different cells including the cell line HCC1937, even though these cells express a truncated BRCA1 
protein which lacks the C-terminus of BRCA1. It has been argued that these additional proteins were 
unlikely to be related to BRCA1 since they were not detected with other BRCA1 antibodies (Wilson 
1997, 1999, Yoshikawa 1999).
 Thus, although the I-20 antibody clearly recognized overexpressed transfected GFP-BRCA1 
(Figs.	R27-R29	and	R34),	it	may	also	bind	cross-reactively	to	other	antigens.	To	definitively	resolve	
the identity of the 120 kDa protein up-regulated after HSV-1 infection we used immunoprecipitation 
from HSV-1-infected Vero cells using the I-20 antibody followed by mass spectrometry analysis to 
obtain the amino acid sequence of the immunoprecipitated proteins, especially the 120 kDa protein 
(Figs. R36 and R37). 
	 These	mass	spectrometry	data	clearly	 identified	 the I-20 reactive band at 120 kDa as the 
HSV-1 tegument protein UL37 (Fig. R38), which has a predicted molecular weight of 120 kDa. 
Interestingly, bands at 150 and 80 kDa which were also subjected to mass spectrometry analysis 
were	also	identified	as	viral	proteins,	the	major	capsid	protein	and	the	tegument	protein	VP13/VP14	
respectively.
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To	further	confirm	the	result	about	the	120	kDa	protein	experiments	involving	immunoprecipitation	
using	the	I-20	antibody	followed	by	western	blot	analysis	with	an	antibody	specific	for	UL37	were	
performed. A clear signal at 120 kDa for this antibody was observed, which indicated that I-20 is 
able	to	bind	UL37	(Fig.	R39-A).	In	further	confirmatory	experiments,	the	I-20	antibody	was	unable	
to	detect	any	120	kDa	protein	when	cells	were	infected	with	a	virus	deficient	in	UL37	(Fig.	R39-B).	
Using different constructs expressing either only the N-terminus of UL37 or lacking this part of the 
molecule	(Fig.	R39-C),	we	confirmed	that	I-20	binds	specifically	to	the	N-terminus	region	of	UL37	
as predicted from the alignment between the peptide used to generate the antibody I-20 and the UL37 
protein. This alignment revealed six identical amino acids between the N-terminus region of UL37 and 
the C-terminus of BRCA1 (BRCT2 domain)  (Fig. R38). Interestingly, the published crossreactivity 
of the C-20 antibody with EGFR was also due to a similarity between the C-20 epitope and EGFR 
consisting of six identical aminoacids as well as three conservative substitutions (Wilson 1996).
 In spite of the similarity between HSV-1 and HSV-2, the alignment between UL37 proteins 
from HSV-1 and HSV-2 revealed that the six aminoacids identical between the I-20 epitope and HSV-1 
UL37 were not conserved in UL37 from HSV-2, explaining why the 120 kDa protein was not detected 
in HSV-2 infected cells.
 It is of additional interest that immunoblotting with I-20 on total protein extracts of uninfected 
cells give rise to a band of 130 kDa approximately, as mentioned before. While it is possible that this 
band represents a BRCA1 species, the fact that it was mainly detected under less restrictive conditions 
and full length BRCA1 cannot be detected suggests that this band represent and additional protein 
different from BRCA1. A BLAST alignment between the I-20 peptide and the human data base 
revealed PAXIP1 (PAX-interacting protein 1) as a possible candidate. This molecule has a molecular 
weight of 130 kDa and the I-20 epitope aligned to the BRCT2 domain of PAXIP1. However, further 
investigation would be needed to clarify this issue.
 We have not observed a 220-230 Kda band representing full-length endogenous BRCA1 
using the commercial antibodies I-20 and D-20 in immunoblots of total cell proteins. However, 
consistent with previous published reports, the commercially available antibodies used in our study 
(I-20, D-20 and MS110) could identify overexpressed BRCA1 protein in immunoprecipitation and/
or	immunofluorescence	analyses	(Figs.	R27-R30	and	R34).		Thus,	the	difficulties	in	detection	of	the	
endogenously expressed molecule could indicate that the abundance of this molecule is limited post-
translationally as previously proposed (Wilson, Payton, Oncogene 1997).
	 In	 the	field	of	breast	cancer	research,	 the	fact	 that	many	BRCA1	antibodies	crossreact	with	
other cellular proteins has given rise to much scepticism about BRCA1 data at protein level. Here, we 
reported	the	first	crossreaction	of	a	BRCA1	antibody	with	a	viral	protein,	and	given	the	track	record	
of BRCA1 antibodies and cross-reactivities these data reinforce the need for careful validation of 
antibodies used in experiments studying this molecule. In particular, some of the antibodies used in this 
thesis have also been used by other groups for example studying the changes in BRCA1 distribution 
during HSV-1 infection. This does not mean that those data are erroneous; simply that great caution 
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should be taken when interpreting past and future results generated using the I-20 antibody in HSV-1 
infected cells. 
 As described in the introduction, IFI16 protein is associated with cell growth inhibition, cell 
cycle arrest and cellular senescence. The function of IFI16 in the regulation of cell proliferation depends 
on its ability to bind other proteins and modulate their activities. Up to now, a number of proteins are 
known to interact with IFI16, including Rb and E2F, BRCA1 and p53. In part, IFI16 could inhibit cell 
proliferation by upregulating p21 expression in p53-dependent and independent manner and potentiating 
the Rb/E2F-stimulated transcriptional inhibition (Xin, Curry et al. 2003; Xin, Pereira-Smith et al. 
2004). Although a variety of evidences indicated that the interaction of IFI16 with p53 enhanced p53 
transcriptional activity (Johnstone, Wei et al. 2000; Fujiuchi, Aglipay et al. 2004; Xin, Pereira-Smith 
et al. 2004), it is not yet clear whether p53 in turn could regulate IFI16 expression or activity. Since 
a number of proteins that regulate p53 functions are in turn regulated by p53 such as p202 (Datta, Li 
et al. 1996; D’Souza, Xin et al. 2001), it seemed reasonable to test whether p53 could regulate the 
expression or activity of IFI16. We have observed that the p53 knockout HCT116 cells barely express 
IFI16 compared to the wt HCT116 cells. The reduced expression of IFI16 in HCT116 p53-/- cells could 
be associated with the lack of p53 if p53 regulates IFI16 expression, at either a transcriptional or 
translational level, or IFI16 stability. Given that IFI16 is localized mainly in the nucleus of HCT116 
cells, any regulation of IFI16 by p53 might be more likely to occur at a transcriptional level. Moreover, 
given that p53 is a well known transcriptional regulator, it seemed plausible that p53 regulated IFI16 at 
transcriptional level, although it is known that p53 acts as more than just a transcription factor (Caelles, 
Helmberg et al. 1994; Haupt, Rowan et al. 1995; Ding, Lin et al. 2000; Chipuk, Maurer et al. 2003; 
Chipuk, Kuwana et al. 2004). Furthermore, two key characteristics of the p53 protein are required for 
its capacity to promote or inhibit transcription of a variety of genes: its ability to recognize and bind 
specific	DNA	sequences	and	to	recruit	components	of	the	transcriptional	machinery	or	transcriptional	
co-regulators.	Therefore,	if	p53	is	a	DNA	sequence-specific	transcriptional	regulator,	and	IFI16	was	
transcriptionally regulated by p53, IFI16 should have p53 DNA-binding sites. However, there is only 
one	report	that	has	identified	a	putative	p53	DNA-binding	site	within	the	first	exon	of	the	IFI16 gene 
(Song 2008). 
 If the marked reduction of IFI16 observed in the p53 knockout HCT116 cells was associated 
with the lack of p53, we wondered if the reconstitution of p53 expression could restore IFI16 
expression. Since no re-expression of IFI16 protein was observed after p53 transfection of HCT116 
p53-null cells, we analysed whether the activation of p53 was required to promote the transcription of 
IFI16 gene. Moreover, the single report about IFI16 up-regulation by p53 showed that the transcription 
of the IFI16 gene was stimulated in response to the functional activation of p53. Therefore, after p53 
transfection we treated the cells with two different DNA-damaging agents: short wave ultraviolet 
radiation (254nm) as a non-ionizing radiation (Fig. R44) or gamma radiation (Cesium 137,10Gy) as 
an ionizing radiation (Fig. R43). Although these results suggested that p53 was not able to induce the 
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up-regulation of IFI16 expression after exposure to ionizing and non-ionizing radiation, the absence 
of a control for p53 activation, for example analysis of the phosphorylation of p53 on Ser15, renders 
difficult	a	confident	interpretation	of	these	data.	An	additional	positive	control	to	verify	the	activation	
of p53 would have been to analyse the levels of known transcriptional targets of p53, such as p21.
 A complementary approach to check if activated p53 could stimulate IFI16 expression would 
have been to treat the wt HCT116 cells with an inhibitor of p53-mediated functions or to silence p53 
expression and observe the effects of these treatments on IFI16 expression levels before and after 
treatment with DNA-damaging agents.
	 Further	planned	experiments	included	verification	of	the	integrity	of	IFI16 gene in the genomic 
DNA of the HCT116 p53-null cells as a necessary validation before proceeding to assay the possible 
p53 transcriptional regulation of IFI16 by comparing the IFI16 mRNA levels of wt and p53-null 
HCT116 cells by quantitative real-time PCR (qRT-PCR).
 Interestingly, a study carried out by other authors, where they assessed whether the p53-
dependent enhancement of IFN signalling and production was mediated by p53 transcriptional 
up-regulation of IRF9, revealed that the tranfection of IRF9 into HCT116 p53-/-	 cells	 significantly	
increased the transactivation of an ISRE reporter but it could not completely restore the levels achieved 
in HCT116 expressing endogenous p53. The authors suggested that p53 might have, in addition to 
IRF9, other IFN-related target genes (Munoz-Fontela, Macip et al. 2008). Since we have observed 
that p53-null HCT116 cells barely express IFI16 compared to the wt cells, we speculated that IFI16 
could be an additional transcriptional target of p53 that might contribute to the enhancement of IFN 
signalling mediated by p53. However, our hypothesis remains at present speculative. 
 Nevertheless, these experiments had to be interrupted because both wt and p53 knockout 
HCT116 cells started to grow as spheroids instead of as a monolayer. When the wt cells formed these 
spheroids they expressed markedly less IFI16 than usual. Intriguingly, no other batches of wt HCT116 
cells supplied by other groups expressed IFI16 protein. Therefore, it proved impossible to continue 
experiments with these cell lines. 
 While the above experiments were in progress the study of IFI16 expression was extended 
to include other cells of known p53 status. Since it is known that levels of IFI16 mRNA and protein 
are frequently decreased in many breast cancer cell lines (Fujiuchi 2004), a possible relation between 
IFI16 expression and p53 status was analyzed in several breast cell lines. However, we did not observe 
an obvious relation between the expression of wt p53 and IFI16 in the breast cell lines analyzed (Fig. 
R45). This could indicate that there are more factors involved in IFI16 regulation than just p53. For 
instance, the MCF7 cell line expresses wt p53 (although the molecule ran slightly slower than the p53 
protein from the normal MCF10A cell line) but they did not express IFI16 (Fig. R45 A-B). Since the 
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MCF7 cell line line is tumoral, it is possible that it expresses wt p53 but has mutated or does not express 
other proteins required for normal IFI16 expression. Moreover, although the majority of the breast 
cancer cell lines that have mutant p53 showed no IFI16 expression, the Hs578T cell line expressed 
IFI16 levels comparable to MCF10A and the BT-549 cell line expressed low levels of IFI16 (Fig. R45 
A,B and C). Although both cell lines have a missense mutation in the p53 sequence, it could be possible 
that	these	mutations	do	not	affect	significantly	to	the	structure	or	function	of	p53	protein	comparing	
to the p53 missense mutations in the other cell lines that do not express IFI16. However, according to 
the data base from T.Soussi the Hs578T cells preserve only 9,06% of p53 functionality (as determined 
by the residual transcriptional activity of mutant p53 on the p21 promoter compared to wt p53) and 
the BT-549 cells maintain 12,42% activity. Both p53 activities are higher than in other cell lines that 
do not express IFI16, but they are also similar to the p53 functionality of other cell lines that do not 
express IFI16.  To clarify this issue more studies would be needed in order to determine the molecular 
factors that regulate IFI16 expression, and then compare them among the different breast cancer cell 
lines. It should be expected that the cancer cell lines that do not express IFI16 have mutations in these 
factors regulating IFI16 expression in addition to p53. And maybe in the BT-549 and Hs578T cell lines 
these factors are unaffected or less affected and for this reason the IFI16 expression is stably or slightly 
maintained in the Hs578T and BT-549 cells, respectively. Moreover, in both BT-549 and Hs578T cell 
lines there could be a mutation in IFI16 gene that increased or maintained its levels of expression in 
spite of the process of tumoral transformation.
 Although the BT-549 cell line expressed IFI16, its levels were considerably reduced compared 
to those of the normal MCF10A cell line. Thus, except the Hs578T cell line, all the breast cancer cell 
lines that have mutant p53 are associated with a loss or reduced expression of IFI16. These results 
were	consistent	with	previous	findings	that	indicate	a	frequent	loss	of	IFI16	expression	in	breast	cancer	
cells (Fujiuchi, Aglipay et al. 2004), thereby supporting the notion that IFI16 is involved in relevant 
tumour suppressor functions in breast cancer. To further analyse the loss of IFI16 function in breast 
cancer development, it would have been interesting to check the expression of IFI16 in a normal 
mammary cell line, for example MCF10A, to test whether IFI16 expression decreases after or during 
the transformation of the mammary epithelium. 
 To study if a reduction of IFI16 expression was a consistent feature of tumour cells, a panel of 
bladder tumour cell lines were also analysed for IFI16 expression. All the bladder cell lines analyzed 
expressed IFI16. Moreover, the p53 status of these bladder tumour cell lines did not correlate with the 
IFI16 levels, since the RT4 cell line that contains wt p53 is the one which expressed the lowest levels 
of IFI16.
 One interpretation of these results might be that the regulation of IFI16 expression by p53 
could be tissue-dependent, which in turn would indicate that the putative oncosuppressive function 
of IFI16 could be dependent on the cellular type. In agreement with this idea, although previous 
observations have supported the idea that the loss of function of IFI16 may provide growth advantage 
to the affected cells, co-expression of AIM2 and IFI16 enhanced the cell growth of an oral squamous 
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cell	carcinoma	cell	line	deficient	for	p53.	This	suggested	that	expression	of	AIM2	and	IFI16	may	have	
oncogenic function in this type of carcinoma that lacks p53 (Kondo, Nagai et al. 2012). Interestingly, 
the expression of both proteins after introducing wt p53 suppressed cell growth. Moreover, this could 
indicate that wt p53 might regulate the activity of IFI16 in these cells.
 The fact that IFI16 has an oncosuppressive function mainly in breast and prostate cells, and 
BRCA1 is a critical tumour suppressor protein involved in the development of many types of breast and 
prostate cancer, suggest that the role of IFI16 in tumour suppressor activities in these type of tumours 
might be related to the capacity of IFI16 to interact with BRCA1. Moreover, the biological function of 
IFI16 in breast and prostate cancer development might also be related to the interaction of IFI16 with 
the glucocorticoid receptor (GR) and the androgen receptor (AR). GR and AR are steroid hormone 
receptors that play important roles in the development of breast and prostate cancers (reviewed in 
(Kach, Conzen et al. 2015)). Since IFI16 has been considered as a modulator of glucocorticoid and 
androgen actions by binding to GR and AR respectively (Alimirah, Chen et al. 2006; Berry, Matthews 
et al. 2010), maybe the loss of IFI16 function in these cells could lead to deregulated GR and AR 
activities promoting breast and prostate cancer.
 One of the hallmarks of human malignancies is their genomic instability due to compromised 
DDR pathways. The fact that viral proteins such as ICP0 can disrupt the DDR by degrading key cellular 
proteins involved in DNA damage sensing, signaling and/or repair, including IFI16, may contribute to 
genome	instability	and	hence	human	cancer	development.	Thus,	clarification	of	mechanisms	underlying	
the interactions between virus and DDR pathways would be a fundamental area of study.
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1. Infection with HSV-1 leads to a marked reduction in IFI16 expression levels. IFI16 protein 
levels	are	slightly	reduced	after	infection	with	an	ICP0	deficient	virus,	but	the	reduction	in	IFI16	
expression levels is markedly enhanced if the HSV-1 expresses ICP0, although the loss of IFI16 
varies to some extent between different cell lines. 
2. Analysis of mutant viruses that express ICP0 but not additional IE gene products showed that loss 
of	IFI16	occurs	even	in	the	absence	of	efficient	viral	replication.
3. Analysis of the expression of p53 after HSV-1 infection showed that p53 expression levels were 
not consistently affected in the cell lines analysed.
4. Analysis of the expression of BRCA1 after HSV-1 infection using the commercially available 
BRCA1 antibody I-20 (Santa Cruz Biotechnology) revealed a marked increased in a 120 kDa 
protein.	This	phenotype	was	observed	in	all	the	cell	lines	analysed	and	was	specific	to	HSV-1	
infection since this band was not observed after infection with other viruses.
5. The proteomic analysis revealed that the 120 kDa-band up-regulated in HSV-1 infected cells 
observed with the I-20 antibody was UL37, an HSV-1 tegument protein. Thus, a BRCA1 
antibody cross-reacts with the HSV-1 UL37 protein. The cross-reactive epitope was localised 
in the N-terminal region of UL37 in transfection studies with plasmids expressing different 
fragments of UL37. 
6. The expression of IFI16 proteins is markedly reduced in the p53 knockout HCT116 colorectal 
carcinoma cell line compared to the levels expressed by wild type HCT116 cells. Reconstitution 
of the expression of wt p53 had no appreciable effect on IFI16 expression. Furthermore, 
transfected p53 did not affect the expression levels of endogenous and transfected IFI16 after 
exposure to either ultraviolet or gamma radiation.
7. Analysis of the expression of IFI16 protein in different breast cell lines showed that the majority 
of the breast cancer cell lines analysed have lost or reduced expression of IFI16. However, a clear 
relation between IFI16 expression and p53 status was not observed. Moreover, analysis of IFI16 
expression in a panel of bladder tumour cell lines showed that all these cells expressed IFI16 and 
IFI16 expression levels did not correlate with p53 status. 
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1. La infección por HSV-1 desencadena una marcada reducción en los niveles de expresión de IFI16. 
Los	niveles	de	proteína	de	IFI16	disminuyen	ligeramente	tras	la	infección	por	un	virus	deficiente	
en ICP0, sin embargo esta reducción en los niveles de expresión de IFI16 se potencia notablemente 
si el virus expresa ICP0, aunque el grado de pérdida de IFI16 varía entre diferentes líneas celulares.
2. El	análisis	mediante	virus	mutantes	que	expresan	 ICP0	pero	carecen	de	otros	genes	 temprano-
inmediatos indica que la reducción de los niveles de IFI16 puede ocurrir incluso en ausencia de una 
replicación	viral	eficiente.
3. El estudio de la expresión de p53 tras la infección por HSV-1 muestra que los niveles de esta 
proteína no varían de manera consistente en las líneas celulares estudiadas.
4. El	análisis	de	la	expresión	de	BRCA1	tras	la	infección	por	HSV-1	utilizando	el	anticuerpo	comercial	
I-20 (Santa Cruz Biotechnology) revela un marcado aumento de una proteína de 120 kDa. Este 
fenotipo	se	manifiesta	en	todas	las	líneas	celulares	analizadas	y	es	específico	de	infección	por	HSV-
1, ya que no se observa tras la infección con ninguno de los otros virus utilizados.
5. El	análisis	de	proteómica	revela	que	la	banda	de	120	kDa	que	aumenta	en	células	infectadas	por	
HSV-1 cuando se utiliza el anticuerpo I-20 es UL37, una proteína del tegumento del HSV-1. Por 
lo tanto I-20, un anticuerpo contra BRCA1, reconoce la proteína de HSV-1 UL37. El epítopo que 
produce esta reactividad cruzada se localiza en la región N-terminal de UL37, como se determinó 
en	estudios	de	transfección	con	plásmidos	que	expresan	diferentes	fragmentos	de	UL37.	
6. La expresión de la proteína IFI16 se reduce marcadamente en la línea celular de carcinoma 
colorrectal	 HCT116	 deficiente	 en	 p53,	 en	 comparación	 a	 los	 niveles	 de	 las	 células	 HCT116	
control. La reconstitución de la expresión de p53 no supone un efecto apreciable en la expresión 
de	IFI16.	Además,	p53	transfectado	tampoco	afecta	a	los	niveles	de	expresión	de	IFI16,	endógeno	
o transfectado, tras la exposición a radiación ultravioleta o gamma.
7. El	análisis	de	la	expresión	de	la	proteína	IFI16	en	diferentes	líneas	celulares	de	mama	muestra	que	
la	mayoría	de	las	líneas	celulares	de	cáncer	de	mama	analizadas	presentan	una	pérdida	o	reducción	
notable de los niveles de expresión de IFI16. Sin embargo, no se observa una clara relación entre 
los	niveles	de	IFI16	y	el	estado	de	p53.	Además,	el	análisis	de	la	expresión	de	IFI16	en	un	panel	de	 
líneas celulares procedentes de tumores de vejiga, muestra que todas estas células expresan IFI16 
y sus niveles de expresión no correlacionan con el estado de p53. 
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